Strategies to improve the immunogenicity of subunit vaccine candidates by Wei, Yangjie
 
Strategies to improve the immunogenicity of subunit vaccine candidates 
By 
[Copy right 2018] 
Yangjie Wei 
 
Submitted to the graduate degree program in Pharmaceutical Chemistry and the Graduate 
Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of 






Chairperson: C. Russell Middaugh, Ph.D. 
 
Wendy L. Picking, Ph.D. 
 
William D. Picking, Ph.D. 
 
Teruna J. Siahaan, Ph.D. 
 
Prajnaparamita Dhar, Ph.D. 





The Dissertation Committee for Yangjie Wei  























Subunit vaccines contain highly defined macromolecular components of a pathogen that 
are capable of eliciting protective immunity. They possess several advantages over other vaccine 
types (e.g. live attenuated and inactivated) such as improved safety profiles, highly defined nature, 
ease of production, and potential for lower cost of goods. One critical limitation of subunit 
vaccines, however, is their weak immunogenicity owing to their inability to replicate, monovalent 
structures, and the absence of other immunostimulatory components. Common approaches to 
enhance the immunogenicity of subunit vaccines include polyvalent antigen display strategies, the 
use of adjuvants, etc. The polyvalent antigen display strategy requires the use of a scaffold, which 
can be protein-based or some other materials. Chapter 2 focuses on the biophysical properties of a 
potential scaffold for polyvalent antigen display-Bacillus anthracis lumazine synthase (LS), an 
icosahedral homo-oligomeric protein. LS in PBS buffer showed a minor thermal transition around 
50 ᵒC, and a major one at 95 ᵒC. The minor transition arose from the dissociation of the 
LS/phosphate complex, which formed in PBS buffer at room temperature. The major transition 
corresponded to the dissociation of LS oligomers, thermal unfolding, and aggregation. In chapter 
3, I describe an attempt to develop ricin vaccine candidates in which LS was used as a scaffold to 
achieve polyvalent display of a linear neutralizing epitope (designated PB10) from ricin. PB10 
was genetically inserted onto the C terminus of LS, and the fusion protein (designated LS_PB10) 
was expressed in an E.coli system. LS_PB10 self-assembled into spherical particles. Fusion of the 
PB10 peptide did not affect the structure and stability of LS. LS_PB10 showed tight binding to a 
mAb targeting the PB10 epitope. Immunization of LS_PB10 in mice elicited a moderate level of 
anti-ricin serum titers, which, however, failed to offer protection during a challenge study using a 
10x lethal dose of ricin. Such an unsatisfactory end result may be attributable to 1) limited 
iv 
 
efficacies of using the PB10 epitope alone, 2) loss of secondary structure of PB10 on LS; 3) an 
epitope suppression effect induced by the highly immunogenic nature of the LS scaffold. 
Studying antigen/adjuvant compatibility is critical for the development of adjuvanted 
vaccine formulations. Chapter 4 discusses the utilization of biophysical tools to understand effects 
of two emulsion-based adjuvants (designated as ME.0 and SE) on the structure and thermal 
stability of alpha-toxin (AT), a potential vaccine candidate for Staphylococcus aureus infection. 
Both adjuvants are oil-in-water (O/W) emulsions using squalene as the oil phase. DSC analysis 
showed the ME.0 emulsion thermally destabilized AT, probably because of changes in the buffer 
composition of AT upon mixing. The SE emulsion caused increased alpha-helix and decreased 
beta-sheet content in AT, and a blue shift in Trp fluorescence emission spectra of AT. DSC analysis 
showed SE exerted a dramatic thermal stabilization effect on AT, probably attributable to an 
interaction between AT and SE. Size exclusion chromatography showed a complete loss in the 
recovery of AT when mixed with SE, but not ME.0, indicating a high degree of interaction with 
SE.  
The goal of protein formulation development is to identify optimal conditions for long-
term storage. Certain commercial conditions (e.g., high protein concentration or turbid adjuvanted 
samples) impart additional challenges to biophysical characterization. Formulation screening 
studies for such conditions are usually performed using a simplified format in which the target 
protein is studied at a low concentration in a clear solution. The failure of study conditions to 
model the actual formulation environment may cause a loss of ability to identify the optimal 
conditions for target proteins in their final commercial formulations. In chapter 5, we utilized a 
steady-state/lifetime fluorescence-based high-throughput platform to develop a general workflow 
for direct formulation optimization under analytically challenging but commercially relevant 
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conditions. A high-concentration monoclonal antibody and an Alhydrogel-adjuvanted antigen 
were investigated. A large discrepancy in screening results was observed for both proteins under 
these two different conditions (simplified versus commercially relevant). This study demonstrates 
the feasibility of using a steady-state/lifetime fluorescence plate reader for direct optimization of 
challenging formulation conditions and highlights the importance of performing formulation 
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Vaccines are considered as one of the most significant medical innovations in modern times 
and are responsible for eliminating medical conditions cause by toxins, pathogenic bacteria and 
viruses. Vaccination has effectively controlled the spread of many diseases and some have even 
been eradicated (e.g. smallpox) with others probably soon to follow. Vaccines are, therefore, 
considered as one of the most significant medical innovations (1, 2). An effective vaccine needs 
to elicit protective immune responses targeting a specific type of pathogen without itself causing 
the disease. Traditional vaccines were primarily based on live attenuated or inactivated pathogens. 
Even though they are typically highly effective in inducing protective immune responses in the 
host, there are often safety concerns with these types of vaccines. For example, live attenuated 
vaccines could possibly regain pathogenicity by reverting to their wild type forms especially in 
people with immuno-deficiencies (3-8). In addition, such vaccines often require critical storage 
conditions to maintain their immunological activity (9). Accidental exposure to environmental 
stresses (e.g. light or temperature) could cause a loss of immunogenicity (10). Inactivated vaccines 
can also sometimes cause side effects at some frequency in target populations (11-13). Batch-to-
batch variability could also be an issue for such vaccines especially when cultures of pathogenic 
organisms are produced at a large scale (14).  Thus, there is a demand for the development of a 
class of safe, effective and stable vaccines. The early development of toxoid-based vaccines 
suggests the viability of such an approach. Advances in immunology and pathology have helped 
to elucidate host-pathogen interactions and identify the components within pathogens that are 
responsible for protective immunity. Furthermore, the development of recombinant DNA 
technology provides the ability to produce large quantities of proteins (often referred to as 
“subunits”) that can be used for this purpose. Subunit vaccines are highly defined biological 
3 
 
entities derived from specific components (e.g. a surface protein) of the pathogen. They have 
improved safety profiles and much less batch-to-batch variation than live attenuated or inactivated 
vaccines (15). In addition, subunit vaccines can be produced in a less expensive and more efficient 
manner. However, the immunogenicity of subunit vaccines is usually relatively low due to their 
monomeric nature and the absence of other immuno-stimulatory components (16).  
As shown in Figure 1.1, common strategies to improve the immunogenicity of subunit 
vaccines include polyvalent antigen display, co-administration of adjuvants, the use of antigen 
delivery systems, etc. The polyvalent antigen display strategy functions by presentation of multiple 
copies of subunit vaccines or epitopes in an ordered manner on the surface of a scaffold. The 
clustering of subunit vaccines creates a polyvalent structure that enables strong “avidity” 
interactions with B cell receptors. The scaffold can be organic (e.g. proteins) or inorganic systems 
(e.g. gold nanoparticles). If a protein-based scaffold is used, this strategy is often referred as a 
virus-like particle (VLP) strategy. Adjuvants activate the immune system by a variety of 
mechanisms including recruitment of immune cells, enhanced antigen uptake, and engagement of 
Toll-like receptors. Though fundamental understandings of the mechanism of adjuvant action have 
been dramatically enhanced in recent decades, a comprehensive mechanistic picture is still lacking. 
An important analytical aspect related to the use of adjuvants is to investigate antigen/adjuvant 
comparability to ensure the stability and efficacy of the mixture. Efficient antigen delivery systems 
use biocompatible and biodegradable polymers to incorporate antigens of interest and slowly 
release antigens in a controlled manner. Such sustained antigen release profiles mimic repeated 
immunizations and results in long lasting immune responses. In this chapter, I will introduce these 




Figure 1.1 Common strategies to improve the immunogenicity of subunit vaccines 
 
1.1. VLP strategy 
An effective means to improve the immunogenicity of subunit vaccines is the use of virus-
like particles (VLP), which have been developed based on an understanding of high intrinsic 
immunogenicity of viral pathogens (17). VLPs form an oligomeric protein scaffold capable of 
presenting immunogenic epitopes and proteins in a highly efficient manner.  VLPs are large protein 
complexes with structures highly analogous to viruses (18). VLPs are considered to be safe since 
they are non-replicative and devoid of nucleic acids (i.e., DNA, RNA) (19). VLPs are highly 
immunogenic in nature. Similar to actual viruses, VLPs present multiple copies of antigenic 
epitopes on their surfaces, resulting in a high local density of structurally ordered epitopes capable 
of high avidity interactions with B-cell receptors (BCRs) (Figure 1.2), which stimulates strong 
BCR signaling and strong immunostimulation (e.g. T helper cell-independent B cell activation) 
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(20-24). Thus, in contrast to monomeric antigens, VLP-based vaccines can elicit immune 
responses much more efficiently (25). Second, due to their particulate nature and relatively large 
size (20-200 nm) (26), VLP are efficiently taken up and processed by professional antigen 
presenting cells (APCs) such as dendritic cells (DCs) and macrophages. DCs present VLP-derived 
peptides to CD4+ T helper cells, facilitating strong humoral and cellular immune responses (21, 
22, 27). VLPs have been successfully employed to develop vaccines for Hepatitis B and human 
papillomaviruses (HPV, cervical cancer). Many additional VLP-based vaccines are under 
development (28).  
 
Figure 1.2. The high avidity interaction between a polyvalent VLP and B cell receptors (“Y” 
shape). The VLP consists of multiple copies of a homo-subunit. Multiple B cell receptors 
recognize and bind to a VLP simultaneously, resulting in stronger downstream immunological 
responses. 
 
The VLP strategy can also be applied to enhance the immunogenicity of a monovalent 
immunogen by employing a self-assembling protein scaffold. A monovalent immunogen of 
interest can be genetically fused to a subunit of the self-assembling protein scaffold. Correct 
assembly of the fusion protein complex enables polyvalent presentation of the immunogen on the 
scaffold surface in an ordered manner to form a pseudo-VLP structure. Currently, various self-
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assembling protein systems have been explored as potential VLP scaffolds. Here, we studied the 
feasibility of an icosahedral bacterial protein-Lumazine synthase-as a protein scaffold for 
polyvalent antigen display using a model epitope derived from ricin toxin. 
1.1.1. Lumazine synthase 
Lumazine synthase (LS) is an enzyme involved in the biosynthesis of riboflavin (vitamin 
B2), a compound essential for a myriad of biological processes. During cellular metabolism, 
riboflavin is converted to flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), 
which function as cofactors for a wide range of enzymes involved in cell-based redox reactions. 
FMN and FAD have also been found to play important roles in several non-redox biological 
processes such as DNA repair (29).  
Humans and other animals cannot synthesize riboflavin by themselves and can only obtain 
it from nutritional sources. Riboflavin is produced de novo in plants, fungi and most 
microorganisms (29, 30). The synthesis pathway of riboflavin in a variety of species has been 
described in detail in several research and review papers (31-35). Of these, the bacterial pathway 
of riboflavin synthesis is the most extensively studied. In bacteria, the synthesis of riboflavin uses 
guanosine-5'-triphosphate (GTP) as the initial substrate and involves reactions catalyzed by several 
enzymes. During the terminal steps of riboflavin biosynthesis, LS synthesizes lumazine, which is 
then converted to riboflavin. LS is composed of homo-oligomers which vary in size and subunit 
number depending on its species of origin. Because of its oligomeric nature, LS has been widely 
used for a variety of biomedical applications including antigen presentation, drug delivery and 
bioengineering among others. Here, we will first briefly discuss the enzymatic mechanism and 
structural properties of LS, and then focus on applications of LS in the biomedical field with an 




Figure 1.3. Biomedical applications of LS 
1.1.2. The discovery of LS 
LS was first discovered from Bacillus subtilis in the 1970s, when two proteins related to 
riboflavin synthesis were purified by sucrose density gradient ultracentrifugation (36). The 
sedimentation velocities of these two proteins were 4.1 S and 26.5 S. They were therefore named 
“light” and “heavy” riboflavin synthase (RS), respectively. The light RS (4.1 S) was found to be a 
homo-trimer, which is now known as RS. The heavy RS (26.5 S) showed two bands on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. One of these two bands corresponded to the 
subunit of the light RS (i.e., 4.1S riboflavin synthase). The second protein was hypothesized to 
consist of sixty copies of a 15 kD monomer that was later named LS, after its biological function 
was fully elucidated. The heavy RS contains both RS subunits (designated as the α subunits) and 
LS subunits (designated as β subunits). The crystal structure of the heavy RS was solved in 1983 
and its unusual α3β60 stoichiometry was confirmed (37). LS from Bacillus subtilis (BsLS) forms 
an icosahedral quaternary structure (T = 1) consisting of 60 identical subunits with a hollow cavity 
8 
 
in which one trimeric RS molecule is enclosed. These two enzymes form a bi-functional protein 
complex which catalyzes the last two steps of riboflavin biosynthesis. 
1.1.3. Enzymatic mechanisms of LS 
The catalytic reaction mediated by RS and LS is illustrated in Figure 1.4. GTP is first 
converted to 5-amino-6-ribitylamino-2, 4 (1H, 3H)-pyrimidinedione (compound 1) through 
several catalytic reactions. Compound 1 is then condensed with L-3, 4-dihydroxy-2-butanone 4-
phosphate (compound 2) to generate 6, 7-dimethyl-8-ribityllumazine (compound 3) by release of 
two water molecules and a phosphate ion. The enzyme catalyzing the formation of lumazine 
(compound 1 + compound 2 → compound 3 + 2 H2O + PO43-) is named lumazine synthase. 
Compound 3 is then converted by RS to form riboflavin (compound 4) and compound 1, which 
can again be used to synthesize riboflavin. The terminal step of riboflavin biosynthesis is thereby 
a cyclic reaction. This cyclic pathway is conserved in all flavinogenic organisms, and the structures 




Figure 1.4. The biosynthetic cycle of riboflavin (38). Compound 1: 5-amino-6-ribitylamino-2, 4 
(1H, 3H)-pyrimidinedione; compound 2: L-3, 4-dihydroxy-2-butanone 4-phosphate; compound 3: 
6, 7-dimethyl-8-ribityllumazine; compound 4: riboflavin. (This figure is from an open-access 
article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium.) 
1.1.4. Structural properties of LS 
The LS subunit shows a typical α/β/α-sandwich topology (Figure 1.5 A). Four parallel 
stranded β-sheets (β2- β5) are flanked by two α-helices on one side (α2, α3) and three on the other 
(α1, α4, α5). An additional β-sheet (β1) may also be present at the N-terminus, but this is not 
always the case (e.g. LS from Bacillus anthracis) (39). If present, each β1 forms an inter-subunit 
β sheet with an adjacent monomer within an oligomeric block of LS. The fifth β-sheet (β1) offers 
additional stability to LS oligomers. LS does not exist in monomeric form in nature, but assembles 
into homo-oligomers with various quaternary structures.  
1.1.4.1. Diversity of the quaternary structures of LS 
The oligomeric states of LS vary depending on its species of origin (Table 1.1). LS can be 
a pentamer, decamer, or even icosahedral sixty-mer (Figure 1.5). The structure of the pentameric 
LS from Brucella abortus (PDB ID: 1DI0) is shown in Figure 1.5 B. Each subunit is shown in a 
different color. Every five α3 helices within this pentamer form a channel along its five-fold 
symmetry axis. The assembly of the decameric LS derived from Brucella spp. RibH2 (PDB ID: 
1XN1) is shown in Figure 1.5 C and 5 D. Two pentameric blocks that bind to form the decamer 
are shown in cyan and magenta. Figure 1.5 C shows the lateral view of this decameric LS. In 
Figure 1.5 D, the view is along its five-fold symmetry axis. In Figure 1.5 E, the icosahedral 
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structure of LS from Aquifex aeolicus (PDB ID: 5MPP) is illustrated. It consists of twelve 
pentamers shown in different colors. Their multiple quaternary orders not only affect the thermal 
stability of LS (40) but also offer diverse choices for vaccine use. 
Table 1.1. Oligomeric states of LS from different organisms 
 








Organism PDB ID 
Pentamer 
 
Brucella abortus  (41) 
Brucella abortus RibH1 (42) 
Brucella Mesorhizobium loti RibH2 (42) 
Brucella melitensis RibH1 (42) 
Candida albicans (43) 
Magnaporthe grisea (44) 
Mycobacterium tuberculosis (45-48) 
 
Mycobacterium leprae (49) 
Saccharomyces cerevisiae (50) 
Schizosaccharomyces pombe (51) 
1DI0 





2VI5; 2C9B; 2C92; 2C94;  
2C97; 2C9D; 1W19; 1W29 
4J07 
1EJB 




Brucella spp. RibH2 (52, 53) 
Candida glabrata (54) 






Aquifex aeolicus (55-58) 
 
Bacillus anthracis (38) 
Bacillus subtilis (59) 
Escherichia coli 
Spinacia oleracea (44) 
Salmonella typhimurium (60) 
1HQK; 1NQU; 1NQV; 









Figure 1.5. Various assembly states of lumazine synthase. (A) Folding pattern of a lumazine 
synthase monomer from Aquifex aeolicus. This LS subunit has a typical α/β/α-sandwich topology. 
Four parallel stranded β-sheets (β2- β5) are flanked by two α-helices on one side (α2, α3) and three 
on the other side (α1, α4, α5). N- and C- termini are also marked. (B) The structure of the 
pentameric lumazine synthase from Brucella abortus (PDB ID: 1DI0). Each monomer is shown 
in a different color. Every five α3 helices within this pentamer form a channel with five-fold 
symmetry axis. (C and D) The assebmly of the decameric lumazine sythase derived from Brucella 
spp. RibH2 (PDB ID: 1XN1) is shown in lateral and frontal views. Two pentameric blocks 
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consisting the decamer are shown in cyan and magenta. (E) The icosahedral structurer of lumazine 
synthase from Aquifex aeolicus (PDB ID: 5MPP). It consists of twelve pentamers shown in 
different colors viewed along its five-fold symmetry. 
Fornasari et al. have performed a combined analysis to identify the sequence determinants 
of the diversity of quaternary structures of LS based on protein sequence, structure, and 
evolutionary information (39). The analysis showed that sequence sites involved in the icosahedral 
contact interfaces were significantly more conserved than the corresponding sites in non-
icosahedral LSs. Eight sequence sites were identified as primarily responsible for the formation of 
icosahedral LSs. A striking finding of this analysis is that the K131 residue is found to be 100% 
conserved among all known icosahedral LSs, but nearly absent in non-icosahedral LSs. The K131 
side chain projects towards its adjacent pentamer, and this residue shows a larger decrease in 
entropy in an icosahedral LS than in a non-icosahedral LS. Chen et al. has studied the effect of 
point mutations at pentamer-pentamer contact sites on the assembly state of LS from Aquifex 
aeolicus (AaLS) (61). These sites involve three different types of interactions: ionic (R40), 
hydrophobic (L121 and I125), and hydrogen bonding (H41). A comprehensive point mutation 
analysis indicates that mutation of two or three of these types of residues could generate pentameric 
LS, suggesting their importance in maintaining the icosahedral assembly of AaLS. 
LS from Bacillus subtilis (BsLS) was the first LS to be identified and is consequently the 
most extensively studied icosahedral LS. BsLS consists of 60 monomers with a triangulation 
number of 1 (T = 1). It has a spherical shape formed by twelve identical pentamers. The particle 
size of BsLS is ~16 nm and the diameter of its hollow cavity around 9 nm (59). The channel formed 




The substrates (compound 1 and 2) bind to active sites on LS, which are located at the 
interface of two neighboring subunits within a pentamer (62). For icosahedral LS, the active sites 
are enclosed inside the LS cavity. The number of active sites of LS is equal to the number of 
subunits, with all active sites being topologically equivalent. The catalyzed condensation reaction 
by LS was found to be strictly regio-specific (63). The interactions between substrates and residues 
in active sites involve electrostatic, hydrogen bonding, hydrophobic and π-π interactions. Main 
residues involved include Arg 127, Thr 86 and Phe 22 (numbered based on BsLS) (64). Both Arg 
127 and Thr 86 are highly conserved among all known LS. Arg 127 provides a binding site for the 
phosphate group of the compound 2 via electrostatic interaction. Mutation of Arg 127 to histidine 
or lysine resulted in the reduction of catalytic rate by 38% and 91%, respectively (55). Compound 
2 also hydrogen bonds with Thr 86 and several other surrounding residues. Phe 22 stabilizes the 
binding of compound 1 to the active site by π-π interaction. Phe 22 is replaced by Trp 22 in some 
orthologs of LSs. 
Another important feature of some icosahedral LSs is the formation of the heavy enzyme 
complex with the trimeric RS. For instance, the icosahedral BsLS encloses RS inside its interior 
cavity and the resulting complex is historically designated as “heavy riboflavin synthase”. The 
formation of the BsLS/RS complex is found to improve the rate of riboflavin formation through a 
substrate-channeling mechanism (65). Inside BsLS/RS complexes, their catalytic sites are in very 
close proximity, which results in the accumulation of the intermediate in a confined volume inside 
the BsLS cavity and thereby an increase of the overall reaction rate. The substrate-channeling 
mechanism is important for the production of riboflavin especially when the substrate 
concentrations are very low. The compartmentalization of the intermediates inside the BsLS/RS 
complex may also contribute to protecting them from side reactions and therefore improve the 
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efficiency of catalysis (62). A variety of Bacillus strains have been found to express the LS/RS 
complex, which, however, does not exist in some other microorganisms (36). For example, LS 
derived from E. coli exists as a hollow icosahedral structure and does not enclose its RS. Currently, 
it is still unknown whether the LS/RS complex is formed in plant cells. 
1.1.4.2. Structural stability of LS 
Several types of non-covalent interactions drive the formation of LS capsids. These include 
hydrophobic interactions, hydrogen bonding and ionic contacts (66). Thermal unfolding studies of 
LSs performed by differential scanning calorimetry have established their exceptional thermal 
stability (67). The apparent melting temperatures of icosahedral AaLS and BsLS were 120ᵒC and 
93ᵒC, respectively. Even the pentameric LS from S. cerevisiae manifested an apparent melting 
temperature of 74 ᵒC. The higher melting temperature of icosahedral LS (relative to pentameric 
LS) is apparently a consequence of the icosahedral LS’s ability to form more stabilizing contacts 
as a capsid, and a reduction in accessible apolar surface areas. Being the most thermally stable LS 
known, AaLS possesses the largest charged surface area consistent with a stabilization effect of 
surface ionic networks (67). 
LS has also shown exceptional stability in response to chemical denaturants such as urea 
and guanidine HCl. Zylberman et al. has studied the chemical unfolding of decameric LS derived 
from Brucella sp. (BspLS) in the presence of urea or guanidine HCl at pH 7.0 and 25 ᵒC (40). It 
was found that BspLS incubated with 8 M urea did not show a significant change in its secondary, 
tertiary or quaternary structure, suggesting its extreme conformational stability. In contrast, a two-
phase denaturation profile was observed for BspLS in the presence of increasing concentrations of 
guanidine HCl. The addition of 2 M guanidine HCl was able to dissociate the decamer into 
pentamers, which further became unfolded monomers at higher guanidine HCl concentration. The 
15 
 
free energies of unfolding of BspLS for each step were found to be 90 ± 20 kJ/mole and 315 ± 15 
kJ/mole, respectively. Wei et al. has recently investigated the chemical unfolding of an icosahedral 
LS from Bacillus anthracis (BaLS) in PBS at 25 ᵒC (68). It was found that the urea induced 
unfolding kinetics of BaLS was much slower than that produced by guanidine HCl. In addition, 
BaLS partially unfolded but still retained its icosahedral assembly in response to 8.5 M urea. 
However, the addition of 3 M guanidine HCl completely unfolded BaLS. The guanidine HCl 
induced unfolding of BaLS was found to be a multiphasic process involving the appearance of a 
molten globular state.  
The conformational stability of LS is governed by various factors such as pH, ligand 
concentration, and ionic strength (40, 69, 70). The effects of each factor are discussed briefly here. 
The capsid of LS from Bacillus subtilis (BsLS) was found to be stable within a relative narrow pH 
range near physiological neutrality. The electrostatic energy for subunit interactions within a 
pentamer of BsLS was calculated as a function of pH (62). The pentamer was found to be most 
stable at pH 8. Icosahedral BsLS was found to dissociate and reform a larger capsid with a size of 
29 nm in 0.1 M Tris buffer at a pH above 7.0 (70). This finding was compatible with a later finding 
by Zhang et al. on the multiple assembly states of  BsLS detected using small angle X-ray 
scattering and electron microscopy (69). Zylberman et al. found that BspLS dissociated at a pH 
less than 5.0 (40). Wei et al. observed that BaLS formed irreversible aggregates at a pH below 4.0. 
Precipitation was observed when the icosahedral BaLS was dialyzed in citrate-phosphate buffer at 
pH 3.0 and 4.0 (68). The thermal stability of BaLS was evaluated across a pH range of 5.0 to 8.0 
using various biophysical techniques. The multiple biophysical data sets collected were further 
processed to generate an empirical phase diagram (71) for visualization of the pH dependent 
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thermal stability of BaLS. The data show that BaLS had its greatest thermal stability at pH 7.0 
followed by pH 6.0 and 8.0. 
The binding of substrate 1 (i.e. compound 1 in Figure 1.4) analogs or divalent phosphate 
ions to the active sites of LS could potentially stabilize the enzyme (70). Substrate 1 analogue (5-
nitroso-6-ribitylamino-2,4(1H,3H)-pyrimidinedione) was found to suppress the dissociation of 
icosahedral BsLS in 0.1 M Tris buffer at a pH above 7.0 (70). Wei et al. studied the role of 
phosphate ions in the thermal stability of BaLS (68). A small but distinct transition was observed 
before the main thermal transition of BaLS in phosphate containing buffers. Further investigation 
revealed that this small thermal transition was derived from the dissociation of phosphate ions 
from the active sites of BaLS. The melting temperature of this thermal transition increases with 
the concentration of phosphate ions. An interfacial energy calculation performed on the subunit 
pentamer based on the known crystal structure of BaLS showed that each phosphate ion stabilized 
the interface contact by approximately 6 kcal/mol. Because the interaction between phosphate ions 
and BaLS is ionic, it can be mitigated by increased ionic strength. Thus, the melting temperature 
of the first transition of BaLS decreased with increasing NaCl concentration. 
1.1.5. Biomedical applications of LS 
Research on the biosynthetic process of riboflavin started in the 1950s (72). The driving 
force to study riboflavin biosynthesis has evolved along with advances in the biotechnology 
industry (Figure 1.3). Its research goal in the early stage was to use flavinogenic microorganisms 
for the production of riboflavin (73). Later, it involved the understanding of the highly conserved 
riboflavin biosynthesis cycle and design of molecular inhibitors of essential enzymes (e.g., LS and 
RS) for the development of broad-spectrum antibiotics. The fact that LS is present in plants and 
microorganisms and absent in humans and other animals has made it a potential antibiotic target 
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(74). Many studies have concerned the development of inhibitors targeting LS by synthesis of 
analogs of substrates and intermediates (38, 45, 75-88). In one such study, Morgunova et al. have 
shown binding of different substrate-analogue inhibitors to the catalytic site of LS from Candida 
albicans (89). Shankar et al. have also designed molecular inhibitors targeting LS derived from 
pathogenic Candida glabrata for the development of antifungal drugs (54). In a recent study, 
Junaid et al. have shown binding between soluble fullerene C60 derivatives and potential drug 
targets, including LS (90). The C60 derivatives showed strong interactions with the binding sites 
of LS with the interaction strength higher than their known protein ligands and inhibitors, thereby 
showing the potential of fullerene C60-like molecules as therapeutics agents targeting LS. 
In recent years, the development of nanotechnology and bioengineering has extended the 
application of LS to modern biomedical applications, including vaccine development (91, 92), 
targeted drug delivery (93-95), and protein “containers” (96-99). Our primary focus in this review 
is on its pharmaceutical applications, especially its use as a vaccine carrier.  
1.1.5.1 Applications of LS in vaccine development 
There is considerable interest in LS as a vaccine platform, especially the decameric and 
icosahedral forms. As an oligomeric protein complex, LS effectively forms a virus-like particle 
(VLP) scaffold capable of presenting immunogenic epitopes and proteins in a highly efficient 
manner.   
LS, especially the decameric and icosahedral forms, have the potential to serve as VLPs 
for the purpose of vaccine development with notable advantages over the HBV and HPV-like 
VLPs.  For example, X-ray crystal structures of most LSs have revealed that both the N and C 
termini of the monomers are surface exposed [10], permitting insertion of foreign antigenic 
sequences at two distinct sites. As discussed above, LS also has exceptional thermodynamic 
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stability. We assume that its highly stable nature would benefit the storage stability of LS-based 
immunogens. Berguer et al. demonstrated that the Brucella spp. LS stimulates mouse bone marrow 
DCs to up-regulate the expression of CD40, CD80 and CD86 and major histocompatibility class 
II (MHC II) antigens (100). The protein has also been shown to enhance levels of mRNA, 
chemokines and cytokines of the TLR4 pathway. A typical workflow for the development of LS 
based vaccines involves the synthesis of chimeric DNA sequences, protein expression and 
purification, thorough biophysical characterizations, and finally the evaluation of immunogenicity 





Figure 1.6. A common workflow for developing a lumazine synthase based vaccine presentation 




1.1.5.2. Research on the use of LS in vaccine development 
Both decameric and icosahedral lumazine synthases have been extensively exploited as 
VLP-like presentation systems for a variety of antigens with significant success. In addition, LS 
itself has shown potential as a protective antigen, mucosal adjuvant, and therapeutic cancer 
vaccine. 
1.1.5.2.1. Decameric LS presentation systems 
The decameric LS derived from Brucella spp. (BspLS) was the first LS explored as a 
vaccine presentation system (101). BspLS is a highly stable scaffold comprising of a dimer of 
pentamers. Laplagne et al. studied BspLS as a protein carrier for foreign peptides. It was found 
that peptides of various lengths (up to 27 amino acids) could be fused to BspLS at its N-terminus. 
The insertion of these peptides did not cause a detectable change in the folding or stability of the 
carrier protein. Polyvalent chimeras presenting more than one type of polypeptide could also be 
generated by dissociation and reassembly of the mixture of monovalent chimeras.  
In another study, Mejias et al. used BspLS as a stable scaffold to display the B subunit of 
Shiga toxin type 2 (Stx2B) as a strategy to elicit antibodies against enterohemorrhagic Escherichia 
coli (EHEC) (102). Stx produced by EHEC is responsible for food-borne diseases, systemic 
complications such as Hemolytic Uremic Syndrome (HUS). In spite of its high incidence, there 
are no available licensed vaccines or therapies for the treatment or prevention of EHEC infections. 
A functional immunogen was designed by the insertion of Stx2B at the amino terminus of BspLS. 
The chimeric immunogen induced strong and sustained anti-Stx2 antibody responses in adult 
BALB/c mice. The immunized and weaned mice showed complete protection against intravenous 
administration of Stx2 and EHEC oral challenge. In a similar study, Sacerdoti et al. demonstrated 
that the BspLS-Stx2B chimera induced the generation of high anti-Stx2B specific antibody serum 
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titers in adult Sprague Dawley female rats and prevented Stx2-induced complications associated 
with pregnancy loss (103). That same study also showed that pups that were nursed by immunized 
dams were protected against a lethal dose of Stx2. The BspLS-Stx2B chimera was studied for 
transferring resistance against Stx to offspring after maternal immunization of BALB/c mice (104). 
The pups were found to be completely protected against a lethal dose of Stx2 by injection and oral 
administration of Stx2 producing E. coli at weaning. In another study, Martorelli et al. vaccinated 
calves with a chimeric protein consisting BspLS and Stx2B (BspLS-Stx2B) or a trivalent 
combination vaccine consisting of BspLS-Stx2B, Intimin C280 and EspB (105). The authors found 
that BspLS-Stx2B appeared to stimulate the humoral responses of the other two antigens (Intimin 
C280, EspB) in the trivalent vaccine after a booster dose. It was concluded that including BspLS-
Stx2B in the trivalent vaccine is necessary to elicit potent humoral responses against Stx producing 
Escherichia coli. 
The decameric LS has also been examined for its use in protection against brucellosis. The 
Brucella parasite can infect livestock, potentially destroying their reproductive systems. The 
infection can also be transferred to humans. In view of the lack of a safe brucellosis vaccine for 
humans, subunit vaccines are potential candidates for protection against brucellosis. Previous 
subunit vaccines are lower in efficacy compared to conventional animal vaccines such as live 
attenuated B. abortus S19 (smooth) or strain RB51 (rough). Du et al. (106) have engineered a 
fusion protein immunogen by attaching a recombinant L7/L12 ribosomal protein of Brucella suis 
to Brucella LS. The fusion protein in rabbits elicited production of high levels of IgA and 
upregulation of interferon gamma in rabbit antiserum. Hence, while the Brucella L7/L12 protein 
is an effective immunogen, Brucella LS served as a suitable transport vector.  In a similar study, 
Brucella outer membrane protein 31 (Omp31) has been presented on LS from Brucella as a potent 
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immunogen for protection against brucellosis in rams (107). The engineered chimera was used for 
immunizing different groups of rams by intramuscular (i.m.) or subcutaneous injections in 
adjuvants such as incomplete Freund’s adjuvant (IFA). A DNA plasmid encoding the chimeric 
protein was also administered through i.m., electroporation, or a heterologous prime-boost strategy 
(multiple electroporations of the DNA plasmid followed by an i.m. injection of the chimeric 
protein in IFA). Both the chimeric immunogen in IFA (i.m.) and the prime-boost strategy were 
effective in inducing high IgG titers against Brucella. The highest levels of specific IFN-γ and 
immunity were conferred using the prime-boost and chimera in IFA strategies. Cassataro et al. 
(108) have explored immunization of BALB/c mice with a DNA vaccine encoding chimeric 
Brucella LS and Omp31. This vaccine elicited stronger protection against Brucella ovis than both 
co-delivering plasmids encoding individual proteins and whole Brucella. In a similar study, Du et 
al. have demonstrated that, compared to free Omp31, fusion of Omp31 with Brucella abortus LS 
elicited a much higher antibody titer in rabbits (109). These studies suggest the potential use of 
Brucella LS as a delivery vector for such antigens.  
The use of Brucella LS as a bovine rotavirus antigen delivery system has been 
demonstrated. The antigen VP8d (the inner core domain from the VP8 spike protein) from C486 
bovine rotavirus was expressed as a fusion protein with decameric LS in E. coli (110). Mice 
immunized with the fusion immunogen were reported to have a significantly higher level of 
protection (97.5-100%) against C486 bovine rotavirus than mice immunized with the mixture of 
Brucella LS and VP8d (44.2-80%) and VP8d alone (36.1-67.4%), confirming the use of the LS 
scaffold as a potent antigen delivery system for protection against bovine rotavirus. Alfano and 
coworkers have expressed the BspLS scaffold in plants fused to the VP8d antigen of bovine 
rotavirus (111). The N-terminally LS fused rotavirus antigen produced very high expression of the 
23 
 
stable and soluble protein in tobacco chloroplasts. The extracted recombinant chimeric protein 
from tobacco leaves elicited neutralizing IgY antibodies in a laying hen model. 
The use of LS from Brucella as a prophylactic cancer vaccine has also been studied. The 
immunogenic peptide OVA257–264 (OVA refers to the ovalbumin peptide 257-264, a known T cell 
epitope) was covalently attached to the N-terminus of BspLS (112). Immunization with this 
chimera even without adjuvants led to strong activation of cytotoxic T lymphocytes and a TLR4-
dependent specific cytotoxic response. In contrast, neither LS nor OVA257–264 triggered any 
cytotoxicity in the absence of adjuvants. This again confirms the highly immunogenic decameric 
LS to be an effective scaffold/carrier for further vaccine development. In a later study, the same 
chimera was evaluated for its effect on inducing toll-like receptor 4 (TLR4) mediated anti-tumor 
immune responses against B16 melanoma in C57BL/6J mice (113). Mice were inoculated with 
B16-OVA melanoma (a B16-F1 cell line expressing non-secretory OVA) 35 days after the 
immunization with LS alone or the LS-OVA257–264 chimera. Both immunogens induced significant 
inhibition of tumor growth and longer survival of tumor bearing mice which was not seen in 
controls employing TLR4 deficient mice. This suggests that LS triggers a tumor suppression effect 
through TLR4. Surprisingly, the chimera produced a lower level of protection than LS alone, 
suggesting the conjugation of OVA257–264 did not contribute further to the overall protective 
responses. The exact reason remained unclear. 
In view of the global threat of Taenia solium (tapeworm) infection in pig and human, a 
study was conducted by Cruz-Revilla et al. (114) that employed the immunogenic peptide KETc1 
(a 13 amino acid protective epitope from an anti-cysticercosis vaccine) linked to BspLS for 
protection against T. solium in a golden hamster model. Oral administration of the chimeric 
immunogen was found to be highly protective and significantly reduced the parasite load. 
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Subcutaneous administration of S3Pvac (anti-cysticercosis synthetic peptide heterologous antigen) 
was equally protective but the former is preferred over the synthetic peptide owing to its suitability 
for mass immunization due to a less invasive and cost effective oral delivery. Following these 
studies, LS from Brucella was again tested to enhance the immunogenicity of KETc1 antigen in 
mice (115) and found to be effective as an oral vaccine in the form of an LS chimera (up to 98% 
protection) compared to the protein alone (39%). This construct was also successfully used for the 
reduction of the parasite load. In yet another study, BspLS was evaluated for its effectiveness as a 
carrier scaffold for the delivery of KETc1 (116). The results showed KETc1 became highly 
immunogenic when expressed as a fusion partner with Brucella LS. In a similar study, researchers 
have orally immunized mice using the Taenia crassiceps protective peptide GK-1 alone or as an 
engineered chimera with the protective peptide covalently linked to Brucella LS (117). Protection 
was found to be significantly greater when administering GK-1 with LS as a carrier (96%) 
compared to GK-1 alone (64.7%). This suggests the potential of LS in vaccine delivery through 
the oral route. 
The use of decameric LS has also been extended to influenza. Despite large antigenic 
variations in the influenza virus, the protein M2e (from the ectodomain of the protein Matrix 2) is 
considered to be very similar among various strains of human influenza A virus. This makes it a 
potential candidate for the development of a broadly protective vaccine against the disease (118). 
Brucella abortus LS (BLS) has been used as a carrier for M2e expressed at its N-terminus in E. 
coli generating decameric oligomers. Chimeras were generated by fusing one or four tandem 
copies of M2e to decameric BLS. Immunizing mice with the chimera containing a single copy of 
M2e required adjuvants to elicit responses equivalent to those elicited by the chimera with four 
tandem copies of M2e alone. The latter also conferred higher levels of protection against influenza 
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challenge when vaccinated with adjuvants including Iscomatrix (100% protection) and aluminum 
salts (80%), compared to the chimera alone (60%). 
BspLS has been exploited to fuse flagellin for the development of a new vaccine platform. 
Hiriart et al. have recently engineered a fusion protein by attaching Salmonella flagellin to the N-
terminus of Brucella LS (119). Protein folding and thermal stability of the protein remained 
unaffected after the genetic fusion. The chimeric protein was recognized by anti-flagellin and anti-
LS antibodies and found to trigger TLR5 in TLR5 deficient mice. The humoral response evoked 
by the chimera was more pronounced than that elicited by equimolar amounts of the component 
proteins administered together.  
1.1.5.2.2 Icosahedral LS presentation systems 
Icosahedral LS has also been used as a vaccine presentation system. Jardine et al. have 
chosen the icosahedral LS from the hyperthermophile Aquifex aeolicus (AaLS) to present sixty 
copies of a germline-targeting gp120 outer domain immunogen (termed eOD-GT6) for the 
development of an HIV vaccine (92). Gp120 is a glycoprotein present on the surface of the HIV 
envelope. This protein recognizes and binds the CD4 receptor, which is located on the surface of 
subset of T-helper cells. Because of its critical role in HIV infection, gp120 has long been 
considered to be a promising target for HIV vaccines. Wild-type gp120, however, is a poor 
immunogen because it does not bind to germline precursors for VRC01-class broadly neutralizing 
antibodies and thus fails to elicit the necessary neutralizing antibodies. In this study, gp120 was 
successfully engineered employing computational guidance and in vitro screening to generate a 
germline-targeting gp120 immunogen (i.e. eOD-GT6), which was then fused onto the surface of 
AaLS for enhanced immunogenicity. A modeling analysis indicated that AaLS could be a suitable 
scaffold to present eOD-GT6 with the critical epitope exposed. Given its excellent thermal 
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stability, AaLS was finally chosen as the scaffold. The resulting chimeric particulate immunogen 
successfully activated the desired germline cells and is a promising candidate for an HIV vaccine 
priming dose.  
AaLS protein cage nanoparticles have also been investigated as efficient vehicles for 
vaccine delivery to dendritic cell (120). An immunogen was engineered by attaching antigenic 
ovalbumin peptides OT-1 and OT-2 to the N- and C-terminus of AaLS, respectively. The results 
showed LS to be an efficient delivery vehicle for antigenic peptides to dendritic cells both in vitro 
and in vivo, leading to the proliferation of OT-1 and OT-2-specific T cells. In a recent study, Wei 
et al. have demonstrated the use of the icosahedral Bacillus anthracis LS as a scaffold to display 
a linear neutralizing epitope from ricin toxin recognized by a neutralizing monoclonal antibody 
called PB10 (121). The chimeric immunogen was created by attaching 60 copies of PB10-peptide 
to the C-terminus of LS using four different linkers. The different linkers had no effect on protein 
assembly, stability, or peptide presentation, but did have a minor impact on protein conformation. 
Chemical crosslinking with formaldehyde further enhanced the complex stability with only a small 
impact on protein structure. When injected without adjuvant, the chimeras elicited anti-ricin serum 
IgG titers in mice, but were not protective when challenged with a 10x lethal dose of ricin. This 
study suggests that the use of the PB10 epitope alone may not be sufficient to provide complete 
protection against ricin. The authors also postulated that the PB10 epitope, which adopts a helical 
structure in the ricin molecule, may lose its structure when presented on the surface of LS and 
thereby elicit antibody titers lacking strong binding to the cognate ricin toxin. Hence, even if LS 
has been proven to be a potential platform for vaccine development, the chimera has to be designed 
carefully with the antigen presented being more structurally relevant. 
1.1.5.2.3 LS as a protective immunogen, mucosal adjuvant, or therapeutic cancer vaccine  
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In addition to its use as a vaccine presentation system, LS alone has been used as a 
protective immunogen. Goldbaum et al. reported that BspLS is a useful antigen for serological 
diagnosis of brucellosis (122, 123). Considering its polymeric nature, the authors proposed that 
this protein could serve as a promising acellular vaccine candidate. A few years later, Velikovsky 
et al. evaluated the immunogenicity of Brucella abortus LS (BLS) using a DNA vaccine (124). 
The LS gene was cloned into a pcDNA3 plasmid downstream of a cytomegalovirus promoter. 
Upon injection into BALB/c mice, it evoked both humoral and cellular immunity. The immunized 
mice showed reduced bacterial burden in comparison to the unvaccinated group. It did not, 
however, fully protect animals from Brucella abortus infection. Mice immunized with 
recombinant LS produced only a humoral response and no protection was seen upon challenge. 
Velikovsky et al. evaluated the immunogenicity and efficacy of Brucella abortus LS (BLS) in 
mice in a later study (125). BLS was administered in the presence and absence of three different 
types of adjuvants including aluminum hydroxide, monophosphoryl lipid A, or incomplete 
Freund’s adjuvant. High IgG1 and IgG2 titers were induced by BLS alone. Co-administration of 
each of the three adjuvants further augmented BLS-specific IgG responses, with incomplete 
Freund’s adjuvant being the most effective. In vitro challenge of spleen cells from mice immunized 
with these adjuvanted BLS formulations resulted in increased levels of interleukin-2, gamma 
interferon, IL-10, and IL-4, indicating a mixed Th1-Th2 response. Mice inoculated with BLS were 
found to be protected against B. abortus 544 challenge. This study reinforced the potential of BLS 
as a vaccine candidate against brucellosis. 
In addition to its use as an effective vaccine presentation system, Brucella LS was also 
tested by Rosas et al. as a mucosal adjuvant for oral immunization of KETc1 (a protective peptide 
of an anti-cysticercosis vaccine) using murine models (126). It produced a higher level of 
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protection (79%) than that induced by KETc1 alone (39%). The level of protection induced by the 
use of LS adjuvant or the cholera toxin adjuvant was similar (79% vs 74%, P = 0.53). LS 
adjuvanted KETc1 elicited both IgG and IgA antibodies and proliferated B and CD4 activated 
cells. Brucella LS as an oral adjuvant for the Taenia crassiceps protective peptide GK-1was 
studied [101]. Adjuvanted GK-1 (91.8%) triggered a significantly higher protection level in mice 
compared to GK-1 alone (64.7%), suggesting the potential use of LS as a mucosal adjuvant.  
In conjunction with the study of LS-OVA as a cancer prevention vaccine candidate 
described above (113), BspLS was further evaluated for its therapeutic effects on cancer cells in 
the same paper. BspLS was injected into mice which had been pre-inoculated with B16 melanoma 
cells for 2 or 10 days. Treatment with BspLS at day 10 produced delayed tumor progression, but 
did not improve the overall survival rate. In contrast, the mice which received BspLS treatment at 
day 2 showed both delayed tumor growth and significantly enhanced survival. This demonstrated 
therapeutic effects of BspLS on melanoma at an early stage. Further immunological analysis 
suggested BspLS might elicit its therapeutic effects by its direct impact on TLR4 from B16 
melanoma cells. The case studies described above are summarized in Table 1.2. 
1.1.5.2.4. Potential issues and solutions 
Almost thirty studies have been published in the literature concerning the use of LS as 
vaccine presentation systems (Table 1.2). LS has shown significant advantages as a scaffold 
system to improve the immunogenicity of conjugated antigens. As with any such macromolecular 
system, potential issues with the use of LS-antigen conjugate need to be considered. For most LS-
antigen systems, antigens are fused genetically to the LS scaffold. This requires the expression of 
fusion proteins and correct folding of self-assembled complex. Common issues of expressing 
fusion protein (127-129) include poor yields, formation of inclusion bodies in bacterial expression 
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systems, etc. These issues limit the general use of LS scaffold systems. Poor yield of fusion 
proteins during expression is not unusual for various reasons such as proteolysis and high 
metabolic burden. Possible solutions include codon optimization, vector optimization, use of 
enriched media, and increased aeration during culturing among others. Another common issue 
involving the expression of fusion proteins is the formation of inclusion bodies, which can be 
primarily caused by poor protein solubility and/or incorrect folding. If protein solubility is an issue, 
adding a fusion tag to enhance solubility (e.g. maltose-binding protein, MBP) and/or a change of 
the expression system can be possible solutions. Incorrect folding can result from undesirable 
interactions between a conjugated antigen and LS. Potential solutions include performing 
expression at lower temperature, use of lower inducer concentration, co-expression of molecular 
chaperones, optimization of linkers joining scaffold and antigen using computational modelling 
(130, 131). In addition, much work has involved the optimization of protocols for dissolution and 
subsequent refolding to obtain soluble and correctly folded fusion proteins (132). 
Many LS based vaccine candidates described above are actually expressed as inclusion 
bodies and a protracted refolding step is required to obtain immunologically functional proteins. 
To develop a more generalized platform for Brucella spp. LS (BspLS), the Goldbaum lab created 
a noncovalent conjugation strategy using a pair of small “adaptors” (133). These adaptors are 
essentially a pair of high affinity coiled coil peptides. These two complementary coiled coil 
peptides were fused to the target protein and the LS scaffold, respectively. These two fusion 
proteins were initially purified separately and then mixed in vitro to allow conjugation of the target 
protein onto the LS scaffold driven by strong interactions between the two coiled coil peptides. 
This strategy is thought to have some general applicability considering that these adaptor peptides 
are small in size and are therefore well tolerated. This strategy was used to couple the RBD3 
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antigen to decameric BspLS. The conjugated construct elicited significantly higher antibody titers 
in mice than the antigen alone. 
Another important issue which may often have been underestimated is the intrinsic 
immunogenicity of LS. As a protein scaffold or carrier, LS itself is highly immunogenic (see 
above). Carrier-induced epitope suppression (CIES) is an issue for epitope-carrier systems that 
may result in the reduction of immune responses due to any preexisting immunity to the carrier 
protein (134-138). CIES can be an issue for LS-antigen systems especially when multiple 
immunizations are used. Wei et al. have observed a much higher immune response to the scaffold 
than a conjugated epitope (PB10) in mice, which may in part explain the unsatisfactory 
neutralizing antibody titers to the epitope after three immunizations (139). An ideal scaffold 
system should have low or negligible immunogenicity. Potential solutions to such problem include 
point mutations guided by computational design (140) and conjugation of glycans or PEG to 
immunologically mask the LS scaffold (141). The antigen might need to be large enough in size 
to significantly cover the LS surface thereby masking the dominant immunogenic effect of the LS 
platform alone. 
1.1.5.3. The use of LS in drug delivery  
In addition to the potential success of LS in vaccine development, applications of this 
protein to drug delivery have also been examined. For example, LS was engineered as a potential 
drug delivery vehicle to achieve improved RNA delivery employing encapsulation of nucleic acids 
(142). In a charge tuning approach, four mutations (T86R, D90N, T120R, and E122R.) were made 
in each subunit of AaLS. This resulted in an increase in the overall positive charge on the inner 
surface of AaLS, which in turn allowed it to bind RNA and serve as a container. The exploitation 
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of charge complementarity led to high selectivity and efficient uptake of cellular nucleic acid 
during synthesis and assembly of the capsid in vivo. 
Icosahedral LSs have also been developed as a targeted delivery system for treating cancer. 
Min et al. have genetically fused cancer cell targeting peptides (e.g. tumor vasculature targeting 
peptides) to AaLS and chemically attached anticancer drugs (aldoxorubicin or bortezomib) (93). 
The targeted delivery system employing AaLS showed specific binding to cancer cells and 
significantly enhanced the cytotoxic effects of aldoxorubicin and bortezomib. In a later study, Kim 
et al. developed a polyvalent antibody-binding LS system (ABD-AaLS) by genetic insertion of an 
IgG Fc binding domain into the C-terminus of AaLS (95). The resulting chimeric protein had 
exposed Fc binding domains, which could serve as a versatile platform to bind IgG molecules for 
targeted IgG delivery. The study also suggested drugs could be encapsulated in the hollow cavity 
of the AaLS system or chemically conjugated to free sites on AaLS. 
1.1.5.4. Other applications 
LS has also been employed in several other applications beyond vaccine development and 
drug delivery. Engineered AaLS has been used as a nanoreactor encapsulating the enzyme 
ascorbate peroxidase (APEX2) for polymerization of 3, 3-diaminobenzidine (DAB). This forms a 
polymer which is strongly attached to the capsids and leads to the formation of polyDAB-capsid 
nanoparticles with similar dimensions (143). Icosahedral LS with negatively charged inner 
surfaces have also been used for efficient in vitro encapsulation and quantitative packing of cargo 
proteins genetically fused to positively supercharged green fluorescent proteins for use as 
nanoreactors (97, 144); (145). In an another application involving enzyme immobilization, 
researchers have described preparation of a synthetic mimic of Primordial Carboxysome by 
32 
 
attaching ribulose-1,5-bisphosphate carboxylase/oxygenase and carbonic anhydrase in a 
genetically engineered LS scaffold (146). The study showed enhanced protection of the above 
biocatalysts from proteolytic damage even if it did not lead to any increase in the overall reaction 
kinetics. Engineered LS with enhanced negative charges in its luminal surface has also been used 
as protein carrier for sequestering cytoplasmically produced HIV protease leading to efficient 
growth of cells even at higher concentrations of the toxic protein inside cells (147). Other 
applications of LS include its use as a bio-nanoreactor for the synthesis of nanophase iron oxide 
(148). 
1.1.6. Summary of the biomedical applications of LS 
LS is an enzyme involved in the biosynthesis of riboflavin. Recent work has elucidated its 
enzymatic mechanisms and structural properties. It forms oligomeric structures and has excellent 
conformational stability. These features have led to exploration of its potential biomedical utility. 
It has shown promising applications in various fields. This review is primarily focused on its use 
as an antigen presentation system for the improvement of antigen immunogenicity. Both decameric 
and icosahedral LSs have been successfully used as scaffolds to accommodate a variety of antigens 
with different sizes. These constructs have significantly increased the immunogenicity of the 
displayed antigens. LS possesses significant flexibility as a versatile scaffold for antigen 
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1.2. Inorganic scaffolds 
Various types of inorganic materials have been explored as potential scaffolds for 
polyvalent antigen display. These scaffold systems include gold nanoparticles (AuNPs), 
polystyrene beads, carbon nanotubes, etc.(149-151) Presentation of antigens onto these scaffold 
systems are achieved by direct adsorption or chemical conjugation. For instance, proteins can 
adsorb onto the surface of AuNPs via hydrophobic interaction, electrostatic interaction, and 
formation of sulfur-gold bonds, etc. However, the structural and stability of antigens upon 
adsorption or conjugation to the scaffold needs to be carefully examined to ensure preservation of 
essential conformational neutralizing epitopes. One advantage of using inorganic scaffolds is that 
their shape and size can be easily customized to achieve the optimal immunogenicity of surface 
displayed antigens. Even though most of these inorganic scaffolds are found to be biocompatible, 
they are not biodegradable. In addition, there is a lack of long-term in vivo safety data. Due to these 
issues, the development of clinical products using inorganic scaffolds has been quite challenging.  
 
1.3. Adjuvants 
Adjuvants are immunological ingredients used in vaccines to create stronger immune 
responses. There are generally three major classes of adjuvants: aluminum salts, squalene-based 
emulsions, and pathogen-associated molecular patterns (PAMPs) (e.g. Monophosphoryl lipid A, 
CpG, etc.). The selection of a suitable adjuvant for a specific antigen depends on the type of 
response the adjuvant can promote and infection mechanisms of a pathogen (intracellular or 
extracellular). For example, aluminum salts increase Th2 antibody responses, but do not elicit 
pronounced Th1 cellular responses. In contrast, emulsion adjuvants are able to induce both Th1 
(CD4+) and Th2 antibody responses (152). MPLA has been found to enhance a strong Th1 (both 
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CD4+ and CD8+) response and therefore is often effective against intracellular pathogens. 
Different types of adjuvants can be used in combination to achieve more desirable immunological 
effects. For instance, GlaxoSmithKline’s AS04 (Aka. “Adjuvant System 04”) consists of 
aluminum hydroxide (AlOH) and Monophosphoryl lipid A (MPLA). It is used in the human 
papillomavirus (HPV) vaccine-Cervarix and results in stronger and more sustained immune 
responses than AlOH alone. Other attempts have also been made to include lipophilic MPLA 
derivatives in the oil phase of emulsions (153). 
1.3.1. Aluminum salts 
Aluminum salts are the first class of approved adjuvants for human use and also currently 
the most widely used adjuvants (154). Common aluminum salts include aluminum hydroxide 
(Alhydrogel®) and aluminum phosphate (Adju-Phos®). There are two major differences between 
these two types: their physical forms and points of zero charge (PZC), the pH value at which the 
surface charge of the adjuvant is neutral. Alhydrogel® exists in a crystalline state, whereas Adju-
Phos® is found to be amorphous. In addition, Alhydrogel® and Adju-Phos® have a PZC of 11 and 
4-5.5, respectively. At pH 6 to 8 (a common formulation pH range), Alhydrogel® and Adju-Phos® 
have positive and negative surface charges, respectively. Such a difference affects their 
electrostatic interaction strength with antigens and possibly the resulting immune responses, since 
it has been long believed that the adsorption of antigens onto adjuvants is essential for enhanced 
immune responses, although this idea has occasionally been disputed. Electrostatic interactions are 
usually considered a dominate force governing interactions between antigens and aluminum 
adjuvants. Other interactions include ligand exchange, van der Waals interaction, hydrogen 
bonding, and hydrophobic interactions (155). The interaction strength between antigens and 
aluminum salts can be affected by a variety of factors: the size of protein antigens, ionic strength, 
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buffer (especially phosphate) concentration, excipient concentration, the size of adjuvant particle, 
etc. It is worth noting that adsorption of antigen to aluminum is not always a prerequisite for 
improved immunogenicity, since several studies have shown that non adsorbed antigens co-
administered with aluminum salts can induce equivalent immune responses compared to adsorbed 
antigens (156).  
1.3.2. Emulsions 
Emulsion adjuvants are classified into several different types: oil-in-water (O/W), water-
in-oil (W/O), water-in-oil-in-water (W/O/W) emulsions, etc. Among these, the O/W emulsions are 
best tolerated by humans and therefore preferable for human use. The other emulsion types are 
often used for veterinary vaccines (157). The O/W emulsions usually use squalene, a naturally 
occurring and fully metabolizable lipid, as the oil phase. A well-established example is MF59 
developed by Novartis. It has been widely used in influenza vaccines for more than two decades. 
MF59 contains emulsion droplets with a size around 160 nm. Many case studies have shown that 
MF59 induces more potent adjuvant effects (antibody levels and CD4+ responses) than aluminum 
salts most probably due to MF59’s better ability to induce Th1 (CD4+) responses. Antigens can 
interact with emulsion adjuvants via various types of interactions since emulsions are complex 
heterogeneous systems. The primary interactions include hydrophobic (with the oil phase) and 
electrostatic (with ionic surfactants) interactions. Antigen molecules hydrophobically adsorbed on 
the surface of the oil phase can establish protein-protein interactions, resulting in protein 
oligomerization and/or flocculation events. Antigen/emulsion interactions can affect the 
biophysical properties of both antigens and emulsion adjuvants. Studies have shown that 
adsorption of antigens onto the oil phase of emulsion adjuvants alters protein secondary and 
tertiary structures and enhanced protein thermal stability (158). Understanding the compatibility 
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between an antigen and an emulsion adjuvant is critical to optimize the formulation and ensure the 
safety and stability of the final vaccine product. 
1.3.3. Pathogen-associated molecular patterns (PAMPs) 
A third important class of adjuvants are also known as PAMPs. PAMPs are molecules 
broadly present in or on pathogens that can be recognized by the host’s innate immune system. 
Multicellular organisms use pattern recognition receptors (PRRs) to recognize PAMPs. Common 
PRRs are Toll-like receptors (TLR), C-Type Lectin receptors (CLR), cytoplasmic PRRs, etc. TLRs 
consist of many subclasses (TLRs 1 to 13) and are responsible for the recognition of a diverse 
array of PAMPs. TLRs are located at the cell surface or inside cell compartments. One of the most 
studied PAMPs is lipopolysaccharide (LPS), also known as lipoglycan or endotoxin. LPS is 
present on the outer cell wall of gram-negative bacteria (e.g. E. coli) and consists of both 
polysaccharide and lipid components. The polysaccharide is composed of an O-specific 
polysaccharide and core oligosaccharide. The lipid component, often called lipid A, binds to TLR 
4 and stimulates proinflammatory cytokine signaling. Although highly immunostimulatory, lipid 
A adjuvant is endotoxic and can cause septic shock. Monophosporylated lipid A (MPLA) is a safer 
version for human use and made from lipid A with deletion of a phosphate group and slight 
alterations in the fatty acid chains. MPLA can elicit both humoral and cellular responses, and is 
used in combination with aluminum hydroxide in the Cervarix vaccine. Other common PAMPs 
include flagellin, ssRNA, CpG, etc. 
1.3.4. Antigen-adjuvant Interactions from a Formulation Perspective 
Understanding the compatibility between antigens and adjuvants is important to rationally 
develop formulations that ensure long-term vaccine stability. If they are found to be compatible 
with each other over the period of the shelf life of a vaccine, they can be stored in the same vial to 
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minimize the storage cost and to simplify injection procedures. Otherwise, they should be stored 
separately and mixed prior to injection. Biophysical tools are often utilized to study the structure 
and stability of antigens in the present of adjuvants. Common techniques suitable for 
characterization of antigen-adjuvant mixtures include differential scanning calorimetry, Fourier-
transform infrared spectroscopy, size exclusion chromatography, etc. Adjuvants (e.g. aluminum 
salts, emulsions) are turbid in nature and thereby pose analytical challenges to many other 
spectroscopic techniques such as UV/Visible absorption spectroscopy, light scattering, 
conventional fluorescence, etc. Thanks to the advancement of modern instrumentation, several 
marketed instruments allow us to directly analyze proteins in highly turbid samples. For example, 
the concentration of protein in turbid sample can be directly quantified by using an integrating 
cavity absorbance spectrometer (159). High quality fluorescence spectra can be collected by 
integrating a high quality laser as the excitation source, several essential optical components to 
eliminate Rayleigh scattering, and a microplate with a suitable detection angle (160). The 
microplate format also enables screening vaccine formulations in a high-throughput manner. 
1.4. Summary and dissertation outline 
In this dissertation, we will first discuss the biophysical properties of LS, a potential protein 
scaffold for polyvalent antigen display. The conformational stability of LS in response to various 
stress conditions (e.g. chemical denaturants, temperature, and pH) will be presented. The effects 
of phosphate ions on the tertiary structure and thermal stability of LS will be discussed as well. In 
chapter 3, we will describe an attempt to use LS as the scaffold to develop highly immunogenic 
vaccine candidates against ricin toxin. The content will include the design, expression, 
purification, biophysical characterization, and in vivo immunization of the vaccine candidates. 
Although the end goal of developing highly effective ricin vaccines is not achieved, this work 
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provides valuable lessons and suggestions for future researchers, who are interested in using LS 
as a vaccine scaffold and/or in developing ricin vaccines. Chapter 4 will include a study utilizing 
biophysical tools to understand antigen-adjuvant interactions. The potential interactions between 
the alpha toxin from S. aureus and two emulsion-based adjuvants will be described, and how these 
interactions affect the protein’s structure and stability will be presented. Chapter 5 will introduce 
an improved fluorescence method for direct screening of challenging formulations (e.g. turbid 
adjuvanted vaccines, and high concentration antibodies). Chapter 6 provides a discussion, 
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Chapter 2: Effect of Phosphate Ion on the Structure of Lumazine Synthase, an Antigen 




Lumazine synthase (LS) is a metabolic enzyme present in plants, fungi and most 
microorganisms which is involved in the biosynthesis of riboflavin (vitamin B2), a compound 
involved in many biological processes (62). The catalytic reaction mechanism of lumazine 
synthase involves a condensation reaction between two compounds (5-amino-6-ribitylamino-2, 
4(1H,3H)-pyrimidinedione and L-3,4-dihydroxy-2-butanone 4-phosphate) to form 6,7-dimethyl-
8-ribityllumazine, which is then converted by riboflavin synthase to riboflavin. LS forms a homo-
oligomeric protein with a highly conserved monomeric structure among different organisms. 
Depending on the organisms, LS can form a pentamer, decamer or icosahedral 60-mer (69). The 
icosahedral LS consists of 60 monomers with a Caspar-Klug derived triangulation number of 1 
(T=1). It has a spherical shape formed by twelve identical pentamers and is often described as a 
dodecamer of pentamers (161).  
Because of its pivotal functional role in microorganism growth and interesting structural 
properties, LS has been a target of interest in recent years. The structure-function relationship of 
LS has been explored extensively to elucidate its enzymatic mechanism during the biosynthesis of 
riboflavin (55). Such knowledge has helped scientists to design antibiotics or anti-fungal drugs 
which target lumazine synthase and block the supply of riboflavin in pathogenic microorganisms 
(38, 74, 84, 162-164). LS has also been used as a carrier protein for a variety of applications in 
biomedical science. These applications include its use as a protein container (96), targeted drug 
delivery (93), bioimaging (165), construction of nanobuilding block (166), enzyme-based 
bionanoreactor (167), and vaccine development as a multi-epitope carrier (91, 168, 169). 
B. anthracis is a gram-positive bacterium and causes the life-threating disease anthrax (170). 
LS derived from Bacillus anthracis (BaLS) has been crystallized in phosphate buffer and its 
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structure was solved using X-ray crystallography (38).  Several competitive inhibitors targeting 
BaLS have been synthesized to develop antibiotics against B. anthracis. BaLS has also been 
recently used as a scaffold system to display a linear neutralizing epitope from the ricin toxin and 
the resulting fusion protein successfully elicited a serum anti-ricin antibody response in mice. 
(171) The stability and dynamic conformation of BaLS, however, has yet not been extensively 
investigated. This work describes biophysical characterizations on BaLS to obtain further 
knowledge of its conformational properties. In the present study, a series of biophysical methods 
was employed to study: 1) the chemical and thermal unfolding of BaLS; 2) the thermal stability of 
BaLS as a function of pH; 3) the origins of thermal transitions and 4) the effect of phosphate 
binding on its structure. Our data show that the native BaLS has two conformational states 
mediated through the binding/dissociation of phosphate ions. These finding provide important 
information for the design of efficient formulation of this protein as an antigen presentation system. 
2.2. Experimental methods 
2.2.1. Cloning, protein expression and purification 
The plasmid producing BaLS (pTBSG) was transformed into E. coli strain BL21 (λDE3) 
pLysS competent cells (Promega, Madison, WI) for protein expression. pTBSG plasmid and 
BL21(λDE3) were described previously (172, 173). The cells were grown in Terrific Broth 
(P212121, MI) at 37 ᵒC under shaking conditions and induced using 1mM IPTG (ThermoFisher 
Scientific, Waltham, MA) at OD600 between 0.8 to 1.0, followed by growing overnight at 20 ⁰C.  
Cells were pelleted, resuspended in anion exchange binding buffer (5 mM Tris, 5 mM EDTA, pH 
8.0) and lysed by sonication. The supernatant of the lysate were loaded onto three HiTrap Q HP 
columns (5 ml; GE healthcare, Germany) connected in series. Protein was eluted by a linear 
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gradient elution method using the anion exchange elution buffer (1M NaCl, 5 mM Tris, 5 mM 
EDTA, pH 8.0). The elution fractions containing BaLS were pooled, concentrated and loaded onto 
a Superose 6 10/300 GL column (GE healthcare, IL, USA) using PBS buffer (10 mM Na2HPO4, 
1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) as the mobile phase. The purity of BaLS 
samples was analyzed by SDS-PAGE (12%, w/v). The SDS-PAGE data has been reported 
previously and showed that BaLS had acceptable purity.(174) Purified BaLS (at 2 mg/ml) was 
stored at -80 ᵒC in PBS buffer for future use. BaLS samples were thawed at room temperature and 
filtered through syringe filters (0.1 μm, Millex, Billerica, MA) before biophysical analysis. The 
molecular weight (MW) of the LS oligomer was determined using multiangle light scattering and 
was reported previously.(174) The determined MW matched with the theoretical MW based on a 
60-mer.  
2.2.2. Far-UV Circular Dichroism (CD) 
Far-UV CD spectra were measured using an Applied Photophysics Chirascan-plus CD 
spectrometer equipped with a 6-position, Peltier-controlled cell holder (Applied Photophysics, 
UK). Protein samples (at 0.2 mg/ml) were loaded into a 1-mm quartz cuvette and the spectra were 
obtained from 200 nm to 260 nm in 1-nm increment with an integration time of 1 sec per data 
point. For thermal melting experiments, the temperature ramp was performed from 10 to 95 o C and 
the CD spectra were recorded every 2.5 ᵒC with an equilibration time of 2 min at each temperature 
point. 
2.2.3. Intrinsic tryptophan fluorescence and static light scattering 
Intrinsic tryptophan (Trp) fluorescence was measured using a steady-state fluorometer 
(Photon Technology International, NJ). Protein samples (at 0.2 mg/ml) loaded in a 1X1 cm quartz 
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cuvette were excited at 295 nm (> 95% Trp emission) and the emission spectra were collected 
from 310 to 400 nm at one nanometer intervals with an integration time of 1 sec per data point. 
Both excitation and emission slit widths were set to 4 nm. The mean center of spectral mass peak 
position (MSM peak position) and ratio of fluorescence intensity at 330 to 350 (F330/F350) values 
were calculated from the buffer-subtracted spectra using an in-house software (Middaugh suite) 
(175). The MSM peak values are approximately 8 to 10 nm higher than the actual peak position 
but results in a better signal to noise ratio. The static light scattering of BaLS was collected 
simultaneously with the measurement of intrinsic tryptophan fluorescence using a second PMT 
detector placed at 180⁰ to the fluorescence detector. The signal was collected at 295 nm with an 
integration time of 1 sec. Thermal melt studies were performed from 10 to 99 ⁰C with an increment 
of 2.5 ᵒC and an equilibration time of 2 min. 
2.2.4. Dynamic light scattering 
Dynamic light scattering (DLS) was performed using a DynaPro (Wyatt Technology, Santa 
Barbara, CA) DLS plate reader. Protein samples were added into a 384-well plate flat clear bottom 
black plate (Corning Incorporated, Corning, NY). Each sample was measured 5 times with an 
acquisition time of 30 sec each time.  A cummulant analysis was performed and intensity-averaged 
hydrodynamic diameters were reported. For thermal unfolding studies, silicone oil was added to 
cover sample surfaces to avoid sample evaporation at high temperature. Temperature was set from 
25 to 80 ⁰C and measurements were taken every 2.5 ⁰C with an equilibration time of 2 min at each 
temperature. 
2.2.5. Extrinsic fluorescence 
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Extrinsic fluorescence study was performed using an Mx3005P qPCR system (Agilent 
Technologies, Santa Clara, CA). A Sypro orange stock (5000 x) (Invitrogen, Inc. Carlsbad, 
California) was added to BaLS samples (at 0.2 mg/ml) at a dilution factor of 1000 and incubated 
for 30 min prior to analysis. The samples were excited at 492 nm and emission was collected at 
610 nm. For thermal studies, the temperature was ramped from 25 to 99 ⁰C using 1 ⁰C as step size 
with an equilibration time of 2 min at each temperature.  
2.2.6. Differential scanning calorimetry 
Differential scanning calorimetry was performed with MicroCal VP-Capillary DSC 
(Malvern, UK) to study the overall conformational stability of BaLS. Four hundred microliters of 
BaLS samples were loaded into a 96-well plate and stored at 5 ⁰C. Samples were scanned from 10 
to 110 ⁰C at a rate of 1 ⁰C/min using a filtering period of 16 sec. The data were processed using 
Origin 7.0 (OriginLab; Northampton, MA). 
2.2.7. Chemical unfolding of BaLS 
Chemical unfolding of the BaLS in PBS buffer containing 1mM DTT (PanReac 
AppliChem, Maryland Heights, MO) was performed by addition of increasing amounts of the 
chaotrope. BaLS samples (at 0.2 mg/ml) containing either urea (up to 8.5 M with an increment of 
0.5 M) or guandidine HCl (up to 6 M with an increment of 0.25 M) were equilibrated for 24 hr or 
4 hr, respectively, to reach equilibrium. The samples were then analyzed using CD, intrinsic Trp 
fluorescence, extrinsic fluorescence, static light scattering, and dynamic light scattering. All 
measurement was performed at 25 ⁰C.  
2.2.8. Thermal stability of BaLS 
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The thermal unfolding profiles of the BaLS (at 0.2 mg/ml) in PBS buffer were collected 
using CD, intrinsic Trp fluorescence, static light scattering and dynamic light scattering. The 
thermal stability of BaLS as a function of pH (5.0, 6.0, 7.0 and 8.0) was further studied. BaLS 
samples were dialyzed against 20 mM citrate-phosphate buffers (I = 150 mM adjusted by NaCl) 
overnight at 4 ⁰C and the protein concentration was adjusted to 0.2 mg/ml. For pH dependent 
thermal stability studies, DSC and extrinsic fluorescence were added as additional methods. 
Thermal unfolding curves were plotted and the melting temperature (Tm) was calculated by a first 
derivative method using Origin 8.0 (OriginLab; Northampton, MA).  
Radar charts were constructed using multiple biophysical data sets collected over a range 
of pH and temperature (CD, DSC, light scattering, extrinsic fluorescence and intrinsic 
fluorescence) to visualize the thermal stability of BaLS using in-house software (MiddaughSuite). 
(175) The construction of the radar chart was previously described. (175) All radar charts were 
then integrated to generate an empirical phase diagram (EPD) (71) showing protein structural 
changes as a function of pH and temperature. A k-means clustering algorithm was applied to define 
boundaries for different regions.(176) Within each cluster, data were averaged to create a radar 
chart with five radial axes corresponding to separate biophysical data sets. For each radial axis, the 
minimal value of that specific data within that cluster was mapped to the center of the radar chart 
and the maximum value to the outer circumference. A polygon generated by connecting values in 
each axis represents the structural state within that cluster.(175-177) A polygon corresponding to 
the native state of proteins has a relatively small area and a larger polygon area indicates more 
structurally altered states. 
2.2.9. The origin of two thermal transitions by DSC 
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To better understand the origin of the thermal transitions detected with BaLS, protein 
samples in PBS buffer of increasing concentration (0.2 to 1.0 mg/ml) were analyzed by DSC. The 
Tm values were plotted as a function of protein concentration. BaLS sample was then dialyzed 
against 10 mM citrate buffer (pH 6.0) at 4⁰C overnight. Final protein concentration was adjusted 
to 0.2 mg/ml for DSC analysis. 
Aldehydes have been found to readily react with the guanidino group of arginine (178, 
179)  and therefore can be used to deactivate phosphate binding sites (in this case Arg126) of 
BaLS. To prepare enzymatically inactivated BaLS, samples were dialyzed against 20 mM citrate-
phosphate buffer pH 8.0 and the protein concentration was adjusted to 1.0 mg/ml. Molar ratio 
excess amounts of formaldehyde (100 µL, 37% w/w, ThermoFisher Scientific, Waltham, MA) 
were mixed with 0.5 mL BaLS samples (at 1.0 mg/ml). The reaction mixture was kept at room 
temperature for 30 min and was then quenched by addition of 250 μL of 1M Tris solution (pH 7.8) 
(Sigma, St. Louis, MO). The formaldehyde-treated BaLS was dialyzed against 20 mM citrate-
phosphate buffer pH 6.0 and analyzed using DSC. 
2.2.10. Phosphate binding on BaLS conformation 
BaLS samples (at 0.2 mg/ml) were prepared in 20 mM citrate buffer pH 6.0 with an 
increasing concentration of sodium phosphate (0 to 500 mM), potassium phosphate (0 to 500 mM) 
or sodium pyrophosphate (0 to 15 mM) or in a base buffer (10 mM citrate, 50 mM phosphate 
buffer, pH 6.0) containing an increasing concentration of sodium chloride (0 to 500 mM). These 
protein samples were subjected to extrinsic fluorescence and intrinsic Trp fluorescence analysis. 
For the extrinsic fluorescence study, the fluorescence intensities at 25 ᵒC or Tm1 values were 
plotted against phosphate or NaCl concentration. BaLS samples containing sodium phosphate (0 
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to 500 mM) were also analyzed by DSC to validate the Tm values obtained from extrinsic fluoresce 
analysis. The intrinsic fluorescence study was performed at 25 ᵒC and the MSM peak position and 
F330/F350 value were plotted against phosphate or NaCl concentration. 
2.3. Results 
2.3.1. Chemically induced unfolding 
Conformational alternations of BaLS at 25 ⁰C in response to increasing concentration of 
urea or guanidine HCl were monitored by various techniques (Figure 2.1). The CD signal was 
collected at 222 nm where both urea and guanidine are CD transparent. The increase in CD signal 
(becoming less negative) is an indication of loss of secondary structure. As shown in Figure 2.1A, 
guanidine is able to unfold the BaLS at a much lower concentration than urea suggesting that 
guanidine is more effective in altering the secondary structure of BaLS, as is usually seen with 
most proteins. Guanidine (at 6 M) was able to unfold to BaLS to a larger extent than urea (at 8.5 
M). Tertiary structure changes of BaLS during chemical unfolding was monitored by Sypro orange 
fluorescence. Sypro orange binds to exposed hydrophobic regions and such binding results in an 
increase in the fluorescence signal. Dramatic differences in the unfolding profiles of BaLS induced 
by urea and guanidine (Figure 2.1B) were observed. Urea unfolding of BaLS shows a simple 
profile with a sigmoidal shape. In contrast, guanidine caused a sudden increase in the Sypro orange 
fluorescence signal followed by a quick drop. Guanidine at low concentration (< 2 M) is able to 
induce much greater exposure of apolar regions in BaLS than urea.  The decrease in the Sypro 
orange fluorescence signal at high guanidine concentration (> 2 M) is probably because of the 
dissociation of the dye from the protein induced by aggregation of the unfolded protein.(180) The 
urea induced unfolding of BaLS monitored by intrinsic Trp fluorescence analysis (MSM peak 
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position and F330/F350) shows one transition, while guanidine induces a biphasic denaturation 
profile (Figure 2.1C and 2.1D). Compared to urea, guanidine, at a lower concentration, is able to 
alter BaLS and expose buried indole side-chains to a more polar environment. The aggregation 
behavior monitored by static light scattering is plotted in Figure 2.1E. Urea (at 8.5 M) induced a 
slight decrease in the static light scattering signal and possibly resulted in the altered BaLS with a 
less dense structure with a decreased dn/dc value. Guanidine (≤ 1 M), however, caused a dramatic 
increase in the signal indicating the formation of large aggregates. At relatively higher guanidine 
concentrations (> 1 M), the static light scattering signal of BaLS considerably dropped and quickly 
reached a level even lower than that of BaLS in 8.5 M urea (Figure 2.1E inset). Such observations 
may reflect that 6 M guanidine rather than 8.5 M urea is able to induce a more complete 
dissociation and unfolding of the icosahedral structure of BaLS.  
The hydrodynamic diameter (dh) of BaLS in the presence of urea or guanidine were then 
studied using dynamic light scattering (Figure 2.1F). Urea (at 8.5 M) only caused a minor increase 
(approximately 0.4 nm) in the dh of BaLS. This indicates that the assembly state of BaLS probably 
remained unchanged in the presence of 8.5M urea. The slight increase in dh was presumably 
because of the “swelling” of the particle which correlates well with a possible reduced dn/dc value 
of BaLS observed by static light scattering. In contrast, guanidine resulted in formation of 
aggregates of BaLS at a concentration above 0.5 M (data not shown). The dh of BaLS in the 
presence of guanidine (at 1 to 2 M) could not be reproducibly measured because of the presence 
of large aggregates and the heterogeneity of the sample. At higher denaturant concentrations (> 
2.0 M), guanidine decreased the dh of BaLS which eventually dropped below 2 nm. Guanidine at 
low concentration, therefore, causes aggregation of BaLS, but completely dissociates and unfolds 
BaLS at a relatively high concentration. 
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Based on the data collected, chemically induced unfolding pathways induced by urea (up 
to 8.5 M) and guanidine (up to 6 M) of BaLS can be proposed. A mono-phasic unfolding profile 
of BaLS by urea (up to 8.5 M) in PBS was observed using all biophysical techniques indicating a 
two-state denaturation process. Urea at 8.5 M is able to convert BaLS into a partially unfolded 
state with a possibly loosen structure but an unchanged assembly state. In contrast, guanidine 
denatures BaLS through multiple phases. A putative intermediate state of BaLS exists in the 
presence of low guanidine concentration (at 1 M). Such state has exposed hydrophobic regions 
and is prone to aggregation which is a phenomenon commonly observed for guanidine 
denaturation of protein (181). The secondary structure of this intermediate remained unchanged 
when guanidine concentration is less than 1.5 M (Figure 2.1A) indicating that the intermediate is 
essentially a molten globular state.  
2.3.2. Thermal unfolding of BaLS 
The secondary structure of BaLS in PBS buffer in response to thermal stress were studied 
using CD (Figure 2.2A). The CD signal at 222 nm plotted as a function of temperature suggests 
thermal unfolding initiating above 80 ⁰C, indicating strong thermal stability of BaLS in PBS 
buffer. The temperature was ramped up to 95 ⁰C at which BaLS was not yet fully unfolded. The 
tertiary structure of BaLS was analyzed using intrinsic Trp fluorescence (Figure 2.2B). BaLS 
contains two Trp residues (Trp 51 and Trp 151) in each monomer. A mean spectral center of mass 
(MSM) method was used to calculate the peak position of the emission spectra at each temperature. 
The ratio of the emission intensity at 330 and 350 (F330/350) was also plotted as a function of 
temperature to monitor alterations in the protein’s tertiary structure. Both MSM peak position and 
F330/F350 plots show two distinct thermal transitions (Figure 2.2B) and correlate well with each 
other. The aggregation behavior of BaLS in PBS buffer was monitored by plotting the static light 
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scattering intensity as a function of temperature (Figure 2.2C). Only one thermal transition 
(starting from 80 ⁰C) was observed. The hydrodynamic diameter of BaLS did not show any 
significant change from 25 to 80 ⁰C as analyzed by dynamic light scattering (Figure 2.2D). The 
thermal transitions were in good agreement with those of BaLS previously determined using DSC 
and Sypro orange extrinsic fluorescence (171). In addition, the first thermal transition was found 
to be reversible (Figure 2.S2). 
The biophysical properties of BaLS as a function of pH and temperature were further 
investigated. Protein samples dialyzed at pH 5.0 overnight at 4 ⁰C precipitated and therefore was 
not subjected to biophysical studies. The thermal stability of BaLS samples (at 0.2 mg/ml) dialyzed 
at pH 6.0, 7.0 and 8.0 were characterized using various methods (Figure 2.3). As shown in Figure 
2.3H, radar charts constructed from multiple sets of biophysical data showed five structurally 
distinct regions over the pH (5.0 to 8.0) and temperature range (25 to 99 ᵒC) studied here. Region 
I corresponds to the native state of BaLS. Region II indicates the early thermal transition of BaLS 
that indicates only a slight conformational alternation. Region III represents the structural state 
post the first thermal transition. Region IV indicates the main thermal transition of BaLS. Region 
V indicates protein precipitation. Overall two pH-dependent thermal transitions were observed. 
Under these pH conditions, BaLS has the highest Tm values for both transitions at pH 7.0. 
Interestingly, the early thermal transition was not observed using CD, static light scattering or 
dynamic light scattering (Figure 2.3A, 2.3C and 2.3D), but clearly appeared in melting curves 
monitored using the other techniques. This suggests that the early transition is associated with an 
alteration in the protein’s tertiary structure rather than its secondary structure or assembly state. 
2.3.3. The origin of the two thermal transitions of BaLS seen by DSC 
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DSC was performed to better tease out the origin of thermal transitions of BaLS. The 
dissociation behavior of an oligomeric protein under thermal stress can be studied using DSC by 
examining protein samples of increasing concentrations. If protein dissociation is coupled with 
thermal unfolding, protein samples at a higher concentration are expected to manifest higher 
apparent Tm values.(182) A previous study has confirmed that LS in solution exists as an 
icosahedral oligomer consisting of 60 identical monomers using multiangle light scattering.(171) 
The concentration dependency of the thermal transitions of LS in 20 mM citrate-phosphate buffer 
pH 6.0 studied using DSC are shown in Figure 2.4A. For protein concentrations ranging from 0.2 
mg/ml to 1.0 mg/ml, Tm1 is independent of the protein concentration, while Tm2 increases with 
increasing protein concentration. This suggests that the dissociation of oligomeric BaLS is 
involved in the second thermal transition. This result correlates with the observation that protein 
hydrodynamic diameters did not change from 25 to 80 ᵒC using DLS. Unfortunately, the DLS 
instrument cannot be used at temperatures exceeding 80 ᵒC where the oligomeric structure could 
be altered. Furthermore, aggregation also prevents any direct observation of dissociation events. It 
can therefore be concluded that the late thermal transition results from the dissociation and 
unfolding of the oligomeric BaLS.  
A phosphate ion has been found to bind to the enzymatic site of BaLS, a pocket located at 
the interface between two neighboring BaLS subunits.(38) Phosphate ions interact with Arg126 
on one monomer, Thr85’ and Ala84’ on a joining subunit (Figure 2.5). Interface energy 
calculations were performed on the subunit pentamer, obtained from lumazine synthase from 
Bacillus anthracis (PDB ID: 1VSW), either bound or unbound with phosphate ions (Table 2.1). 
The starting conformations were minimized in Yasara Structure (183) for 5 nanoseconds. The two 
pentamers (bound & unbound), were then analyzed for interfacial residue stabilization energy with 
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the PISA module (Proteins, Interfaces, Surface, and Assemblies service at the European 
Bioinformatics Insitute) (184). The calculations showed that each phosphate ion increased the 
stability of the interface assembly by approximately 6 kcal/mol (with both intra and inter-chain 
contacts, Table 2.1). 
The effect of phosphate binding on the conformational stability of BaLS was studied by 
DSC. Figure 2.4B shows that the early thermal transition of BaLS completely disappeared in a 
non-phosphate containing buffer (10 mM citrate buffer, pH 6.0) or in a phosphate containing buffer 
(20 mM citrate-phosphate buffer, I = 150 mM adjusted by NaCl, pH 6.0) after the deactivation of 
active sites by formaldehyde treatment. The disappearance of Tm1 of BaLS in a non-phosphate 
containing buffer or after formaldehyde treatment confirms the direct correlation of 
BaLS/phosphate binding events with the occurrence of the early thermal transition (Tm1). Thus, 
the first thermal transition can presumably be attributed to the thermal dissociation of phosphate 
ions from active sites on BaLS. 
2.3.4. Phosphate binding on the conformation of BaLS 
The level of exposure of hydrophobic regions on BaLS and the Tm1 values of BaLS in the 
presence of varying concentrations of three different phosphate salts were monitored using Sypro 
orange extrinsic fluorescence. In the absence of phosphate ions, BaLS did not show the early 
transition (Figure 2.S1) and this result was in good agreement with the DSC data (Figure 2.5B). 
As shown in Figure 2.6A, Tm1 increased as sodium phosphate concentration increases and these 
Tm1 values are in good agreement with Tm values obtained from the DSC analysis. Sodium 
phosphate at 500 mM is able to increase the Tm1 by more than 30 ⁰C. Such a large shift is attributed 
to the stabilization of the protein by phosphate binding. It was also noted that the Sypro orange 
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fluorescence intensity of BaLS decreased when sodium phosphate concentration increased at 25 
⁰C (Figure 2.6A). This suggests that sodium phosphate decreased the exposure level of apolar 
regions of LS. Both potassium phosphate and sodium pyrophosphate resulted in a similar trend on 
the Tm1 value and the exposure level of hydrophobic regions as sodium phosphate (Figure 2.6B 
and 2.6C). Compared to phosphate salts, sodium pyrophosphate, a diphosphate ion, was able to 
more efficiently decrease the Sypro orange fluorescence intensity of BaLS to the same level as at 
a much lower concentration, possibly because it has a higher association constant with BaLS.  
In the base buffer (10mM citrate, 50mM phosphate buffer, pH 6.0), titration of NaCl, 
however, resulted in a decrease in protein Tm1 values but an increase in the Sypro orange 
fluorescence intensity of BaLS (Figure 2.6D). Because ionic interactions of Arg126 are involved 
in formation of the BaLS/phosphate complex, addition of NaCl increases the ionic strength and 
weakens interactions between phosphate and BaLS. Such an effect thereby drops Tm1 values and 
increases the exposure of hydrophobic regions. This result in turn confirms that titration of 
phosphate salts into BaLS samples alters protein conformation (Figure 2.6A, 2.6B and 2.6C) 
through specific BaLS/phosphate interactions rather than just increases in ionic strength.  
The effect of phosphate ion on the tertiary structure of BaLS at 25 ⁰C was studied using 
intrinsic Trp fluorescence. The MSM peak position and F330/F350 value of a protein are 
associated with the overall polarity of the neighboring environment of tryptophan in the protein. 
These two parameters were recorded to monitor alterations in protein tertiary structures in response 
to increasing concentration of phosphate ions or sodium chloride. All three phosphate salts resulted 
in changes with the same trend (Figure 2.7A, 2.7B and 2.7C). LS in the presence of higher 
phosphate concentrations underwent a blue shift of λem with an increased F330/F350 value 
indicating reduced solvent accessibility of Trp residues. Addition of NaCl into BaLS stored in a 
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base buffer (10 mM citrate, 50 mM phosphate, pH 6.0) resulted in a red shift of λem and a decrease 
in the F330/F350 ratio (Figure 2.7D). This presumably reflects a reduction in BaLS/phosphate 
interactions in response to the increasing ionic strength. The data correlate well with the Sypro 
orange extrinsic fluorescence analysis. It can therefore be concluded that BaLS/phosphate 
interactions are able to reduce the solvent accessibility of Trp residues in BaLS.  
2.3.5. Pathway 
A hypothetical pathway of the thermal unfolding of BaLS is proposed in Figure 2.8. In 
phosphate-free buffers, BaLS adopts a conformation (N2) with icosahedral symmetry. In the 
presence of phosphate ions, they bind to BaLS rendering a subtle conformational change and 
resulting in protein conformation (N1) that is a relatively more “compact”, with lower exposure of 
hydrophobic regions and Trp residues. Upon heating, the complex starts to pay an entropy penalty 
until eventually phosphate ions dissociate from BaLS at a high temperature (e.g. 50 ⁰C in PBS 
buffer) and BaLS turns into N2 conformation again. Further thermal stress on LS (N2) causes the 
dissociation and unfolding of BaLS. 
2.4. Discussion 
A comprehensive biophysical analysis of the conformation of BaLS was performed in the 
present study. This analysis required a total of 45 mg of protein. The chemically induced unfolding 
of BaLS using urea or guanidine HCl showed two distinct unfolding profiles. In contrast to 
guanidine, urea was much less effective in altering the conformation of BaLS both kinetically (urea 
unfolding takes approximately one day to reach equilibrium) and thermodynamically. Even in the 
presence of 8.5 M urea, BaLS is only partially unfolded and apparently still maintains its 
icosahedral assembly. Goldbaum et al has reported that a decameric BaLS derived from Brucella 
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sp. showed no changes in protein secondary or tertiary structures in the presence of 8 M urea.(40) 
This indicates an exceptional stability of the quaternary structure of BaLS to high urea 
concentration. In contrast, BaLS was completely denatured by guanidine HCl at 3M. Because 
BaLS/phosphate binding involves ionic interactions with R126, an ionic shielding effect by 
electrolytes such as guanidine HCl can weaken and perhaps even dissociate the BaLS/phosphate 
complex with induction of a conformational change. Thus, the dissociation of the BaLS/phosphate 
complex was apparently involved in the guanidine denaturation of BaLS and may in part contribute 
to its multi-phasic unfolding profile. 
The thermal unfolding study showed that BaLS in PBS has considerable thermal stability 
with a primary thermal transition above 80 ⁰C. The transition with a Tm around 50 ⁰C is only 
observed by techniques which are expected to detect protein tertiary structure and overall 
conformation changes (intrinsic fluorescence, extrinsic fluorescence and DSC). Further 
investigation using these techniques showed that the first thermal transition of BaLS originates 
from the dissociation of phosphate ions and the second from the dissociation and unfolding of the 
icosahedral structure. The presence of the two conformational states was further confirmed using 
Sypro orange extrinsic fluorescence and intrinsic fluorescence. The binding of phosphate to BaLS 
(N2) induces a slight conformational change rending a protein state (N1) with less exposed 
hydrophobic regions and Trp residues. Conformation N1 seems to be more compact which could 
be attributed to phosphate ions having polar interactions with residues from two neighboring 
subunits along the twofold icosahedral axis. The difference between the two states (N1 and N2) 
was relatively minor and was not detected using dynamic or static light scattering. 
This work may offer insights into the molecular mechanism of the enzymatic function of 
BaLS. Phosphate binding to the enzymatic pocket is highly conserved for LS from various 
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organisms. Therefore, the observed conformational change of BaLS upon phosphate binding may 
also occur for other orthologous LS as well. Because phosphate ions and the phosphate moiety of 
the substrate (L-3,4-dihydroxy-2-butanone 4-phosphate) bind to the same pocket on LS, binding 
of this substrate may also induce a similar or even more pronounced (because of more extensive 
interactions) structural changes to LS to render a relatively closed conformation. Upon the 
formation and subsequent release of the product, LS changes back to the open conformation (N2). 
These structural dynamics of LS during catalysis may also explain the unsolved question of how 
the product is released from the inside of the complex. 
The enzymatic activity of BaLS occurs in the interior of the oligomer to produce lumazine 
which is further used to synthesize riboflavin by riboflavin synthase which is encapsulated inside 
the BaLS cavity.(62) X-ray crystal structures of BaLS show that the size of the largest port (i.e. 
the channel along the fivefold symmetry axes) in BaLS is still not wide enough to permit these 
two bulky compounds to diffuse out of the enzyme’s interior. This indicates that an alternative 
conformation with a wider opening must exist for BaLS during catalysis. The X-ray crystal 
structures of icosahedral BaLS from various organisms (B. anthracis, B. subtilis, S. pombe, and A. 
aeolicus) have all been obtained in phosphate-containing buffers in which LS may adopt a 
relatively closed conformation (N1) with a narrow port not sufficient for product exit. Our data 
shows that BaLS without phosphate bound has an “open” conformation (N2) with possibly broader 
channels that may serve as an intermediate conformation permitting the exit of product. The 
binding of the substrate and release of the product may sequentially alter the size of the channel 
and control the release of the product.  This work also supports the “breathing” motions of the 
enzyme during catalytic cycles proposed by Ladenstein et al.(62) These results may also explain 
why LS has never been successfully crystallized in a phosphate-free buffer system.(43) This may 
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be attributed to an increased hydrophobicity of LS in the absence of phosphate ions. Lastly, these 
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2.6. Figures and Tables 
2.6.1. Tables 
 











Pentamer 1298.8 -13.5 0.3 9 6 
Pentamer_PO4 1273.2 -12.9 0.3 10 6 
PO4_intrachai
n 
80.8 -5.1 0.7 2 0 
PO4_interchain 41.7 -1.1 0.9 2 0 
 
Table 2.1. Average interface energy of Lumazine Synthase pentamer in the absence and presence 
of phosphate ions. The intra and inter-chain contribution of phosphate binding is also shown. The 
energy calculations (184) were performed on pentamer constructs that were minimized for 5 ns in 
Yasara Structure (183), with and without bound phosphate ions (Pentamer derived from PDBid: 
1VSW). Interface area (Å2) represents the difference in surface area that is accessible between 
monomeric and pentameric assembly states. ΔG of the interface is a thermodynamic term 
describing the change in solvation free energy when transitioning from a monomer to an assembled 
pentamer. The P-value of the interface indicates the probability of interfacial hydrophobicity, with 









Figure 2.1. Chemically induced unfolding of BaLS in PBS buffer using urea and guanidine 
chloride at 25 ⁰C monitored by (A) CD signal at 222 nm; (B) Sypro orange fluorescence; (C) Mean 
spectral center mass peak position calculated from intrinsic Trp fluorescence measurement; (D) 
The ratio of fluorescence intensity at 330 nm by 350 nm calculated from intrinsic Trp fluorescence 
measurement; (E) static light scattering; (F) dynamic light scattering; (G) Proposed chemical 






Figure 2.2. Thermal unfolding of BaLS (at 0.2 mg/ml) in PBS buffer monitored by (A) the CD 
signal at 222 nm; (B) intrinsic Trp fluorescence; (C) static light scattering at 295 nm; (D) dynamic 





Figure 2.3. The thermal stability of BaLS as a function of temperature and pH monitored by (A) 
the CD signal at 222 nm; (B) Sypro orange fluorescence; (C) static light scattering; (D) dynamic 
light scattering; (E) MSM peak position; (F) The ratio of fluorescence intensity at 330 nm by 350 
nm; (G) differential light scattering; (H) Empirical phase diagram and radar charts of BaLS 
constructed using data from CD, light scattering, MSM peak position, Sypro orange extrinsic 





Figure 2.4. DSC thermograms of (A) BaLS (at 0.2 to 1.0 mg/ml) in citrate-phosphate buffer pH 
6.0. The inset graph shows Tm values as a function of the concentration of BaLS; (B) BaLS (at 
0.2 mg/ml) in citrate-phosphate buffer pH 6.0, BaLS in 20 mM citric buffer pH 6.0, formaldehyde 





Figure 2.5. Structural representations of the BaLS/phosphate complex. (A) A pentameric block of 
BaLS viewed along the fivefold symmetry axis. Each monomer is shown in a different color and 
phosphate ions shown as red spheres at the active sites. (B) An expanded view of the active site of 
BaLS with bound phosphate ion. Each phosphate ion make polar interactions with Arg126, Thr85’ 
and Ala84’ indicated using blue dashed lines. Figures were made based on the crystal structure of 





Figure 2.6. Effects of the phosphate concentration on Tm1 values and the Sypro orange 
fluorescence intensity of BaLS (in 10 mM citrate pH 6.0) at 25 ᵒC by titration of (A) sodium 
phosphate. The open square represents the DSC Tm values; (B) potassium phosphate; (C) sodium 





Figure 2.7. Effects of phosphate concentration on the MSM peak position and F330/F350 value 
of BaLS (in 10 mM citrate pH 6.0) by titration of (A) sodium phosphate; (B) potassium phosphate; 
(C) sodium pyrophosphate; (D) sodium chloride in presence of 50 mM sodium phosphate. Error 










Figure 2.S1. Melting curve of BaLS in PBS buffer measured using Sypro orange extrinsic 






Figure 2.S2. Thermal unfolding and refolding of BaLS (at 0.2 mg/mL) in PBS buffer measured 
using intrinsic tryptophan fluorescence. BaLS samples were excited at 295 nm and emission 
spectra were collected from 300 to 400 nm. To investigate the reversibility of the first transition 
of BaLS (at ~50 ᵒC), a temperature ramp was run from 25 to 60 and finally returned to 25 ᵒC. The 
fluorescence was recorded every 2.5 ᵒC with an equilibration time of 2 min at each temperature. 
MSM peak position was calculated employing Matlab (Natick, MA). This transition was found to 
be thermally reversible. Error bars are standard deviations (N=4). 
 
  




























Chapter 3: Evaluation of Lumazine Synthase from Bacillus anthracis as a 




Polyvalent antigen display has become a powerful strategy to enhance the immunogenicity 
of subunit vaccine antigens (185). This strategy generates vaccine candidates which present 
multiple copies of an antigen on the surface of a scaffold and thereby mimic the surface of 
microbial pathogens. B cells, in particular, react strongly to exogenous antigens that have repetitive 
structures. At the molecular level, a high local density of structurally ordered antigens triggers 
activation of the B cell receptor (BCR), which promotes B cell activation and proliferation (20). 
In contrast to monomeric antigens, polyvalent antigen display can generate IgG secretion and long-
lived memory B cells in a more efficient manner. For example, Baschong et al. found that the 
presentation of antigenic systems in a repetitive array on viral surfaces elicited higher antibody 
level than those elicited by non-oligomeric proteins (25). This general strategy has been 
successfully employed with natural self-assembling antigens to develop vaccines for prevention 
of hepatitis B virus and human papillomavirus and others under development  (28).  
Many classes of scaffold nanoparticle systems have been examined for use in polyvalent 
antigen display including synthetic polymers, self-assembled proteins, inorganic particles, and 
various others (186). Self-assembling proteins are one of the more attractive scaffold systems 
because they offer precise size control, ease of production using recombinant DNA technology, 
and biocompatibility (173). The aim of this work is to evaluate the potential of a self-assembling 
protein, lumazine synthase (LS), as a scaffold system for polyvalent antigen display. LS is an 
enzyme involved in the biosynthesis of riboflavin in bacteria, fungi and plants. LS synthesizes 6,7-
dimethyl-8-ribityllumazine, which is then catalyzed by riboflavin synthase to form riboflavin (62). 
LS exists as a homo-oligomer and its oligomeric state (e.g., pentamer, decamer, or 60mer) varies 
depending on the species.  
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The structure of LS, especially the 60-mer capsid, has inspired immunologists to explore 
its use as a scaffold for vaccine development (92, 93). LS consists of 60 identical monomers 
forming an icosahedral quaternary structure (T = 1 state) capsid with a diameter of about 16 nm. 
The least-common multiple assembly unit for LS is a pentameric block, of which twelve pentamers 
coalesce into a quasi-sphere, forming along the five-fold symmetry axes of an icosahedron.  The 
N- and C-termini of all LS monomers are surface exposed and face outwards (38). Antigens of 
interest can be fused to either or both of the two termini without inhibiting scaffold formation. 
Moreover, the icosahedral LS system shows significant conformational stability (187). These 
features make icosahedral LS an attractive scaffold to display antigens. For example, the 
icosahedral LS from Aquifex aeolicus has been used for the presentation of the HIV-1 envelope 
glycoproteins gp120 (92). LS derived from B. anthracis is an icosahedral oligomer (38) and has 
not been studied as a vaccine delivery system, even though it is a potentially attractive platform 
for subunit vaccines. Therefore, a B. anthracis variant of LS was studied here as a vaccine display 
platform by presenting a known linear neutralizing epitope from ricin. 
Ricin is a ribosome-inactivating protein (RIP) produced by the castor bean plant, Ricinus 
communis, which is grown worldwide for the production of castor oil. Ricin is toxic to humans 
through several routes of exposure, including injection and inhalation (188). Due to its ease of 
preparation and high toxicity, ricin is classified as a biothreat agent (189). There are, however, no 
available FDA-approved vaccines or antidotes against ricin (190). Therefore, there is an urgent 
need to develop an effective ricin vaccine to protect both first responders and the public from the 
threat of ricin.  
Several linear B-cell epitopes have been identified on ricin, as defined by a collection of 
toxin-neutralizing monoclonal antibodies (MAbs) (191). The MAb PB10, for example, binds an 
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immunodominant linear epitope on ricin’s enzymatic subunit (RTA). PB10 has an estimated 
equilibrium dissociation constant (KD) of less than 10 pM and has been shown to passively protect 
mice against lethal dose ricin challenge via injection or inhalation.  Kumar et al. successfully 
displayed on the surface of tomato bushy stunt virus a 16-amino acid peptide that encompasses 
12-residues of PB10 epitope (192). The resulting construct elicited serum antibodies in mice that 
recognized RTA by Western blot analysis. However, no in vivo challenge studies were attempted 
to test the efficacy of the candidate vaccine. Nonetheless, the study successfully demonstrated that 
the PB10 epitope when conjugated onto a virus-like particle is immunogenic in mice. For that 
reason we chose to display PB10 peptide as model epitope to be fused to the C terminus of LS to 
develop novel ricin vaccine candidates (designated here as LS_PB10).  
Since the immunogenicity of epitopes displayed on a scaffold system is influenced by 
several factors including the length and rigidity of the linker (193, 194) as well as the plasticity of 
the scaffold (140), LS_PB10 constructs containing four linkers with varying length and rigidity 
were produced and the effects of linkers on protein stability and immunogenicity were examined. 
The rigidity of the LS_PB10 scaffold was also enhanced by intra-molecular crosslinking using 
formaldehyde which is a commonly used chemical crosslinker and has been previously used to 
stabilize HIV virions and induce high-titer neutralizing antibodies against HIV in mice and rabbits 
(195, 196). In the present study, the feasibility of LS as a potential presentation platform for 
polyvalent antigen display was systematically investigated.  
3.2. Experimental Procedures 
3.2.1. Plasmids and Bacterial Strains 
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The plasmid producing LS (pTBSG) was transformed into E. coli strain BL21 (λDE3) competent 
cells for protein expression. pTBSG plasmid and BL21(λDE3) were described previously (172, 
173). The PB10 epitope was fused to the C terminus of LS with a linker. The chimeric gene 
fragment (LS_PB10_78) was cloned into a pET9a vector by Genscript® (Piscataway, NJ). The 
restriction sites used were BamHI and HindIII. The upstream T7 tag was later removed by PCR 
with the primers Forward 5’-
GGAGATATACATATGGTTTTTGAAGGTCATCTGGTGGGCACG-3’ and Reverse 5’-
CATATGTA TATCTCCTTCTTAAAGTTAAACAAAATT-3’. The resulting T7 tag free 
sequence was verified by DNA sequencing. The original LS_PB10 construct (LS_PB10_78) has 
a 14-aa flexible linker-“GGSGGSGGSGGSGG”. Three more LS_PB10 constructs with different 
linker sequences were also generated employing LS_PB10_78 as template by an In-fusion HD 
Plus cloning kit (Takara Bio, CA). The primer sequences for the linker modification are 
summarized in Supplemental Table 3.S1. The LS_PB10 plasmids were transformed into E. coli 
strain TunerTM (DE3) pLysS (Novagen, WI) competent cells for protein expression. 
3.2.2. Protein expression and purification 
Recombinant proteins were expressed and purified using the protocol described below. Ten 
milliliters of starter culture was grown in LB media (P212121, MI) at 37 ⁰C overnight. The next 
morning, the 10 ml starter culture was transferred into a 1 L Terrific Broth media (P212121, MI) 
at 37 ⁰C. Protein expression was induced by addition of 1 mM IPTG after the OD600 of the culture 
reached approximately 0.8-1.0 and the media was incubated at 20 ⁰C overnight. After harvesting, 
the cell pellet was then resuspended in the hydrophobic interaction binding buffer (0.75 M 
ammonium sulfate, 20 mM phosphate, 5 mM EDTA, pH 7.0). The cells were lysed by sonication 
and the supernatant was collected after centrifugation at 15,000 g for 30 min. The supernatant was 
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passed through a HiTrap Butyl HP column (5 ml; GE healthcare, Germany) which had been pre-
equilibrated with the hydrophobic interaction binding buffer. The column was then washed with 
the elution buffer (20mM phosphate, 5 mM EDTA, pH 7.0) with a linear gradient elution method 
in a total volume of 200 ml. The elution fractions were analyzed by SDS-PAGE and those 
containing the protein of interest were then dialyzed against anion exchange binding buffer (5 mM 
Tris, 5 mM EDTA, pH 8.0) overnight. The dialyzed sample was loaded onto three HiTrap Q HP 
columns (5 ml; GE healthcare, Germany) in tandem. The bound protein was eluted using the anion 
exchange elution buffer (1M NaCl, 5 mM Tris, 5 mM EDTA, pH 8.0). 
 Each of the four purified LS_PB10 constructs was further stabilized by formaldehyde 
treatment. LS_PB10 samples were buffer exchanged into citrate-phosphate buffer (pH 8.0) using 
spin filters (10K MW cutoff, EMD Millipore, Germany).  Protein concentration was then adjusted 
to 1 mg/ml by dilution. Molar ratio excess amounts of formaldehyde (100 µL, 37% w/w, Fisher 
Scientific) were added to 0.5 mL protein samples (1 mg/mL) and thoroughly mixed. After 30 min, 
the reaction was quenched by adding 250 μL of 1 M Tris solution (pH 7.8). Protein samples were 
dialyzed against storage buffer (20 mM sodium phosphate, 0.1 M NaCl, 5mM EDTA, pH 7.0) and 
filtered through 0.1 μm syringe filters (Millex®, Germany). Protein samples (non-crosslinked and 
crosslinked) were analyzed by SDS-PAGE under reducing condition (16.7 mM DTT). The gel was 
stained by Coomassie blue R-250 dye (Teknova, CA) and imaged using an Alpha Imager HP 
system (ProteinSimple, San Jose, CA). LS_PB10 samples were purified from one batch of protein 
expression and were used for the following analysis. 
3.2.3. Size exclusion chromatography and multi-angle light scattering 
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LS and LS_PB10 samples were injected onto a Superose 6 10/300 GL column connected to an 
ÄKTA explorer (GE healthcare, IL, USA) equipped with UV absorbance and conductivity 
detectors. Protein samples were analyzed by SEC with PBS buffer (10 mM Na2HPO4, 1.8 mM 
KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) running at a flow rate of 0.5 ml/min. SEC purified 
protein samples were then analyzed for the measurement of absolute molecular weights by multi-
angle light scattering (MALS). The concentration of each protein was first measured by an Agilent 
8453 UV-visible spectrophotometer (Agilent Technologies, Santa Clara, CA) and the value was 
used for MW calculation. An automated Calypso sample delivery unit (Wyatt Technology, Santa 
Barbara, CA) was used to pump protein samples into the MALS detector (Wyatt Technology, 
Santa Barbara, CA) equipped with a 661 nm laser at a flow rate of 0.5 ml/min. The detector was 
equilibrated with PBS buffer until a stable baseline was obtained (< 0.0001 AU). Otherwise, 
Contrad 70 (Decon Labs, PA) was used to thoroughly clean the tubing and detector. One hundred 
microliter of the sample was sequentially injected into the detector 5 times, and 500 microliter two 
times followed by a prime using PBS buffer. A narrow segment from the highest plateau of the 
intensity-time plot was selected and used for data analysis. Sample eluted from the MALS detector 
was fractionated and the concentration of the fraction corresponding to the selected segment for 
data analysis was measured to calculate the concentration factor. The absolute molecule weight 
was calculated by Zimm’s equation (197). Three replicates were performed for each sample. 
3.2.4. Dynamic light scattering 
The hydrodynamic diameters of the LS and LS_PB10 samples at 25 ⁰C were measured by a 
Brookhaven ZetaPALS Analyzer (Brookhaven Instruments Corporation, Holtsville, NY). The 
instrument was equipped with a laser (653 nm) and the detector was placed at 90 degree. Two 
hundred microliter of protein sample at a concentration of 0.2 mg/ml was added to a 1X0.2 cm 
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quartz cuvette. For each run, three acquisitions were taken with an acquisition time of 30 sec. 
Three runs were measured for each sample. The viscosity value used for calculation was 1.019 cP. 
The data was analyzed using a polynomial distribution model and number-averaged diameters 
were determined.  
3.2.5. Transmission electron microscopy 
Protein samples were applied to a carbon grid (Ted Pella, Redding, CA) and left to air dry. 
Glutaraldehyde solution (1%, v/v, Sigma-Aldrich) was then added to fix the sample. The grid was 
washed twice with ultrapure water. The sample was then negatively stained by adding 2% uranyl 
acetate (Sigma-Aldrich) for 2 min. The morphology of the LS and LS_PB10_78 was studied using 
a FEI Tecnai F20 XT Transmission Electron Microscope equipped with a CCD camera (FEI 
TecnaiTM, Oregon). The particle size was calculated by averaging the diameters of 50 particles 
using ImageJ (https://imagej.nih.gov/ij/). 
3.2.6. Sample preparation for analysis of protein conformations 
Protein samples were dialyzed overnight at 4 ⁰C into PBS buffer. Samples for spectroscopic 
analysis (circular dichroism, intrinsic and extrinsic fluorescence) were prepared at a concentration 
of 0.2 mg/ml and 0.5 mg/ml for DSC analysis. Three replicates were performed for each technique. 
3.2.7. Circular dichroism 
The secondary structure of LS and LS_PB10 constructs was studied by recording circular 
dichroism (CD) spectra from 200 to 260 nm in 1-nm increments with a Chirascan-plus CD 
spectrometer equipped with a 4-position, Peltier-controlled cell holder (Applied Photophysics, 
106 
 
UK). Measurements were made in a 1-mm pathlength cuvette at 25 ⁰C. The content of secondary 
structure for each protein sample were calculated employing the online server BeStSel (198). 
3.2.8. Intrinsic fluorescence 
The tertiary structure of LS and LS_PB10 constructs was studied by measuring tryptophan 
fluorescence emission spectrum at 25 ⁰C. The samples were excited at 295 nm and emission 
spectra were recorded from 310 nm to 400 nm by a steady-state fluorometer (Photon Technology 
International, NJ). Data was collected at one nanometer interval with an integration time of 1 sec 
per data point. The excitation and emission slit widths were set to 4 nm. Spectra were buffer 
subtracted and normalized for comparison using in-house software (Middaugh Suite) (199). 
3.2.9. Extrinsic fluorescence  
An Mx3005P qPCR system (Agilent Technologies, Santa Clara, CA) was used to perform extrinsic 
fluorescence melting studies of the LS and LS_PB10 constructs. Sypro orange dye (5000x, 
Invitrogen) was added as a sensitive probe to monitor protein structural change during thermal 
unfolding. Sypro orange was added into protein samples at a dilution factor of 1000. The excitation 
and emission wavelength were set at 492 nm and 610 nm, respectively. The temperature ramp was 
set from 25 to 99 ⁰C with an increment of 1 ⁰C per step and an equilibration time of 2 min at each 
temperature. Tm values for LS and LS_PB10 constructs were calculated by a first derivative 
method employing Origin 8.0. 
3.2.10. Differential scanning calorimetry 
Differential scanning calorimetry was performed with a MicroCal VP-Capillary DSC (Malvern, 
UK) to investigate the conformational stability of LS and LS_PB10. The temperature was ramped 
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from 10 to 110 ⁰C at a scan rate of 1 ⁰C/min. The sample cell was equilibrated for 15 min at 10 ⁰C 
at the beginning of each run. The filtering period was set to be 16 sec. Four hundred microliter of 
sample was loaded into a 96-well plate for each run. The plate was sealed and kept inside a sample 
container maintained at 5 ⁰C through all of the runs. Apparent transition temperatures were 
calculated using a non-two-state equilibrium model in Origin 7.0 (OriginLab; Northampton, MA). 
3.2.11. Stability study in storage buffer 
Purified LS_PB10 samples were stored in storage buffer (20mM phosphate, 5 mM EDTA, 0.1 M 
NaCl, pH 7.0). A long-term stability study of LS_PB10 constructs in storage buffer was performed 
at 4 and 37 ⁰C for a period of 1 month. Samples were analyzed on days 15 and 30. The colloidal 
stability and chemical stability of LS_PB10 constructs were evaluated by DLS and reducing SDS-
PAGE, respectively. 
3.2.12. In-vitro antibody binding 
The binding kinetics of LS_PB10 constructs with a murine monoclonal IgG targeting the PB10 
epitope was characterized with an Octet Red 96 system employing anti-mouse IgG Fc capture 
biosensors (Pall ForteBio, Fremont, CA). The PB10 murine IgG was as described (191). The 
biosensors were hydrated for 20 min before use. Buffers, antibody samples, and LS_PB10 samples 
were loaded into a black bottom 96 well plate with a volume of 200 μL in each well. A stable 
baseline was obtained on the sensorgram for 300 sec. PB10 IgG (at 30 nM) prepared in kinetic 
buffer (PBS, 0.02% Tween 20, 0.2% BSA, pH 7.4) was then loaded onto the biosensors for a 
period of 300 sec. The biosensors with bound PB10 IgG were dipped into kinetic buffer for 300 
sec to remove any non-bound PB10 IgG. The biosensors were then dipped into 4.17 nM LS_PB10 
samples prepared in kinetic buffer for 300 sec to induce the association between PB10 IgG and 
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LS_PB10 constructs. The biosensors were then dipped into kinetic buffer for 0.5 hr for 
dissociation. Ten regeneration cycles were performed to fully regenerate biosensors by incubating 
biosensors in 10 mM glycine (pH 1.7) for 10 sec followed by a 10-sec incubation in kinetic buffer. 
The data were processed using Data Analysis 8.2 (ForteBIO, Fremont, CA). 
3.2.13. Mouse immunization 
The mouse immunization study was conducted at the Wadsworth Center. Animals were housed 
according to conventional specific-pathogen-free conditions and animal experiments were 
performed in strict accordance with the Center’s Institutional Animal Care and Use Committee 
guidelines.  Female Swiss Webster mice, 5-6 weeks of age, were purchased from Taconic Labs 
(Hudson, NY).   LS and LS_PB10 constructs were diluted in a 20 mM sodium phosphate, 100 mM 
sodium chloride, 5 mM EDTA buffer (pH 7.0) and cohorts of Swiss Webster mice were I.P. 
immunized on days 0 and 24 with either 100 μg of a single LS_PB10 construct or LS as a non-
protective control; on day 60 mice were I.P. immunized with an increased dose of 250 μg LS_PB10 
construct or LS to compensate for weight gain. Serum was collected by retro-orbital bleed from 
each mouse to determine anti-ricin antibody titers by ELISA. Mice were administered ricin by I.P. 
injection equal to 10-times the LD50 based on average weight (4 μg/mouse) on Day 95. Mice were 
monitored and weighed daily for signs of intoxication and were euthanized if they became 
moribund.  
3.2.14. ELISA 
Ricin-specific serum IgG titers were determined by ELISA, as previously described (191).  Briefly, 
Nunc Maxisorb F96 microtiter plates (ThermoFisher Scientific) were coated and incubated with 1 
μg/ml ricin toxin or 1 μg/ml lumazine synthase and then treated with dilutions of mouse serum. 
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Horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (SouthernBiotech) was used as the 
secondary reagent and the plates were developed using 3,3’,5,5’ tetramethylbenzidine (Kirkegaard 
& Perry Labs, Gaithersburg, MD). The plates were analyzed with a SpectroMax 250 
spectrophotometer with Softmax Pro 5.4.5 software (Molecular Devices, Sunnyvale, CA).   
3.3. Results 
3.3.1. Purity and integrity of LS_PB10 samples 
LS_PB10 constructs containing one of the four linkers with varying length and rigidity 
were designed, produced, purified and treated with formaldehyde (Figure 3.1). The purity of each 
LS_PB10 construct was analyzed by reducing SDS-PAGE (Figure 3.2). Since the interactions 
between LS subunits are non-covalent, LS and non-crosslinked LS_PB10 samples were 
dissociated into monomers in the presence of DTT and SDS at room temperature (Figure 3.2, 
samples 12, 34, 56 and 78). All four non-crosslinked LS_PB10 showed acceptable purity on SDS-
PAGE and had a higher monomer molecular weight than LS itself (sample LS).  
Formaldehyde is a reactive electrophile and primarily reacts with the amine groups of 
lysine residues or the N-terminus (200, 201). Formaldehyde can covalently link two neighboring 
amine groups within a protein molecule to generate covalent oligomers, potentially enhancing the 
rigidity and stability of the protein. LS as a scaffold has several exposed neighboring lysine 
residues (e.g. three K28 residues along the three-fold symmetry axis). In contrast, the PB10 epitope 
does not contain free amine groups and should not be chemically modified upon formaldehyde 
treatment. Hence, formaldehyde crosslinking was performed in this study to study its effect on the 
stability and immunogenicity of LS_PB10 constructs. The formaldehyde crosslinking reaction was 
performed under relatively mild conditions (pH 8.0, 30 min) to generate intra-molecular covalent 
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linkages rather than inter-scaffold crosslinking. As shown in Figure 3.2 (samples 12CL, 34CL, 
56CL and 78CL), formaldehyde crosslinking induced a partial formation of oligomers (primarily 
dimer and slightly higher order oligomers). The disappearance of oligomeric bands observed in 
Figure 3.2 (samples 12CL_B, 34CL_B, 56CL_B and 78CL_B) show a conversion of covalent 
oligomers back to monomers after 30 min of boiling, indicating that formaldehyde crosslinking is 
reversible at elevated temperature. This observation is consistent with the finding that 
formaldehyde crosslinked bonds are relatively stable at room temperature, but tend to break at high 
temperature (202). 
3.3.2. Protein assembly state: DLS, SEC, MALS and TEM 
The assembly states of LS_PB10 capsid were investigated by DLS, SEC, MALS and TEM. 
Table 3.1 summarizes the hydrodynamic diameter, elution volume and molecular weights 
(experimental and theoretical MWs) of each of the LS and LS_PB10 samples. DLS measures the 
hydrodynamic size of a protein sample and uses polydispersity as a measure of the size distribution 
of a sample. All samples showed low polydispersity (< 0.1) indicating a relatively homogenous 
size distribution (Table 3.1). The diameters of icosahedral lumazine synthases from various 
microorganisms have been found to be around 16 nm (38). DLS analysis shows that LS had a 
hydrodynamic diameter of 15.5 ± 0.19 nm in storage buffer at 25 ⁰C, consistent with the size of 
LS oligomers with icosahedral geometry. All four non-crosslinked LS_PB10 constructs were 
larger in size than LS by 2 to 3 nm. This can be attributed to the addition of the peptide linker and 
PB10 epitope on LS. LS_PB10 constructs with longer linkers (samples 56 and 78) had slightly 
larger hydrodynamic diameters than those with short linkers (samples 12 and 34). All of the 
crosslinked LS_PB10 constructs had similar or slightly larger diameters compared to their 
corresponding non-crosslinked counterparts. 
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To minimize the variation caused by varying injection volumes among samples, SEC 
chromatographs for LS_PB10 samples were normalized for comparison. SEC analysis shows that 
all LS_PB10 assemblies eluted earlier than LS indicating LS_PB10 had a larger hydrodynamic 
size than LS (Table 3.1 and Supplemental Figure 3.S1). LS_PB10 56 and 78 had an earlier elution 
volume than LS_PB10 12 and 34. These data are in good agreement with the DLS results. In 
contrast, all of the crosslinked LS_PB10 constructs had longer elution volumes than non-
crosslinked LS_PB10. This counterintuitive phenomenon is probably attributable to the reduction 
of surface positive charges (primarily amine groups) induced by formaldehyde, increasing the 
surface hydrophobicity of LS_PB10 thereby potentially enhancing weak protein-column 
interactions. 
MALS analysis shows that LS_PB10 constructs had larger absolute molecular weights 
(MWs) than LS (Table 3.1). The experimental MWs of LS and non-crosslinked constructs match 
their theoretical MW values calculated based on a 60-mer. All crosslinked LS_PB10 had higher 
MWs than the parent non-crosslinked constructs presumably due to the covalent changes induced 
by formaldehyde.  
As an example of the microscopic morphology of the capsid constructs, TEM images 
(Figure 3.3) of LS_PB10_78 and LS show that they share a highly similar spherical shape and 
hollow interior, suggesting that LS_PB10_78 successfully assembled driven by interactions 
between LS subunits. The size analysis shows LS and LS_PB10_78 having a size of 14.5 ± 1.0 
nm and 18.5 ± 0.9 nm, respectively, which are in good agreement with DLS data. Since all of the 
LS_PB10 constructs shared similar hydrodynamic diameters, SEC elution times and absolute 
molecular weight, it seems reasonable to assume all of the other LS_PB10 constructs would show 
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a similar morphology to LS_PB10_78, even though TEM images were not performed for the other 
samples.  
3.3.3. Protein conformation: CD, intrinsic fluorescence, extrinsic fluorescence, DSC 
To characterize the structural integrity of the various LS_PB10 assemblies, the secondary, 
tertiary, and overall conformational stability of the protein molecules within the capsid were 
studied by several biophysical techniques. As shown in Figure 3.4 and Supplemental Figure 3.S2, 
at 25 ⁰C LS and LS_PB10 constructs share similar CD spectra. In contrast to LS, however, all 
LS_PB10 showed slightly less negative signals at 222 nm suggesting a small loss of secondary 
structures (Figure 3.4B). The content of secondary structures for each construct was deconvoluted 
by BeStSel for comparison (198). The secondary structure content of LS based on its crystal 
structure (PDB: 1VSX) was also plotted and shows good agreement with the experimental data 
(Supplemental Figure 3.S2). All LS_PB10 constructs showed decreased helical contents compared 
to LS. This reduction was relatively minor for non-crosslinked LS_PB10 constructs, but more 
pronounced for crosslinked constructs indicating that formaldehyde treatment slightly reduced the 
helical content in the LS_PB10 constructs. 
The tertiary structure of LS_PB10 was studied using intrinsic tryptophan (Trp) 
fluorescence spectroscopy. The LS_PB10 particles contain two Trp residues (Trp 51 and Trp 151) 
in each subunit. Neither PB10 peptide nor peptide linkers contain any Trp residue. The mean 
spectral center of mass (MSM) peak position was used instead of λmax to study protein tertiary 
structure because MSM peak position shows better sensitivity for detecting subtle conformational 
changes. To minimize inter-day variations, the emission spectra for LS_PB10 samples were 
normalized for comparison (Figure 3.5A and Supplemental Figure 3.S3). As shown in Figure 3.5A, 
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LS and all LS_PB10 constructs showed emission λmax around 330 nm indicating that the proteins 
are in a folded state. Compared to LS, non-crosslinked LS_PB10 showed a minor red shift in MSM 
peak position (by 0.2 to 0.4 nm). This suggests that fusion of the linker and PB10 epitope produced 
only minor alterations of the overall tertiary structure of LS. Formaldehyde crosslinking, however, 
red shifted the MSM peak position by 1.1 to 1.4 nm suggesting greater alteration of the tertiary 
structure of the modified LS_PB10 constructs. Additionally, ratios of fluorescence intensity at 350 
nm to 330 nm (F350/F330) were calculated to compare protein tertiary structures. The 330 and 
350 nm values are taken to correspond to the emission maxima of Trp in buried and exposed 
environments, respectively. F350/F330 thus reflects the relative population of exposed Trp versus 
buried Trp and the overall exposure level of Trp residues in proteins. Proteins with more exposed 
Trp have higher F350/F330 values. The F350/F330 value for each sample manifested the same 
trend as the MSM peak position (Figure 3.5B). It should be noted that there are only two Trp 
residue in each LS monomer which contains 153 amino acid. Trp fluorescence may not however 
be able to sufficiently probe the overall protein’s tertiary structure. Extrinsic fluorescence was 
therefore further performed to study protein tertiary structure and showed good agreement with 
Trp fluorescence data (see below). 
The stability of the tertiary structure of LS_PB10 was investigated using extrinsic Sypro 
orange fluorescence. Sypro orange is a fluorescent dye commonly used to probe changes in protein 
tertiary structure. At 25 ⁰C, all of the crosslinked constructs showed higher initial Sypro orange 
fluorescent intensity than their parent non-crosslinked particles. This suggests that formaldehyde 
crosslinking treatment increases the exposure of hydrophobic regions of LS_PB10 constructs. 
Upon heating of the samples, LS showed two major thermal transitions (52.0 and 93.6 ⁰C) in PBS 
buffer (Figure 3.6A). The first thermal transition (52.0 ⁰C) results from a conformational change 
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induced by the thermal dissociation of phosphate ions from LS/phosphate complex (Y. Wei and 
CR Middaugh, manuscript in preparation). The second transition presumably corresponds to the 
dissociation and unfolding of LS oligomers. All four non-crosslinked LS_PB10 constructs had Tm 
values similar to LS, suggesting that the display of PB10 on the LS surface by four different linkers 
had no significant effect on the thermal stability of LS. Interestingly, the first transition (52.0 ⁰C) 
disappeared in all four formaldehyde crosslinked constructs. The disappearance of this transition 
could potentially be attributed to the change in the conformation of the scaffold induced by 
formaldehyde crosslinking. The Tm2 value of all crosslinked constructs are above 100 ⁰C and are 
thus dramatically higher than those of non-crosslinked ones. The exact values of Tm2 were not 
obtained due to the limitation of the thermal control (max 99 ⁰C) of the instrument. The significant 
increase in the Tm2 value for crosslinked particles indicated a considerable thermal stabilization by 
formaldehyde on LS_PB10 constructs. 
The overall conformational stability of the LS_PB10 variants was studied by DSC from 10 
to 110 ⁰C. Two major thermal transitions were observed for LS and non-crosslinked LS_PB10 
constructs while only one major transition was observed for crosslinked LS_PB10 varients (Figure 
3.6B). Compared to LS, there is no significant shift in the first transition for the four non-
crosslinked LS_PB10 constructs, indicating that fusion of the linkers and the PB10 epitope had no 
significant effect on the first transition. This transition, however, was not detected in crosslinked 
LS_PB10 constructs and this is consistent with results observed by the extrinsic fluorescence 
thermal melt study described above.  All four crosslinked constructs showed a Tm around 105 ⁰C, 
which is about 9 ⁰C higher than the Tm2 of the non-crosslinked particles. Therefore, formaldehyde 
crosslinking significantly stabilized the LS_PB10 constructs. 
3.3.4. Storage stability: Chemical and Colloidal Stability 
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Reducing SDS-PAGE was performed to analyze the chemical stability of the LS_PB10 
constructs, including the stability of formaldehyde crosslinked bonds, proteolysis and covalent 
oligomerization, in storage buffer. As shown in Figure 3.7B and 3.7C, all samples stored at 4 ⁰C 
did not produce significant degradation bands or any changes in the pattern of bands on days 15 
and 30. This shows that all particles tended to be chemically stable at 4 ⁰C for at least 1 month. At 
37 ⁰C, all of the non-crosslinked constructs did not manifest significant changes on the gel. 
However, each of crosslinked constructs stored at 37 ⁰C showed a significant decrease in the 
intensity of the dimer band on days 15 and 30. The probable explanation is that formaldehyde 
crosslinked bonds were unstable and tended to break at elevated temperature (202, 203).  
The hydrodynamic diameter of each LS_PB10 construct was measured by DLS to monitor 
their colloidal stability at 4 and 37 ⁰C over 30 days (Supplemental Figure 3.S6). The sizes of all 
constructs remain unchanged except for LS_PB10_78 and LS_PB10_78CL stored at 37 ᵒC which 
showed a small but statistically significant increase (p < 0.05) in the hydrodynamic diameter on 
day 30.  
3.3.5. In-vitro antibody binding 
The murine MAb PB10 was used to test the accessibility of the PB10 epitope on LS_PB10 
constructs using Bio-layer interferometry (BLI). BLI is a label-free technique for measuring 
biomolecular interactions between the ligand captured by the biosensor and the analyte in solution. 
This technique monitors the real-time changes of the interference pattern of white light reflected 
from two surfaces (i.e. an internal surface layer and the ligand/analyte interaction interface) upon 
the analyte binding to the ligand. The readout is recorded in the form of wavelength shift (in nm) 
and is a direct measure of the level of binding. In the context of this study, the ligand and analyte 
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are PB10 MAb and LS or LS_PB10 constructs, respectively. As shown in Figure 3.8A and 
Supplemental Figure 3.S7, all eight constructs (at 4.2 nM) were readily recognized by PB10 MAb. 
LS, at the same concentration, was not bound by PB10. These results indicate that the PB10 epitope 
is successfully presented on the surface of LS and readily accessible on all of the constructs. It is 
interesting to note that the four linkers of different length and rigidity did not influence the 
exposure of the epitope, because there was no significant differences in their association constant 
with PB10 MAb (Figure 3.8B). This may be due to the inherent flexibility of the C-terminus of 
LS, which could diminish the effect of the linker length or rigidity. The PB10 epitope was also 
impervious to formaldehyde treatment, since formaldehyde crosslinking did not significantly 
affect the association rate of LS_PB10 constructs. Because no discernible dissociation was 
observed for any of the LS_PB10 constructs even though the dissociation was monitored for 30 
min (only the first 7 min is shown in Figure 3.8A and Supplemental Figure 3.S7), dissociation rate 
constant values could not be obtained (i.e. they are lower than the detection limit: 1.0-7 1/s), which 
is consistent with MAb PB10 having picomolar binding affinity for ricin (Y. Rong and N. Mantis, 
manuscript in preparation). The multivalency of the PB10 epitope displayed on the surface of 
LS_PB10 particles might also contribute to the tight binding to the antibody.  
3.3.6. Immunogenicity of LS_PB10 constructs 
The LS_PB10 constructs were administered to groups of Swiss Webster mice three times by the 
intraperitoneal route. All eight LS_PB10 candidates elicited measurable levels of anti-LS as well 
as anti-ricin antibodies in mice (Table 3.2), as determined by ELISA. The LS_PB10 constructs 
stimulated detectable levels of anti-ricin antibodies after the second immunization, with a 
discernible further increase in endpoint titers after a third immunization for LS_PB10_12CL, 
34CL, 56 and 78. It should be noted that the levels of anti-ricin antibodies in mouse sera following 
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the second and third LS_PB10 construct immunizations were variable. Moreover, there was no 
discernible effect of linker length or formaldehyde crosslinking on the immunogenicity of 
LS_PB10 constructs. The LS-PB10 mice were challenged with ricin (10 x LD50) approximately 
three months following the first immunization.  Ultimately, all groups of ricin-challenged mice 
succumbed to ricin intoxication 36-48 hours post challenge (data not shown), indicating that the 
LS_PB10 constructs did not confer any benefit against ricin exposure, possibly because the serum 
antibody titers were not sufficiently high. 
3.4. Discussion 
In this study, an immunodominant linear B cell epitope derived from ricin toxin’s 
enzymatic subunit was chosen as a model epitope to evaluate the feasibility of B. anthracis LS as 
a platform for polyvalent antigen display. The PB10 epitope is a 12-amino acid peptide that adopts 
a helical conformation within the context of ricin (204).  The PB10 epitope was fused to the C 
terminus of the LS monomer through different peptide linkers. Four linkers of varying length and 
amino acid composition were chosen to study their effect on the stability and immunogenicity of 
LS_PB10. In addition, LS_PB10 constructs were further stabilized by formaldehyde crosslinking. 
The addition of PB10 epitopes with linkers onto the LS scaffold retained correct macromolecular 
assembly and had only a minor effect on the conformation of LS_PB10 constructs. This 
demonstrates the versatility of LS in presenting peptides with different sequences and lengths. 
LS_PB10 constructs with four different linkers showed rapid binding to a PB10 MAb, but the 
extremely slow off-rates prevented accurate determination of KD values.  Indeed, it is estimated 
that PB10’s binding affinity for ricin is less than 10 pM (Y. Rong and N. Mantis, manuscript in 
preparation). Formaldehyde crosslinking only slightly altered the protein’s overall secondary and 
tertiary structure, but dramatically stabilized the protein’s conformation by an increase of 9 ⁰C in 
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the Tm values determined by DSC and extrinsic fluorescence. Such crosslinking did not affect the 
presentation of the PB10 epitope which showed no significant difference between their association 
rate constants with a murine PB10 antibody. After three immunizations, all LS_PB10 constructs 
successfully elicited detectable levels of anti-ricin antibodies in mouse sera, as measured by 
ELISA. This illustrates the potential of LS as a presentation system for the generation of an 
immunogenic response to a short monomeric non-immunogenic peptide via polyvalent antigen 
display which permits B-cell receptor crosslinking. 
The LS_PB10 constructs, however, failed to elicit a protective antibody response in mice. 
This suggests that protective immunity may not be achievable by a single immunogen containing 
just the PB10 epitope. Thus, a vaccine candidate containing multiple epitopes may be required to 
offer improved protection. Alternatively, the LS_PB10 constructs could be used with other ricin 
vaccine antigens in a prime-boost regimen to “focus” the immune response against the PB10 
epitope.  Our data also suggest that antibody titers were not sufficiently robust. This issue could 
be overcome with the addition of an adjuvant. In fact, we are currently in the process of testing the 
immunogenicity of LS_PB10 constructs in the presence of Alhydrogel® and other adjuvants in 
mice. Several possible reasons are proposed as follows to explain the suboptimal level and 
specificity of antibodies elicited by these LS_PB10 constructs. 
At physiological pH, the PB10 peptide fused to the C terminus of LS contains four negative 
charges (NQEDAEAITHLF) and negligible positive charge which could potentially make it a 
poor immunogen. The presentation of sixty copies of the PB10 epitope on the LS scaffold gives 
the surface of LS_PB10 a high density of negative charge. It has been shown that extensive 
negative charge on the surface of an immunogen could significantly inhibit and even completely 
shut down its immunogenicity (205).  
119 
 
The X-ray crystal structure of ricin shows that the helical PB10 epitope interacts with 
several surrounding positively charged residues (e.g., R48, R56, and R114) (204). These 
interactions reduce the negative charge density on the PB10 epitope and may have a stabilizing 
effect on its helical structure. When this peptide was displayed on LS, the absence of stabilizing 
interactions may alter the conformation of the PB10 peptide. High charge density has been shown 
to destabilize helicity because of increased side chain repulsion and disruption of intramolecular 
hydrogen bonding (206). In fact, deconvolution of the far-UV circular dichroism spectrum of the 
PB10 peptide (synthesized by Genscript®, Piscataway, NJ) in PBS buffer at 25 ⁰C (at 0.2 mg/ml) 
shows that it has completely lost helical structure and exists primarily as disordered structure 
(Supplemental Figure 3.S8). Thus, the PB10 peptide displayed on the surface of LS may also 
possess little structure because of the lack of stabilizing interactions. This assumption is further 
supported by the following two experimental observations. First, there is a general decreasing trend 
in the helix content in the non-crosslinked LS_PB10 constructs (Supplemental Figure 3.S2E). The 
second observation is that all four non-crosslinked LS_PB10 constructs showed almost the same 
thermal transitions as LS alone (Figure 3.6B and 3.S5). If the fused PB10 peptide had adopted 
helical structure on the surface of LS, it might have produced an alteration in the thermal melting 
curve. It is, therefore, possible that the unstructured PB10 peptide presented on the capsid of the 
LS elicited an antibody response which lacked the strong binding affinity to the cognate ricin 
molecule.  
Finally, it is worth mentioning that a large immunogenic response to the LS itself in all 
mice immunized was detected presumably due to the strong immunogenicity of the scaffold. The 
possibly immunodominant role of the LS may somehow suppress the immunogenicity of the PB10 
epitope which resulted in only moderate levels of anti-ricin antibodies. A scaffold system with low 
120 
 
or no immunogenicity is preferred for polyvalent antigen display (140). Therefore, efforts, such as 
mutation and guided computational design, could be undertaken to improve the immune response 
of the epitope displayed by minimizing or re-directing the intrinsic immunogenicity of the LS 
scaffold.  
Even though the end goal of designing neutralizing and protective ricin vaccine candidates 
based on LS was not shown within this work, we established the potential of LS from B. anthracis 
as a platform for antigen display. The next step is to incorporate a combination of more diverse 
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3.6. Figures and Tables 
3.6.1 Tables 
Table 3.1. Size analysis of LS and LS_PB10 capsid constructs. Hydrodynamic diameter and 
polydispersity was determined by DLS, elution volume (VR) by SEC, and absolute molecular 
weight by MALS. Error values are standard deviations (N=3). See Figure 3.1 for description of 
samples. 
 
Theoretical MW was calculated by multiplying the average molecular weight of each monomer 






Table 3.2. Anti-ricin and anti-lumazine synthase antibody titers in sera of mice immunized with 
LS_PB10 constructs. Groups of mice (n=3 mice/group) were immunized with 100 µg of LS_PB10 
constructs. Serum samples were collected from the mice after the second (Day 42) and third (Day 
84) immunizations. NT indicates “not tested” because of insufficient sample volume for analysis. 






Supplemental Table 3.S1. The amino acid sequence of linkers and corresponding DNA primers 









Figure 3.1. Schematic overview of design of vaccine antigens in this study. (A) LS_PB10 
constructs with four different linkers and corresponding sample identification code; the sequence 
of PB10 peptide is “NQEDAEAITHLF” (B) Hypothetical 3-D structure of LS_PB10 and 
LS_PB10_CL constructs (CL indicates formaldehyde crosslinking). The in silico model was 
manually constructed by combining the 60-fold lumazine synthase structure from B. anthracis 
(PDBID: 4V7G), with the linear PB10 epitope from R. communis (PDBID: 3SRP), enjoined by an 
extended glycine-serine linker. The PB10 epitope is shown in dirty violet color. The possible 
covalent bonds induced by formaldehyde crosslinking are shown in red color. The hypothetical 




Figure 3.2. Reducing SDS-PAGE (12%) analysis of LS and LS_PB10 capsid constructs. Two 
micrograms of protein were loaded in each lane. M, (molecular ladder); 12, (LS_PB10_12); 12CL, 
(LS_PB10_12 CL  no boiling); 12CL_B, (LS_PB10_12 CL 30 min boiling); 34, (LS_PB10_34); 
34CL, (LS_PB10_34 CL no boiling); 34CL_B, (LS_PB10_34 CL 30 min boiling); 56, 
(LS_PB10_56); 56CL, (LS_PB10_56 CL no boiling); 56CL_B, (LS_PB10_56 CL 30 min 
boiling); 78, (LS_PB10_78); 78CL, (LS_PB10_78 CL no boiling); 78CL_B, (LS_PB10_78 CL 
30 min boiling); LS (LS no boiling). See Figure 3.1 for description of samples. For boiling 
treatment, samples were mixed with sample buffer and boiled for 30 min before sample loading, 
while other samples were kept at room temperature in presence of sample buffer for 30 min. Two 
microgram of protein was loaded in each lane. The theoretical molecular weights of the monomer 





Figure 3.3. Transmission electron microscopy images of (A) LS (With kind permission from 





Figure 3.4. Comparison of the secondary structure of LS and LS_PB10 constructs in PBS buffer 
at 25 ⁰C (A) Circular dichroism spectra of LS, LS_PB10_12 and LS_PB10_12CL samples; (B) 
Comparison of the mean residual molar ellipticity at 222 nm for LS and LS_PB10 constructs. Error 











Figure 3.5. Comparison of the tertiary structure of LS and LS_PB10 constructs in PBS buffer at 
25 ⁰C. (A) The emission spectra of for LS, LS_PB10_12 and LS_PB10_12CL (B) The mean 
spectra mass peak position and the ratio of fluorescence intensity at 350 nm to 330 nm for LS and 






Figure 3.6. Thermal stability of LS and LS_PB10 constructs in PBS buffer. (A) Extrinsic SYPRO 
Orange fluorescence thermal melting curves of LS, LS_PB10_12, and LS_PB10_12 CL 
constructs. (B) DSC thermograms of LS, LS_PB10_12, and LS_PB10_12 CL constructs. The 
corresponding Tm values for LS and LS_PB10 samples are displayed. Error values are standard 




Figure 3.7. Chemical stability study of LS_PB10 constructs at 4 ᵒC and 37 ᵒC for a period of one 
month by SDS-PAGE analysis. (A) Day 0; (B) Day 15 at 4 ᵒC; (C) Day 30 at 4 ᵒC; (D) Day 15 at 
37 ᵒC; (E) Day 30 at 37 ᵒC. M, (molecular ladder); 12, (LS_PB10_12); 12CL, (LS_PB10_12 CL  
no boiling); 12CL_B, (LS_PB10_12 CL 30 min boiling); 34, (LS_PB10_34); 34CL, 
(LS_PB10_34 CL no boiling); 34CL_B, (LS_PB10_34 CL 30 min boiling); 56, (LS_PB10_56); 
56CL, (LS_PB10_56 CL no boiling); 56CL_B, (LS_PB10_56 CL 30 min boiling); 78, 
(LS_PB10_78); 78CL, (LS_PB10_78 CL no boiling); 78CL_B, (LS_PB10_78 CL 30 min 





Figure 3.8. Binding kinetic of LS_PB10_12 (at 4.17 nM) with mouse PB10 IgG. (A) Sensorgram 
of LS_PB10_12, LS_PB10_12_CL and LS; Association phase (0 to 300 sec) and dissociation 
phase (300 to 700 sec) were shown. (B) The association rate constants of LS_PB10 samples with 
mouse PB10 IgG determined from bio-layer interferometry.  Error bars are standard deviations 






Supplemental Figure 3.S1. Normalized elution peaks of LS and LS_PB10 constructs by size 
exclusion chromatography. (A) LS_PB10_12 and LS_PB10_12_CL; (B) LS_PB10_34 and 
LS_PB10_34_CL; (C) LS_PB10_56 and LS_PB10_56_CL; (D) LS_PB10_78 and 





Supplemental Figure 3.S2. Circular dichroism spectra of LS and LS_PB10 constructs in PBS 
buffer at 25 ⁰C (A) LS_PB10_12 and LS_PB10_12CL samples (A) LS_PB10_34 and 
LS_PB10_34_CL; (B) LS_PB10_56 and LS_PB10_56_CL; (C) LS_PB10_78 and 
LS_PB10_78_CL. The far-UV CD spectrum of LS was plotted in each spectrum and graph for 
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comparison.  (D) The secondary structure content for LS and LS_PB10 constructs deconvoluted 





Supplemental Figure 3.S3. Intrinsic fluorescence spectra of LS and LS_PB10 constructs in PBS 
buffer at 25 ⁰C. (A) LS_PB10_34 and LS_PB10_34_CL; (B) LS_PB10_56 and LS_PB10_56_CL; 
(C) LS_PB10_78 and LS_PB10_78_CL. The emission spectrum of LS was plotted in each image 





Supplemental Figure 3.S4. Extrinsic SYPRO Orange fluorescence thermal melting curves of LS 
and LS_PB10 constructs in PBS buffer. (A) LS_PB10_34 and LS_PB10_34_CL; (B) 
LS_PB10_56 and LS_PB10_56_CL; (C) LS_PB10_78 and LS_PB10_78_CL. The thermal 
melting curve of LS was plotted in each graph for comparison. Error values are standard deviations 





Supplemental Figure 3.S5. DSC thermograms of LS and LS_PB10 constructs in PBS buffer. (A) 
LS_PB10_34 and LS_PB10_34_CL; (B) LS_PB10_56 and LS_PB10_56_CL; (C) LS_PB10_78 
and LS_PB10_78_CL. The thermogram of LS was plotted in each graph for comparison. See 





Supplemental Figure 3.S6. Colloidal stability study on LS_PB10 capsid constructs at 4 ᵒC and 
37 ᵒC for a period of one month. The hydrodynamic diameter of each sample was measured by 
DLS. LS_PB10_78 (day 30, 37 ᵒC) and LS_PB10_78 CL (day 30, 37 ᵒC) showed significant 
differences from their corresponding samples on day 0 in hydrodynamic diameter (* indicates p < 
0.05). Comparisons were analyzed with paired t-tests. Values of p < 0.05 were considered 






Supplemental Figure 3.S7. Kinetic binding curves of LS_PB10 constructs (4.17 nM) with mouse 
PB10 IgG (30 nM). Association phase (0 to 300 sec) and dissociation phase (300 to 700 sec) were 
shown. The measurements were done in triplicate. (A) LS_PB10_34 and LS_PB10_34_CL; (B) 
LS_PB10_56 and LS_PB10_56_CL; (C) LS_PB10_78 and LS_PB10_78_CL. The binding curve 







Supplemental Figure 3.S8. Far UV circular dichroism spectrum of PB10 peptide (at 0.2 mg/ml) 
in PBS at 25 ⁰C; the content of secondary structure was deconvoluted using BeStSel (198). Error 







Chapter 4: Effect of Two Emulsion-Based Adjuvants on the Structure and 





Subunit vaccines contain defined macromolecular components identified from a pathogen 
that are capable of eliciting protective immunity.(207) They are usually recombinant proteins and 
possess many advantages over other vaccine types (e.g. live attenuated and inactivated viruses and 
bacteria) such as an improved safety profile, a highly defined nature, ease of production and 
potential for lower cost of goods.(207, 208) One important limitation of subunit vaccines is that 
they usually induce relatively weak immunogenicity owing to their inability to replicate and/or 
lack of other immunostimulatory components such as pathogen-associated molecular pattern 
molecules to induce innate and cellular immunity.(209) To ensure the successful immunization of 
subunit vaccines, they are often administered with adjuvants to boost host immune responses.(209) 
Oil-in-water (O/W) emulsion-based adjuvants are an important class of adjuvants used for 
subunit vaccines.(210-212) These emulsions usually use squalene as the oil phase, which is a 
naturally occurring lipid found in plants, animals and humans. Suitable surfactants (e.g., Tween 
80, Span 85 etc.) are used to stabilize oil droplets dispersed in the aqueous environment. Currently, 
two squalene-based emulsion adjuvants (MF59 and AS03) have been approved for commercial 
use. (213-215) Potent immunopotentiators, such as monophosphoryl lipid A (MPLA), can be 
added to emulsion-based adjuvants to further improve their adjuvanticity. For example, a squalene 
emulsion containing a Glucopyranosyl Lipid Adjuvant (GLA), a synthetic form of MPLA, is 
currently used in a phase II trial for a respiratory syncytial virus vaccine.(216, 217) In this work, 
MedImmune emulsion. 0 (ME.0) and Stable Emulsion (SE) O/W emulsions were investigated. 
Both contain squalene as the oil phase. ME.0 and SE use histidine and ammonium phosphate 
buffers as their aqueous phase, respectively. The surfactants used in ME.0 and SE are PS 80 and a 
combination of 1, 2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and Pluronic F68, 
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respectively. In ME.0, sucrose is employed as an osmolyte, whereas glycerol is used in SE. SE 
also contains vitamin E which serves as an antioxidant and has also been shown to exert 
immunostimulatory activity.(218, 219) 
The protein antigen studied in this work is alpha toxin (AT) derived from Staphylococcus 
aureus. AT is one of the key virulent factors involved in S. aureus infection (220) and has been 
found to be protective in animal models.(221) AT is a promising vaccine candidate for protection 
against antibiotic resistant staphylococcus infection in high risk populations, especially patients 
hospitalized for surgery.7 The wild type AT is expressed by S. aureus extracellularly as a water 
soluble monomer and self-assembles into a homo-oligomeric heptamer with a transmembrane 
domain.(222) The AT monomer consists of 293 amino acid with a molecular weight of 33.2 kDa. 
The AT used in this study is a mutant of the wild type AT which lacks the ability to self-assemble. 
Emulsion adjuvants can be formulated with vaccine antigens in two different formats: 
single vial or separate vials in which antigen and adjuvant are mixed prior to administration.(223) 
If antigen and adjuvant are compatible with each other, they can be formulated in a single vial to 
reduce manufacturing costs and provide ease of administration. Single vial formulation is therefore 
a more favorable option, especially as the commercial dosage form.(208) However, if antigens are 
not compatible with adjuvants over long-term storage, they must be stored separately before 
administration to ensure the safety and efficacy of a vaccine. This option is often implemented in 
early clinical trials when limited stability data are available. An understanding of emulsion/antigen 
interactions and how these interactions influence the structure and stability of antigens is necessary 
to rationally decide the type of formulation (e.g. single vial or separate vial) and to further optimize 
the formulation to offer maximum antigen stability.(224-226) 
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Since emulsions are usually optically turbid due to strong light scattering, this poses 
challenges for analytical characterization of antigens in their presence. Many routinely used 
spectroscopic techniques (such as Circular Dichroism (CD), UV absorption, and some forms of 
fluorescence) are often not suitable for this purpose because of the interference by light 
scattering.(227)  In the present study, a set of biophysical techniques capable of analyzing turbid 
protein samples were selected to investigate the secondary, tertiary structural integrity and overall 
conformation stability of protein antigens upon mixing with emulsion-based adjuvants. These 
techniques include Fourier transform infrared (FT-IR) and intrinsic fluorescence spectroscopy and 
differential scanning calorimetry (DSC). (228) We have successfully used these techniques to 
characterize the effects of two oil-in-water (O/W) emulsion systems (designated as ME.0 and SE) 
on Staphylococcal aureus alpha toxin (AT), a potential vaccine antigen.  
4.2. Materials and Methods 
4.2.1. Materials 
Frozen stock of recombinantly produced and purified AT in PBS buffer (pH 7.4) was 
obtained from Medimmune LLC (Gaithersburg, MD). The AT stock concentration was found to 
be 0.51 mg/ml (extinction coefficient, A . %
 
 = 1.93) by UV absorption spectroscopy and this 
value was used for sample preparation. Two oil-in-water emulsion-based adjuvants, ME.0 stock 
(2X) and SE stock (3X), were provided by MedImmune LLC (Gaithersburg, MD). ME.0 stock 
(2X) contains 20mM histidine at pH 6.0, 10% sucrose, 4% squalene and 1% PS80. SE stock (3X) 
is composed of 25mM ammonium phosphate, 5.1% squalene, 1.1% DMPC, 30ug/mL vitamin 
E, 2.37% w/v glycerol, and 0.037% w/v pluronic F68, at pH 5.6. 
4.2.2. Sample preparation 
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ME.0 stock (2X) and SE stock (3X) were prepared by MedImmune LLC (Gaithersburg, 
MD) using a previously described protocol.(208) Briefly, squalene and surfactant were mixed and 
sonicated to achieve homogenous mixing of the oil phase. The aqueous phase was then added to 
the oil phase. The mixture was again homogenized using a Silverson L5M-A standard mixer (East 
Longmeadow, MA) and then subjected to microfluidization to generate milky emulsions of around 
100 nm in size using a Microfluidics 110P microfluidizer (Microfluidics, Boston, MA). AT/ME.0 
or AT/SE mixtures were prepared by mixing AT in PBS with an emulsion stock (ME.0 stock (2X) 
or SE stock (3X)) to achieve a final protein concentration of 0.2 mg/ml containing emulsion at 1X 
concentration.  
In the component study, we aimed to study the effects of different emulsion components 
on AT (as per Table 4.1). AT was mixed with each water-soluble component of the emulsions at 
the same volumetric ratio as used in the AT/ME.0 or AT/SE mixture. S0 was prepared by diluting 
AT in PBS to achieve a concentration of 0.2 mg/ml. The compositions of all test samples and their 
identification codes (M1 to M5 and S1 to S5) are listed in Table 4.1. For example, M1 was prepared 
by mixing AT in PBS (at 0.4 mg/mL) with 20 mM Histidine buffer, pH 6.0 at a volumetric ratio 
of 1:1. ME.0 (1X) and SE (1X) diluted using PBS were used as control samples. M2 was made by 
mixing AT in PBS (at 0.4 mg/mL) with a mixture solution containing 20 mM Histidine buffer (pH 
6.0) and 10% sucrose at a volumetric ratio of 1:1. ME.0 (1X) and SE (1X) diluted using PBS were 
used as control samples. The mixtures were equilibrated at 4 ᵒC overnight before analysis. 
4.2.3. UV-visible absorption spectroscopy 
The absorption spectrum of AT stock was collected using a UV/Visible spectrophotometer 
(Agilent Technologies, Santa Clara, CA) equipped with a diode array detector. The absorption 
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spectra were corrected for scattering contributions by subtraction of an extrapolation of the 
logarithm of the optical density in a non-absorbing region (350 nm to 400 nm) to the far UV region. 
4.2.4. FT-IR spectroscopy 
FT-IR spectroscopic analysis was performed using a Tensor-27 FT-IR spectrometer 
(Bruker, Billerica, MA) equipped with a Bio-ATR cell. The detector was cooled with liquid N2 for 
20 min prior to use and the interferometer was purged continuously with N2 gas.  A total of 256 
scans were recorded from 4000 to 900 cm-1 with a 4 cm-1 resolution. Buffer/emulsion background 
spectra were collected and subtracted from the sample spectra. Atmospheric compensation, 
baseline adjustment and second derivative calculations were applied using OPUS V6.5 (Bruker, 
Billerica, MA) software. To compare the initial state of the samples, spectra collected at 20 °C 
were deconvoluted into a set of mixed Gaussian/Lorentzian bands, using the build-in Levenberg-
Maquardt algorithm from the OPUS V6.5 software. Thermal unfolding experiments were 
performed with the temperature ramped from 20 to 90 ᵒC or 99 ᵒC (for AT in SE) at increments of 
2.5 ᵒC per step and an equilibration time of 2 min at each temperature. The second derivative of 
each spectrum was calculated with nine point smoothing. The thermal unfolding curves of AT 
were constructed by plotting the second derivative signal at 1621 cm-1 (an indication of 
intermolecular β-structure and protein aggregation) as a function of temperature. The melting 
temperature (Tm) was calculated by a first derivative method using Origin 2017 (OriginLab; 
Northampton, MA). 
4.2.5. Intrinsic fluorescence spectroscopy 
Intrinsic tryptophan fluorescence spectra were obtained using a fluorescence plate-reader 
(Fluorescence Innovations, Minneapolis, MN) equipped with a tunable pulsed dye laser, a high-
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speed digitizer and a temperature controlled 384-well sample holder (Torrey Pines Scientific, 
Carlsbad, CA). This fluorometer has two detectors: a charge coupled device (CCD) spectrometer 
and a photomultiplier tube (PMT), permitting recording of steady-state fluorescence and time-
resolved intrinsic fluorescence, respectively. The emission signal was collected at 180ᵒ (front face 
geometry) and then sent through a 300 nm long pass filter (Thorlabs Inc., Newton, NJ), which 
blocks the excitation light from entering the detector. For time-resolved fluorescence recording, 
the signal was further passed through a 360 nm (± 23 nm) band-pass filter before reaching the 
PMT. For steady-state fluorescence measurement, a right angle prism mirror was placed behind 
the 300 nm long pass filter to direct the emission light through an optical fiber to the CCD detector. 
Samples were loaded into a 364 well plate (Hard-Shell 384-well PCR plates) and silicon oil 
(ThermoFisher Scientific, Waltham, MA) was added to avoid sample evaporation by covering the 
sample surface during temperature runs. Samples were excited at 295 nm (˃95% tryptophan 
emission). Temperature ramps were set from 20 to 99 ⁰C with an increment of 1 ⁰C per step and 
an equilibration time of 2 min at each temperature. 
Steady-state emission spectra were collected using a CCD detector from 310 to 400 nm 
with an integration time of 100 ms. The mean center of spectra mass peak position (MSM peak 
position) and ratio of the area under the curve (AUC) from two regions (315 to 325 nm and 345 to 
355 nm; F345-355/F315-325) were calculated using Matlab (MathWorks; Natick, MA). The MSM peak 
values are approximately 8 to 10 nm higher than the actual peak position but their use results in a 
better signal to noise ratio.(229) 
Time-resolved intrinsic fluorescence data was obtained by recording fluorescence lifetime 
decay waveforms within a time scale of 100 ns. Two parameters (sum and moment) were 
calculated from the raw waveform by the FII data analysis software (Fluorescence Innovations, 
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Minneapolis, MN). Sum (in mV*ns) is the peak area under the waveform curve and represents the 
intensity of the overall emission collected by the PMT during an acquisition whereas moment (in 
ns) is defined as the center of the waveform where it equally divides the peak area under the curve. 
The moment represents the intensity-averaged lifetime of the waveform plot and its mathematical 
definition was previously described.(230, 231) Those two parameters were plotted against 
temperature and a first derivative method was used to find the Tm employing Origin 7.0 
(OriginLab; Northampton, MA). 
4.2.6. Differential scanning calorimetry (DSC) 
DSC was performed using a MicroCal VP-Capillary calorimeter (Malvern, UK) equipped 
with an autosampler. The temperature was ramped from 10 to 100 ⁰C at a scan rate of 1 ⁰C/min. 
The sample cell was equilibrated for 15 min at 10 ⁰C at the beginning of each run using a filtering 
period of 16 sec. Samples were loaded into a 96-well plate. The plate was sealed and kept inside a 
sample container maintained at 5 ⁰C. Apparent transition temperatures were calculated using a 
non-two-state equilibrium model in Origin 7.0 (OriginLab; Northampton, MA). 
4.2.7. Dynamic light scattering (DLS) and zeta potential 
DLS and zeta potential measurements were performed using a Zetasizer Nano ZS Helix 
(Malvern Instruments, Columbia, MD) equipped with a He-Ne laser 633nm and backscattering 
detection (173o). In the DLS experiment, emulsion samples were run without dilution because the 
hydrodynamic size of emulsions were previously found to be independent of dilution (up to 1000 
fold).(208) Samples (50 μL) were loaded into a Helix micro cuvette (Malvern Instruments, 
Columbia, MD) with a Teflon stopper. Ten measurements were taken with an acquisition time of 
10 sec per measurement. Samples were heated from 15 to 90 oC with a step of 2.5 oC and an 
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equilibration time of 2 min at each step. The Z-average diameters were calculated for emulsion 
samples using a cumulant analysis. AT in PBS failed to produce consistent Z-average diameters 
due to its low molecular weight (33 kDa) and low concentration (0.2 mg/mL), therefore the derived 
count rate was reported instead. For the zeta potential measurement, samples were diluted two fold 
in water before analysis. Samples were measured in disposable folded capillary cells at 25 oC. The 
zeta-potential was calculated based on net electrophoretic mobility of sample particles using 
Henry’s and the Smoluchowski approximations. 
4.2.8. High-Performance Size-Exclusion Chromatography (HPSEC) 
HPSEC analysis was performed using a Shimadzu HPLC system by measuring the 
fluorescence intensity at 330 nm upon excitation at 295nm. For HPSEC analysis, a TSKgel 
G3000SWXL column (7.8 mm × 300 mm) was used along with a TSKgel SWXL guard column 
(6.0 mm × 40 mm) from Tosoh Bioscience (King of Prussia, PA). A mobile phase composed of 
0.2 M sodium phosphate, pH 6.8 was used. The concentrations of AT were maintained at 0.2 
mg/mL by diluting with PBS, ME.0 or SE and 50 µL of sample was injected. The flow rate was 
0.7 mL/min, and samples were held at 5°C in the auto sampler tray prior to injection. 
4.2.9. Statistics 
Statistical analyses between the control sample (i.e. AT in PBS or S0) and other test 
samples were performed using an independent two-sample t-test with equal variance. The variance 
equality was confirmed using the Levene’s test. Values of p < 0.05 were considered to be 
statistically significant. 
4.3. Results 
4.3.1. FT-IR analysis of Recombinant AT with O/W Emulsions 
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The FTIR spectra in the Amide I region (1600-1700 cm-1) of AT under various conditions 
and the corresponding deconvoluted spectra are shown in Figure 4.1 (panels A1 to A3). At 20 ᵒC, 
in contrast to AT in PBS buffer, AT showed a statistically significant increase in alpha-helix 
content and decrease in beta-sheet content in the presence of SE rather than ME.0 (Figure 4.1, 
panel C1). Upon thermal stress, AT under all three conditions showed increases in the peak 
intensity at 1621 cm-1 corresponding to an increasing inter-molecular β-sheet content indicative of 
protein aggregation. This change is substantial for AT in PBS and in ME.0, but relatively minor 
for AT in SE (Figure 4.1, panels B1 to B3). Thermal unfolding profiles of AT monitored by the 
second derivative signal at 1621 cm-1 showed two transitions (Figure 4.1, panel C2). AT in PBS 
had two transitions at 56.6 ± 0.5 (Tm1) and 69.7 ± 0.5 (Tm2). In contrast to AT in PBS, AT in ME.0 
showed slightly lowered Tm1 values, but decreased Tm2 values to a larger extent. SE significantly 
thermally stabilized AT as reflected by an increase of 15 ᵒC and 22 ᵒC in Tm1 and Tm2 values, 
respectively. The decreased extent of thermally induced protein aggregation observed for AT in 
SE can possibly be attributed to a stabilizing interaction between AT and SE. 
4.3.2. Steady state intrinsic fluorescence spectroscopy analysis of recombinant AT with O/W 
Emulsions 
Intrinsic fluorescence spectra of AT in PBS, ME.0 and SE at 20 ⁰C were background 
subtracted and normalized for comparison. AT in PBS and in ME.0 shared similar emission spectra 
with an emission λmax around 332 nm at 20 ⁰C, suggesting the protein’s overall tertiary structure 
was not significantly altered by the presence of ME.0. AT in SE, however, manifested a blue 
shifted spectrum with a λmax at 327 nm (Figure 4.2 A) reflecting on average less exposure of the 
Trp residues to the aqueous environment. Since each AT molecule contains eight Trp residues, 
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blue shifts are indicative of overall protein tertiary structure changes and may indicate hydrophobic 
interactions between AT and SE.  
Both emulsions contains fluorescent components and shows significant fluorescence 
emission signals from 310 to 400 nm when excited at 295 nm. Thermal melting curves were plotted 
for both protein samples and emulsions to separately study their thermal transitions. ME.0 itself 
showed a thermal transition around 67 ᵒC. SE, however, did not show a clear transition from 20 to 
99 ᵒC. Thermal unfolding profiles of AT in PBS showed only one thermal transition (Figure 4.2B 
and 4.2C). This transition was accompanied by a red shift in the MSM peak position and an 
increasing F320-330/F350-380 ratio, suggesting AT had a greater solvent exposure of tryptophan 
residues during thermal unfolding. AT in ME.0 showed combined transitions derived from AT and 
ME.0 (Figure 4.2B and 4.2C). The protein transition of AT in ME.0 showed similar changes (i.e. 
increasing MSM peak position and F320-330/F350-380 ratio) as seen in PBS. Conversely, AT in SE 
showed an opposite trend (i.e., a blue shift in MSM peak position and a decrease in F320-330/F350-
380 ratio) during its thermal transition (Figure 4.2B and 4.2C). One possible explanation could be 
that AT interacted with SE during thermal unfolding with increasing exposure to the oil phase. 
Unfolding profiles monitored by both MSM peak positon and F320-330/F350-380 ratio showed similar 
Tm values (Figure 4.2 D). ME.0 slightly destabilized AT by a decrease of 4 - 5 ᵒC in Tm, whereas 
SE enhanced the Tm of AT by approximately 12 ᵒC.  
4.3.3. Time-resolved intrinsic fluorescence analysis of Recombinant AT with O/W Emulsions 
To tease out the effects of these complex O/W emulsions on AT protein stability, a 
component study was performed by studying the thermal stability of AT in the presence of water-
soluble components using time-resolved intrinsic fluorescence spectroscopy. In the sum-
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temperature plot (Figure 4.3, panels A1 and A2), the decreasing trend line indicates thermal 
quenching of AT fluorescence. Moment is a lifetime-derived empirical parameter which reflects 
the overall polarity of the neighboring environment of tryptophan residues within a protein. AT in 
PBS (S0) monitored by both sum and moment showed one thermal transition (Figure 4.3, panels 
A1 and A2). The thermal transition exhibited an increase in the sum (collected at 360 nm) 
indicating an increasing population of exposed tryptophan residues in the protein during unfolding. 
An increase in the moment was observed for AT in PBS during thermal unfolding.  
In contrast to S0, AT in M1 had a lower Tm by 4 ᵒC probably because of a pH drop and/or 
change in salt composition after mixing AT in PBS (pH 7.4) with histidine buffer (20 mM, pH 6.0) 
(Figure 4.3, panel A3). Compared to M1, a minor drop in the Tm of AT was observed when mixed 
with 1% PS80 (M2), while adding 10 % sucrose (M3) slightly stabilized AT. Mixing both 1% 
PS80 and 10 % sucrose with AT (M4) showed effects by both of these two components (i.e., a 
thermally destabilizing and stabilizing effect from PS80 and sucrose, respectively). Compared to 
S0, AT in ME.0 (M5) produced decreased protein thermal stability probably attributable to a 
change in the buffer composition upon mixing AT with ME.0.  
In the component study of SE, AT mixed with water-soluble components of SE (samples 
referred to as S1 to S4) showed similar Tm values which were lower than that of S0. This suggests 
that ammonium phosphate (25 mM, pH 5.6) thermally destabilized AT, probably because of a drop 
in pH and/or change in salt composition. This effect was also observed for M1. In S4, because of 
the poor water solubility of DMPC, saturated DMPC aqueous solution was used and its 
concentration was lower than that used in SE (1.1%). It is possible that DMPC at the higher 
concentration present in SE may affect AT stability to a larger extent. AT in SE (S5), however, 
had a Tm as high as 71 ᵒC (Figure 4.3 B1 to B3). This dramatic thermal stabilization effect on AT 
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is probably due to interactions between AT and the oil phase of SE consisting of squalene, vitamin 
E and DMPC (at 1.1%, a concentration higher than its aqueous solubility).  
4.3.4. Differential scanning calorimetry analysis of recombinant AT with O/W Emulsions 
DSC was performed to study the effect of emulsions on the overall conformational stability 
of AT. AT in PBS (S0) underwent two distinct thermal transitions (Tm1 = 58.0 ⁰C and Tm2 = 69.2 
⁰C, a relatively minor transition) (Figure 4.4A). The thermal unfolding of AT in PBS, ME.0 and 
SE was found to be irreversible as determined by rescanning the sample after one thermal 
unfolding cycle (data not shown). ME.0 showed two major transitions: the first one centered near 
65.9 ⁰C and the second one with a sudden large increase in heat capacity above 80 ⁰C (see 
Supplementary Figure 4.S1). The first transition, also seen by intrinsic fluorescence spectroscopy, 
may correspond to a structural change in the emulsion, while the second one probably reflects the 
complete decomposition of the emulsion system. The AT/ME.0 mixture (M5) exhibited transitions 
from both protein and emulsion with the second thermal transition of AT and that of ME.0 partially 
overlapped. ME.0 lowered both Tm1 and Tm2 of AT significantly (compare samples M5 vs. S0 in 
Figure 4.4A). On the other hand, the Tm of ME.0 decreased by 3.5 ᵒC in the presence of AT 
indicating that partially unfolded AT may slightly destabilize ME.0. For the component study, 
DSC was performed to study the effects of various components on the Tm of AT. Each component 
showed a similar effect on melting temperatures (Tm1 and Tm2) of AT as indicated by the lifetime 
fluorescence component study (Figure 4.4A M1 to M4). This result further suggests that the 
destabilization effect of ME.0 on AT is because of the change in buffer composition upon mixing. 
In the range of 10 to 100 ⁰C, SE showed one thermal transition around 25.3 ⁰C, 
corresponding to a gel-liquid phase transition of DMPC (232) (Figure 4.4B and Supplementary 
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Figure S1). This result was further confirmed by examining saturated DMPC solution in 25 mM 
ammonium phosphate (the concentration of DMPC is less than 1.1%) by DSC which showed a 
transition at 24.6 ⁰C (Figure 4.4B). Upon mixing AT with SE (S5), the Tm of SE was not 
significantly altered by AT. SE, however, increased both Tm1 and Tm2 of AT by 13.7 and 25.9 ⁰C, 
respectively (compare samples S5 vs. S1 in Figure 4.4B). The component study was continued by 
mixing AT with the water-soluble components present in SE. The DSC results correlate well with 
the intrinsic fluorescence data. It shows that the change in buffer composition upon mixing (S1) 
induced a destabilization effect on AT thermal stability while neither 2.37% glycerol (S3) nor 
0.037% F68 (S2) had a further significant effect on the Tm of AT. Mixing saturated DMPC (S4) 
with AT produced only a minor increase in protein Tm1 and Tm2. Overall, all of water soluble 
components of SE did not show a major stabilization effect on AT Tm. The dramatic stabilization 
effect of SE (S5) on AT is therefore probably due to the interaction between AT and the oil phase 
containing squalene, vitamin E and DMPC (at 1.1%). 
4.3.5. Dynamic light scattering (DLS) and zeta potential analysis of recombinant AT with 
O/W Emulsions 
DLS was performed to investigate the effect of temperature on the colloidal stability of the 
samples. As shown in Figure 4.5A, the derived count rate (i.e. the intensity of light scattering) of 
AT in PBS showed a dramatic increase above 52.5 oC, indicating the aggregation of AT in PBS. 
This result is in good agreement with the stability data reported above. SE did not show dramatic 
changes in their hydrodynamic sizes between 15 and 90 oC, suggesting the high colloidal stability 
of SE upon thermal stress (Figure 4.5B).  The size of SE above 90 oC was not measured because 
of instrumental constraint. The addition of AT to SE did not change the overall size of emulsion 
nanoparticles. In addition, the first unfolding event of AT (around 70 oC seen by DSC etc.) did not 
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significantly alter the emulsion size. In contrast, heating caused ME.0 to aggregate above 60 oC 
(Figure 4.5C). The addition of AT into ME.0 further decreased the onset aggregation temperature 
by approximately 3 oC, which is consistent with the DSC data. Zeta potential analysis shows that 
AT had a slight negative zeta potential at pH 7.4 due to its pI value (~ 6.85) (Figure 4.S2). Both 
ME.0 and AT in ME.0 had a slightly negative zeta potential, presumably due to negatively charged 
impurities (such as free fatty acids (233)) in PS80. In contrast, SE showed a neutral zeta potential. 
AT in SE also showed a near zero potential probably because the mixing AT (pH 7.4) with SE (pH 
5.6) results in a mixture with a pH closer to the pI of AT. 
4.3.6. High-Performance size-exclusion chromatography (HPSEC) analysis of recombinant 
AT with O/W Emulsions 
SEC was performed to study the impact of the interactions of AT and ME.0/SE on retention 
time of the protein and the individual emulsions. Figure 4.6 shows the SEC chromatograms for 
AT in PBS, and when mixed with ME and SE. AT has a single peak eluting at ~16.9 min (Fig. 
6A). Both ME.0 and SE elute at 8 to 9 min (Figure 4.6A and 4.6B). When mixed with ME.0, the 
retention time of AT does not change significantly and the recovery of AT was found to be 99.7 ± 
0.1 % (Supplementary Table 4.S1). When AT is mixed with SE, the peak corresponding to AT is 
missing while the peak at 9 min had a larger peak area than the peak area of SE alone (Figure 
4.6B). This result may indicate that the AT is bound to the SE and co-elutes with the emulsion.  
4.4. Discussion 
In the present study, the effects of two squalene based emulsion adjuvants (ME.0 and SE) 
on the structure and stability of recombinant AT, a potential vaccine candidate for antibiotic 
resistant Staph infection, were investigated. The wild type AT is expressed as water soluble 
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monomer and self-assembles into a heptameric structure with a transmembrane domain.(222) AT 
used in this study is a mutant of the wild type AT and may still have favorable interactions with 
phospholipid bilayers (i.e. DMPC) and/or the hydrophobic oil phase in the emulsion adjuvants. 
FT-IR, intrinsic tryptophan fluorescence, DSC and DLS were performed to investigate protein 
structure and the thermal stability of AT in the presence of emulsions. These results are 
summarized in Table 4.2. FTIR spectra of AT at 20 ᵒC indicate that AT had an increased alpha 
helix content, but decreased the amount of beta sheet in the presence of SE. This effect on AT is 
negligible for ME.0, but more pronounced in the presence of SE. Previous work has reported that 
protein/oil interactions induced a protein to undergo a transition from beta sheet to more non-
native alpha helix content in a β-lactoglobulin/hexadecane system.(234) At 20 ᵒC, a significant 
blue shift (λmax changed from 332 to 327 nm) was observed in the intrinsic fluorescence emission 
spectrum of AT in SE, rather than AT in ME.0. This result correlates with FTIR data indicating 
that SE but not ME.0 induced substantial structural alterations of AT in SE.  
Protein thermal stability analysis shows that ME.0 slightly decreased the Tm of AT, while 
it was significantly enhanced in the presence of SE. A component study was further conducted by 
characterizing AT in the presence of the individual water-soluble components of the test emulsions 
with the goal of identifying the components responsible for alterations of protein stability. The 
data shows that the destabilizing impact of ME.0 on AT is probably because of a change in the 
buffer composition upon mixing ME.0 which contains 20 mM histidine (pH 6.0) with AT in PBS 
(pH 7.4). In the case of AT in SE, because none of the water soluble components produced a 
thermal stabilization effect on AT, it seems probable that the thermal stabilization of SE is due to 
interactions between AT and the oil phase of SE consisting of squalene, vitamin E and DMPC.  
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SE significantly altered the secondary and tertiary structures of AT and improved its 
thermal stability. This was again probably because of the adsorption of AT onto the oil phase. 
Proteins at oil-water interfaces have previously shown enhanced resistance to thermal stress.(234) 
Zhai has reported no significant changes in the secondary structure of β-lactoglobulin adsorbed to 
nonpolar hexadecane up to 76 ᵒC at which point the same protein in solution lost its secondary 
structure.(234) When protein molecules interact with hydrophobic oil, they usually tend to reorient 
their apolar patches towards the oil surface to enhance apolar interactions. This is usually 
accompanied by structural changes in proteins. In this case, an interconversion from beta sheet to 
alpha helix was observed for AT in the presence of SE. Upon adsorption to SE, AT showed less 
exposure of Trp residues to the polar environment and an increased thermal stability. DLS analysis 
indicates that SE exhibited higher colloidal stability than ME.0 in response to heating. The addition 
of AT decreased the stability of ME.0 but did not impact SE (at least up to 90 o C). The zeta potential 
data show that SE had a relatively neutral surface, suggesting that the ionic attraction between SE 
and AT is probably negligible, further arguing that the potential interaction is hydrophobically 
driven. In addition, HPSEC data showed a nearly complete loss in the recovery of AT when mixed 
with SE, but not ME.0, indicating a high degree of interaction with SE, which possibly resulted in 
the co-elution of AT with SE. 
Both ME.0 and SE are squalene based oil-in-water emulsions, but they interact with AT 
quite differently. They mainly differ in the type and concentration of surfactants. This might be 
responsible for the difference in their effects on protein structure and stability. In a stable emulsion 
system, oil droplets are coated by stabilizing surfactants. Protein molecules need to displace 
surfactant to adsorb onto the surface of an oil phase. In the case of ME.0, AT probably failed to 
compete with polysorbate 80 (at 0.5%) for binding to the surface of oil droplets. On the other hand, 
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AT probably was better able to displace the surfactants of SE (DMPC and pluronic F68) to 
establish interactions with its oil phase. It is also possible that AT interact with the lipid layer of 
DMPC at the concentration of 1.1% used in SE, which is significantly higher than its aqueous 
solubility. It is worthwhile mentioning that during the unfolding of AT, the emulsions had 
undergone (SE) or were undergoing (ME.0) thermal transitions (Figure 4.4). It is possible that 
emulsion structural changes contribute to the observed changes in protein thermal stability. 
FTIR, intrinsic fluorescence spectroscopy and DSC have shown significant robustness in 
characterizing the structure and conformational stability of alpha-toxin (AT), a vaccine candidate 
for Staph infection, in the presence of highly scattering squalene based emulsion adjuvants. The 
component study further helped to dissect the effect of each water soluble component on the 
protein antigen. These biophysical methods along with the component study can be considered a 
case study to be applied to study the structure and stability of other protein antigens in a variety of 
adjuvant emulsion systems, further guiding the development and optimization of emulsion-
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4.6. Figures and Tables 
4.6.1. Tables 
Table 4.1. Identification codes and components of test samples subjected to the component study. 
All test samples used for the component study contained AT with a concentration of 0.2 mg/ml. 
S0 is AT in PBS (at 0.2 mg/ml). ME.0 (1X) and SE (1X) diluted using PBS were used as control 
samples. S0, M5 and S5 are denoted as AT in PBS, AT in ME.0 and AT in SE, respectively in 
FTIR, steady-state fluorescence, and HPSEC studies. * For S4, AT was mixed with saturated 
aqueous solution of DMPC with a concentration lower than 1.1% used in SE. 










1% PS80 4% Squalene 
M1 +    
M2 + +   
M3 +  +  
M4 + + +  





















S1 +     
S2 + +    
S3 +  +   
S4 +   +*  
S5 + + + + + 
169 
 
Table 4.2. Summary of biophysical data sets of AT in ME.0 or SE compared to AT in buffer alone. 
The biophysical techniques used in this study and corresponding parameters investigated are listed. 
The relative change in these parameters for AT in ME.0 or SE relative to AT in PBS. 
Technique Biophysical parameter studied AT in ME.0 AT in SE 
FT-IR 
2nd structure 
content at 20 ⁰C 
α-helix no change ↑ 12% @ 20 ⁰C 
β-sheet  no change ↓13% @ 20 ⁰C 
random coil  no change no change 
Tm1 ↓ 2.9 ⁰C ↑ 14.6 ⁰C 
Tm2 ↓ 9.3 ⁰C ↑ 23.2 ⁰C 
Steady-state  
fluorescence 
Tm by MSM peak position ↓ 4.0 ⁰C ↑ 12.0 ⁰C 
Tm by ratio ↓ 5.4 ⁰C ↑ 10.7 ⁰C 
Time resolved 
fluorescence 
Tm by moment ↓ 4.2 ⁰C ↑ 12.2 ⁰C 
Tm by sum ↓ 4.3 ⁰C ↑ 13.6 ⁰C 
DSC 
Tm1 ↓ 2.0 ⁰C ↑ 13.7 ⁰C 
Tm2 ↓ 8.4⁰C  ↑ 25.9 ⁰C 




Supplemental Table 4.S1. Peak areas and recovery of AT elution peaks from the size exclusion 
chromatography analysis. Both AT in PBS and AT in ME.0 have a protein concentration of 0.2 
mg/mL. Errors indicate standard deviation (N=3). 
 
Samples 
Protein peak area 
(mAU*min) 
Recovery of AT 
(%) 
AT in PBS (0.2 mg/mL)  4539987 ± 26168 100 
AT in ME.0 (0.2 mg/mL) 4527663 ± 6454 99.72 ± 0.14 
 
The recovery of AT in ME.0 = 
      .









Figure 4.1. Structure and stability of AT in presence and absence of ME.0 and SE emulsions as 
measured by FTIR.  FTIR spectra of (A1) AT in PBS at 20 ᵒC; (A2) AT with ME.0 at 20 ᵒC; (A3) 
AT with SE at 20 ᵒC. The black and red lines represent the raw and fitted FTIR spectra, 
respectively. The deconvoluted spectra are shown in various colors. Spectra with peaks between 
1649-1659 cm-1 are assigned as α helix; spectra with peaks between 1620-1640 cm-1 or 1661-1700 
cm-1 are assigned as β sheet. Other peaks are assigned as disordered. Second derivative of FTIR 
spectra monitoring the thermal unfolding of (B1) AT in PBS from 20 to 90 ᵒC; (B2) AT with ME.0 
from 20 ᵒC to 90 ᵒC; (A3) AT with SE from 20 ᵒC to 99 ᵒC. (C1) The secondary structural contents 
of AT determined by deconvolution analysis. AT in SE, but not AT in ME.0, showed a statistically 
significant difference with AT in PBS in protein secondary structure contents. * p < 0.05. (C2) 
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Thermal melting curve of AT monitored by changes in the signal at 1621 cm-1. Round dots on each 
melting curves indicate melting temperatures. (C3) Comparison of thermal melting temperature 





Figure 4.2. Tertiary structure analysis of AT in presence and absence of ME.0 and SE emulsions 
as monitored by intrinsic fluorescence spectroscopy. (A) Normalized fluorescence spectra of AT 
at 20 ᵒC. Thermal unfolding profiles monitored by (B) MSM peak position and (C) ratio of the 
area under the curve (AUC) from two regions (F320-330/F350-380) (E) Summary of Tm values. Error 
bars indicate standard deviation (N=3). * p < 0.05. 
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Figure 4.3. Thermal unfolding profiles of AT in the presence of various components of ME.0 
emulsion as measured by time resolved fluorescence spectroscopy. The sum (A1) and moment 
(A2) values of AT emission waveforms; of SE monitored by sum (B1) and moment (B2) of AT 
emission waveforms. Corresponding Tm values are summarized (panels A3 and B3). Error bar 




Figure 4.4. DSC thermograms of AT, emulsions, and AT in the presence of various components 
of emulsions (A) ME.0 and (B) SE. The first (Tm1) and second (Tm2) thermal transitions of AT 
are indicated by red and blue dashed lines, respectively. The transition derived from emulsions 
(ME.0 and SE) is indicated using black dashed line. Apparent melting temperature values are 
summarized in the table. Errors indicate standard deviation (N=3). See Table 1 for sample 
composition. * p < 0.05. 
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Figure 4.5. The temperature dependent colloidal stability of AT in PBS (A), AT in ME.0 (B), and 
AT in SE (C) measured by dynamic light scattering. Errors indicate standard deviation (N=3). See 
Table 1 for sample composition. 
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Figure 4.6. HPSEC chromatograms of ME.0 and AT in ME.0 (A); SE and AT in SE (B). The 
chromatography of AT in PBS was shown in both plots for comparison. 
  







































Supplemental Figure 4.S1. Uncorrected DSC thermograms of ME.0 alone and AT in ME.0 (A) 
and SE alone and AT in SE (B). Black arrow indicates the thermal transitions of the protein. Red 
arrows point to transitions derived from the emulsion. Both ME.0 and AT in ME.0 samples showed 








Supplemental Figure 4.S2. The zeta potentials of AT in PBS, ME.0, AT in ME.0, SE and AT in 





































Proteins are complex molecules with unique three-dimensional structures. The integrity of 
such structures is critical to protein biological function. Proteins in solution, however, are only 
marginally stable with a relative low free energy of unfolding (~ 5-10 kcal/mole at 25 ᵒC) (235). 
Therefore, optimization of formulation conditions for proteins must ensure their structural stability 
during manufacturing, shipping, and storage. Protein formulation optimization requires the 
identification of the optimal pH, ionic strength, and excipient conditions from a large set of 
potential conditions in a rapid and cost-effective manner. To quickly differentiate protein stability 
in various formulations, the structural stability of a protein is usually evaluated under a stressed 
condition (commonly elevated temperature). During a thermal melting experiment, protein 
structural stability can be reflected by melting temperatures (Tm), which are measured by 
monitoring a biophysical signal sensitive to protein structure. For example, vibrational 
spectroscopy and far UV circular dichroism (CD) can monitor protein secondary structures, and 
fluorescence and near UV CD is often used to probe protein tertiary structures. The overall thermal 
stability of proteins is frequently investigated using differential scanning calorimetry. 
Specific therapeutic needs often call for unique formulation conditions for optimal clinical 
uses, which presents substantial analytical challenges during formulation development. For 
example, subunit vaccines often are often formulated with adjuvants (e.g. aluminum salts, 
emulsion, etc.) for enhanced immunogenicity. Another example is monoclonal antibodies (mAbs), 
which frequently need to be formulated at high concentrations (50 to 200 mg/mL) to enable 
subcutaneous or intramuscular administration for better patient compliance (236). The highly 
scattering adjuvanted samples or strongly absorbing high concentration mAbs are not easily 
analyzed using absorption or conventional intrinsic fluorescence based techniques. In addition, the 
182 
 
formulation development of high concentration mAbs is limited by the large consumption of 
protein. The optimization of such protein formulations is therefore often conducted indirectly in 
transparent solutions containing relatively low protein concentrations (e.g. 0.1 to 1 mg/mL) for the 
sake of ease of analysis and conservation of materials (237). Formulation screening data obtained 
under such convenient conditions, however, may fail to predict the situation under a more 
commercially relevant condition. In fact, many studies have found the destabilization effects by 
protein adsorption to Alhydrogel (238, 239). Research has also shown that the thermal stability of 
proteins (e.g. mAbs) can be concentration dependent (240). It is possible that protein thermal 
stability in a commercial formulation (e.g. at high concentrations or in the presence of adjuvants) 
may be affected to different extents by excipients compared to that in model conditions (i.e. low 
concentrations in clear solutions). Therefore, there is a need to develop a high-throughput platform 
permitting direct optimization for analytically challenging, but pharmaceutically relevant 
formulations. 
In the present study, we explored the utility of an intrinsic fluorescence based system 
integrating a front face geometry (suitable for the analysis of turbid and high concentration 
samples) into a high-throughput microplate. This platform has the following features: 1) low 
sample consumption: 2) rapid fluorescence acquisition; 3) front-face geometry; 4) free of the use 
of external dyes; 5) capability to record both time-resolved (TRF) and steady-state fluorescence 
(SSF). We have developed a general workflow using this system for direct optimization of 
challenging protein formulations. A key step of this workflow is the selection of a suitable method 
to generate Tm values. The effect of Tm calculation methods on Tm values was investigated and 
differences seen can be attributed to the linear nature of the response to unfolding. Choosing a 
parameter with a linear response is preferable to generate accurate Tm values. It is also shown that 
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TRF may be used as an alternative technique to SSF for formulation screening purpose. We also 
found significant discrepancies in the excipient screening results performed under simplified 
conditions (i.e. proteins at 0.2 mg/mL in clear solutions) and pharmaceutically relevant conditions 
(e.g. adjuvanted or high protein concentrations). This result demonstrates the importance of direct 
formulation optimization of commercially relevant conditions. In addition, we also show the 
potential use of intrinsic fibril fluorescence to study the thermally induced formation of fibrils in 
high concentration mAb samples. 
 
5.2. Materials and Methods 
5.2.1. Reagents 
Lysozyme, RiVax, and a mAb were selected as model proteins. Lyophilized lysozyme powder 
from chicken egg white was purchased from Sigma-Aldrich (St. Louis, MO). RiVax (a mutated 
form of the A-chain of ricin used as a vaccine (237)) was expressed and purified in-house using a 
protocol previously described (241). The mAb was obtained from Janssen Research & 
Development, LLC (Horsham, Pennsylvania) (242, 243). Sodium phosphate dibasic, sodium 
citrate, and sodium chloride were purchased from Fisher Scientific (Hampton, NH). Excipient 
stock solutions used in this study were obtained from the Solubility & Stability Screen Reagents 
(Hampton Research, Aliso Viejo, CA) unless otherwise stated. The Solubility & Stability Screen 
Reagents are a set of commonly used excipients formulated in water. 
5.2.2. Sample preparation 
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For the pH screening study, these three model proteins were prepared in 20 mM citrate 
phosphate isotonic (having an ionic strength of 150 mM adjusted by NaCl) buffers (pH 3.0, 4.0, 
5.0, 6.0, 7.0, and 8.0) at a concentration of 0.2 mg/mL. RiVax or the mAb was then subjected to 
an excipient screening study in which each protein (at 0.4 mg/mL) was mixed with an equal 
volume of each of 40 excipient stock solutions such that the final buffer contained 20 mM citrate 
phosphate isotonic buffer, pH 6.0. 
Out of the 40 excipients studied, nine excipients with three different effects (stabilizing, 
destabilizing, and neutral) were selected to further investigate their effects on the thermal stability 
of proteins in commercially relevant conditions. These conditions include the presence of 
Alhydrogel (Brenntag Biosector, Denmark) in the final formulation of RiVax and high protein 
concentrations (50 to 200 mg/mL) commonly used in formulations of mAbs. For this study, RiVax 
(at 0.2 mg/mL) was prepared in 10 mM histidine isotonic buffer (pH 6.0) containing 2 mg/mL of 
Alhydrogel in the absence or presence of excipients. Protein was adsorbed for 2 h at room 
temperature prior to further analysis. The binding efficiency of RiVax was evaluated by 
quantifying protein using the Bradford assay (Pierce™ Coomassie Plus Assay Kit, Thermo 
Scientific, Waltham, MA) after centrifuging down the Alhydrogel. mAb samples at various 
concentrations (80, 40, 16, 1.6, and 0.2 mg/mL) were prepared in 20 mM citrate phosphate isotonic 
buffer (pH 6.0) for the thermal stability study. mAb samples at 80 mg/mL in the same buffer 
containing excipient stock solutions were also prepared. All the protein samples were analyzed on 
384-well plates (Hard-Shell 384-well PCR plates, Bio-Rad, Hercules, CA) and silicon oil 
(ThermoFisher Scientific, Waltham, MA) was added onto sample to avoid evaporation during 




The diagram of the fluorescence plate reader which is manufactured by Fluorescence 
Innovations, Inc. (Minneapolis, MN) used in this study is shown in Figure 5.1A (244). It contains 
four key components: a laser source, a photomultiplier tube (PMT), a charge-coupled device 
(CCD) spectrometer, and a temperature controlled sample plate holder. The laser source consists 
of two lasers: a tunable dye laser (280 nm to 305 nm) and a combination laser (350 and 532 nm). 
The PMT measures the time-resolved fluorescence (TRF), while the CCD records the steady state 
fluorescence (SSF) from 300 to 450 nm. The temperature controlled sample holder is able to 
accommodate a 384-well plate. This instrument has two modes: TRF and SSF. The mode can be 
switched by a mirror referred to here as the “emission mirror”. The emission mirror is not used in 
the TRF mode in which the emitted light goes to the PMT after a band pass filter. When the 
emission mirror is in place, the emission signal is directed to the CCD for the measurement of SSF.  
5.2.4. Steady State and Time Resolved Fluorescence 
In the SSF mode, the emission mirror is placed to acquire Trp emission spectra. The 
excitation laser wavelength was set at 295 nm (> 95% Trp emission). A 310 nm long pass dichroic 
mirror was used to block excitation light from entering the CCD. Measurements were performed 
using an integration time of 100 ms. A temperature ramp from 10 to 90 ᵒC with an increment of 
2.5 ᵒC per step was used. Samples were equilibrated for 2 min at each temperature at which point 
the signal stopped changing. The same temperature ramp was also used for the TRF mode.  
The TRF mode records fluorescence decay waveforms as previously described (245). The 
PMT voltage was set at 500 V. The dye laser (at 295 nm) was used for measuring Trp TRF. A 310 
nm long pass dichroic mirror and a 360/23 nm band pass filter were used. The combo laser (at 350 
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nm), a 405 long pass dichroic mirror, and a 485/20 nm band pass filter were used to monitor the 
TRF derived from the formation of fibrils in high concentration mAb samples upon thermal stress. 
5.2.5. Data Analysis 
As shown in Figure 5.1 C1 and 5.D1, raw data (spectra from SSF and waveforms from 
TRF) were used to calculate melting temperatures (Tm). The raw data were first processed with in-
house Python scripts to derive the following two parameters: intensity and moment at each 
temperature (Figure 5.1 C2 and 5.D2). Intensity represents the peak area under the curve for a 
spectrum or waveform. Moment is defined as the center of a spectrum or waveform where it 
vertically divides the peak area under the curve into two halves. The mathematical expressions for 
these two parameters are shown as follows: 
                                                Intensity = ∫ 𝐼(𝑥)𝑑𝑥                                                                              (1) 
                                                   Moment = 
∫ ( )
∫ ( )
                                                                              (2) 
where x is wavelength (SSF) or time (TRF), I(x) is the fluorescence signal. Intensity was integrated 
from 300 to 400 nm (SSF) or from 10 to 60 ns (TRF). Moment can also be described as mean 
spectral center of mass in intrinsic tryptophan fluorescence studies as previously described (68, 
174). Plotting intensity or moment versus temperature generates a melting curve to describe a 
thermal unfolding event. Each melting curve was further processed to obtain Tm values employing 
two commonly used methods: a six parameter fitting (fit) method (Figure 5.1 C2 and D2) or a 1st 
derivative (f’(T)) method (Figure 5.1 C3 and D3). The six parameter fit was performed with 
Matlab (MathWorks, Natick, MA) using the following expressions: 
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       Observed signal = ∗ (𝑏 + 𝑚 ∗ (𝑇 + 273.15)) + ∗ (𝑏 + 𝑚 ∗ (𝑇 + 273.15))                   
(3) 






)                                                                (4) 
where K is the unfolding constant and b1 and m1 are the intercept and slope of the native state 
baseline, respectively. b2 and m2 are the intercept and slope of the unfolded state baseline, 
respectively. T is the temperature in ᵒC and ΔH is the enthalpy of unfolding. R is the ideal gas 
constant (1.987e-3 kcalmol−1K−1) and Tm is the melting temperature in ᵒC. For the 1st derivative 
method, a cubic spline was used to interpolate all points of a melting curve. Intensity or moment 
were interpolated every 0.01 ᵒC. The temperature at the absolute maximum value was taken as the 
Tm. 
As illustrated in Figure 5.1B, both types of fluorescence (SSF vs. TRF) were recorded in 
the pH screening study. Two parameters (moment and intensity) were calculated from each set of 
fluorescence data to generate four melting curves in total. Two fitting methods (1st derivative vs. 
six-parameter fitting) were then applied to each melting curve to calculate Tm. Therefore, eight Tm 
values can be obtained at most for each sample. The optimal Tm generation method for each protein 
was selected for the excipient screening study. Eight sets of Tm values can be obtained at most for 
each sample. The method used to generate the Tm was expressed using an abbreviated 
nomenclature consisting of the type of fluorescence, the parameter used to measure the melting 
curve, and the derivation method. For example, “TR_moment_f’(T)” indicates that time resolved 
fluorescence is performed, moment is plotted as a function of temperature to generate the melting 





5.3.1. pH screening for lysozyme, RiVax and a mAb 
The pH dependent thermal stability of three model proteins (lysozyme, RiVax, and a mAb) 
were investigated using both SSF and TRF. These proteins were analyzed at 0.2 mg/mL in 20 mM 
citrate phosphate isotonic buffers (pH 3.0 to 8.0). At pH 3.0, RiVax did not show a thermal 
transition presumably due to the unfolding of RiVax at low pH. This is confirmed by a large red 
shift in the emission peak position of RiVax at pH 3.0 at 10 ᵒC (data not shown). The other two 
proteins showed thermal transitions in all pH conditions examined. As shown in Figure 5.2 A1, 
eight Tm values were obtained for the mAb at pH 4.0 to 8.0. For the other samples (the mAb at pH 
3.0 or the other proteins under all pH conditions), however, melting curves derived using some 
parameters did not show a detectable transition and the corresponding Tm values can not be 
calculated. For example, intensity based melting curves of lysozyme from SSF measurement did 
not show an observable thermal transition. The order of thermal stability of RiVax (Figure 5.2 
A2) and lysozyme (Figure 5.2 A3) is as follows: pH 6.0 > 5.0 > 7.0 > 8.0 > 4.0 > 3.0 and pH 5.0 
> 4.0 > 6.0 > 7.0 > 8.0 > 3.0, respectively. These results are in good agreement with previously 
published data (237, 243, 246). The mAb at pH 4.0 and 3.0 showed significantly lower thermal 
stability compared to the other pH conditions. The mAb at pH 5.0 to 8.0 showed similar Tm values. 
By averaging the Tm generated from all methods, the mAb at pH 6.0 showed the highest Tm value 
and was therefore selected as the base buffer condition for the following excipient study. 
5.3.2. Tm correlation plots 
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For the same protein sample tested using this fluorescence plate reader, Tm values 
generated using different methods can be slightly different. For instance, the Tm of RiVax 
generated using TR_moment_f’(T) is higher than that obtained using TR_intensity_f’(T) (Figure 
5.2 A2). We therefore studied the dependency of Tm values on each of three factors: the type of 
fluorescence measurement (SSF vs. TRF), the parameter derived (intensity vs. moment), and the 
data fitting method (1st derivative vs. six parameter fitting). Three Tm correlation plots for each 
factor were then constructed (Figure 5.2 B1-B3) by varying one factor at a time while keeping the 
other two factors the same. Lysozyme data are only included in the Tm correlation plot for the data 
fitting method (Figure 5.2 B2) because of its limited Tm data sets. As shown in Figure 5.2 B1, the 
data sit exactly on the Y = X line indicating that the Tm values obtained from SSF and TRF agree. 
This suggests that TRF may be used as an equivalent alternative to SSF for protein fluorescence 
screening. A high degree of correlation was again observed for the Tm values obtained by using 
the six parameter or 1st derivative method (Figure 5.2 B2). We found, however, that the 1st 
derivative procedure seems to be a more sensitive method than the six parameter fit. As shown in 
Figure 5.2 A2, TR_intensity_f’(T) and SS_intensity_f’(T), but not TR_intensity_fit or 
SS_intensity_fit, generated reliable Tm values. The better sensitivity of the 1st derivative method 
may be because it is less susceptible to the noisy baseline and is parameter free. Therefore, the 1st 
derivative method was selected to calculate Tm values in the following excipient screening studies. 
Tm values generated using moment or intensity, however, are offset from the Y = X line for both 
RiVax and the mAb (Figure 5.2 B3). In the case of RiVax, the moment Tm is significantly higher 
than the intensity Tm. For the mAb, however, the opposite trend was observed. 




To explain the discrepancy in Tm values generated using the intensity and moment 
methods, we simulated thermally induced changes of these two parameters as a function of the 
degree of unfolding (i.e. the percentage loss of native state) during a SSF thermal melt study. 
Thermal unfolding of proteins usually results in a red shift in Trp emission spectra due to increased 
exposure of the indole side chains to the polar aqueous solvent. Depending on the relative intensity 
of the emission spectrum of the unfolded state, three scenarios (I, II and III) are proposed here 
(Figure 5.3A). To simplify the simulation, the intrinsic thermal quenching effect on the 
fluorescence of native and unfolded state is not considered and a two-state unfolding process is 
assumed. At any extent of unfolding, the observed emission spectrum is assumed to be a linear 
combination of both native and unfolded state signals: 
            Observed spectrum (λ, X) = native spectrum (λ) * (1-X) + unfolding spectrum (λ) * X          
(5) 
where X is the degree of unfolding and λ is wavelength. The moment and intensity are calculated 
from the observed emission spectrum and are then plotted as a function of degree of unfolding 
(Figure 5.3B-5.3D). The corresponding temperature for each degree of unfolding is calculated 
using the Van't Hoff equation (equation (4)) to plot melting curves (Figure 5.3B-5.3D Inset). For 
case I, the unfolded state shows increased intensity compared to the native state. As illustrated in 
Figure 5.3B, intensity is found to be linearly proportional to the degree of unfolding. The 50% 
intensity alteration point (indicated by red dots) corresponds to a degree of unfolding of 50% and 
a “true” Tm of 72 oC. Moment, however, shows a concave down relationship with the degree of 
unfolding. At the 50% moment alteration point, the degree of unfolding is only 21% resulting in 
an “erroneous” Tm with a lower value (~70 oC). The thermally unfolded state of the mAb falls 
under case I and therefore shows a moment Tm lower than the intensity Tm (Figure 5.2 B3). In the 
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case of scenario III, an opposite trend is observed in which the unfolded state has a lower intensity 
than the native state. Intensity and moment show a linear and concave up dependency with the 
degree of unfolding, respectively, causing the moment Tm to be higher than the intensity Tm. This 
scenario applies to RiVax. Scenario II is an extreme case where the unfolded state has the same 
intensity as the native state. The intensity remains constant through thermal unfolding making it 
an uninformative parameter with which to monitor thermal unfolding. The moment under such 
circumstance has a linear relationship with the degree of unfolding and therefore can be used to 
obtain the “true” Tm. These guidelines will also apply to explain the differences of Tm values 
observed in the TRF mode. In summary, the parameter with a linear dependence on the degree of 
unfolding should be used to generate the accurate Tm values. Intensity is such one type of parameter 
and should be preferred over moment to derive a Tm. Therefore, intensity is selected for the mAb 
for the following excipient screening studies. In the extreme case II, moment, but not intensity, 
can be used to derive the true Tm. RiVax showed only a very weak transition when monitored by 
intensity, causing difficulty in deriving the Tm using intensity (Supplemental Figure 5.S1). This, 
in fact, suggests that the fluorescence of unfolded RiVax is only slightly different than its native 
state, indicating moment is nearly linear with the degree of unfolding. In addition, moment derived 
melting curves should result in Tm values with better reproducibility for RiVax compared to 
intensity derived ones because moment melting curves show a more pronounced transition with a 
better sensitivity and are less effected by spectral noise. Therefore, it seems reasonable to use the 
moment instead of intensity for RiVax during the excipient screening study. 
5.3.4. Excipient screening for RiVax and the mAb at 0.2 mg/mL in solution 
The mAb and RiVax were further subjected to an excipient screening study. Lysozyme 
was not examined due to its high intrinsic stability. An isotonic buffer of 20 mM citrate phosphate 
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at pH 6.0 was chosen for this study because both proteins showed the highest thermal stability in 
this buffer based on the pH screening study described above. The stabilization or destabilization 
effects of excipients are indicated by the change in Tm (ΔTm) of the protein in their presence. A 
positive ΔTm generally indicates an increase in protein thermal stability. Based on the study 
performed above, we selected SS_intensity_f’(T) and SS_moment_f’(T) to generate Tm values for 
the mAb and RiVax, respectively. As shown in Figure 5.4, most osmolytes tested (1 M sucrose, 1 
M sorbitol, 0.375 M trehalose) were found to be stabilizers for both proteins probably due to 
preferential exclusion effects (247). The addition of glycerol (25%, v/v) resulted in an increase in 
RiVax Tm, but had no significant effect on the mAb. An approximately 4 ᵒC increase in Tm was 
observed for the mAb in the presence of 0.5 M sodium sulfate, which had negligible effects on 
RiVax. Most amino acid excipients did not show dramatic effects on both proteins except arginine 
chloride, which decreased the Tm values by 3 and 10 ᵒC for the mAb and RiVax, respectively. The 
destabilizing excipients for both proteins include chaotropes (e.g. 250 mM urea, 250 mM 
guanidine HCl, 250 mM KSCN), cyclodextrins and polymers (e.t. PEG, PVP etc.). The 
mechanisms responsible for the destabilizing effects of these excipients have been discussed 
previously (247, 248).  
5.3.5. Excipient screening of RiVax with/without Alhydrogel 
RiVax, as a subunit vaccine candidate, is formulated with adjuvants (e.g. Alhydrogel) to 
enhance its immunogenicity. In this study, a base buffer of 10 mM histidine isotonic buffer (pH 
6.0) was used to avoid the use of phosphate buffers, which could significantly reduce the binding 
of RiVax to Alhydrogel (AlOH). The thermal stability of RiVax (at 0.2 mg/mL) in the absence or 
presence of AlOH (2 mg/mL) was studied and the effects of excipients on RiVax under these two 
conditions were studied. Based on the initial excipient study (Figure 5.4), nine agents were tested 
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to illustrate an array of effects. The excipients were classified into three categories: stabilizing, 
destabilizing, and neutral. Accordingly, the melting curves for each type of excipient were plotted 
together. All excipients showed a similar effect on the thermal stability of RiVax in histidine-
containing solution compared to the study performed in 20 mM citrate phosphate buffer (pH 6.0). 
Similar to the results of Peek and coworkers (249), we found that RiVax adsorbed to AlOH had 
significantly lower thermal stability, reflected by a decrease in Tm or an increase of the moment 
peak position at 10 o C or a combination of both (Figure 5.5). For instance, RiVax in the base buffer 
adsorbed to AlOH had a decrease of about 17 ᵒC in Tm and an increase of almost 2 nm in moment 
peak positon. This indicates that the perturbed tertiary structure of RiVax on the surface of AlOH 
is associated with a dramatic decrease in its thermal stability. All three stabilizers (sucrose, 
glycerol, and glycine) decreased the initial moment peak position of RiVax in the presence of 
AlOH to a level equivalent to the folded state and increased the Tm, but less than the Tm increase 
of RiVax in the His buffer (Figure 5.5 A1). This indicates that these compounds are able to 
stabilize the tertiary structure of adsorbed RiVax but fail to fully rescue its solution stabilization. 
Figure 5.5 A2 also shows that some excipients do not produce significant effects on the thermal 
stability or tertiary structure of RiVax in both the absence or presence of AlOH. Figure 5.5 A3 
shows that RiVax adsorbed onto AlOH in the presence of destabilizers did not show any thermal 
transitions and had an increased moment peak position at 10 ᵒC, suggesting an unfolded state. This 
indicates an extensive loss of protein tertiary structure. The binding of RiVax to AlOH in these 
experiments was tested by quantifying RiVax in the supernatant after centrifugation. As shown in 
Figure 5.5 B1, all excipients except the stabilizers (sucrose, glycerol, and glycine) produced 
complete adsorption onto AlOH. The three stabilizers significantly reduced the amount of RiVax 
bound to AlOH by 4-14%. This suggests that these stabilizers may thermally stabilize adsorbed 
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RiVax by weakening their interactions with AlOH, which destabilizes the tertiary structure of 
RiVax.  The addition of 0.05% PS 80 only slightly destabilized RiVax, but it was completely 
unfolded when absorbed to AlOH (Figure 5.5 B2 and B3). The increase in the initial moment peak 
position somewhat correlates with the decrease in the Tm. In solution, sucrose (0.5 M) and glycerol 
(12.5%) show better stabilization effects on RiVax than glycine (250 mM). However, when 
adsorbed to RiVax, glycine (250 mM) is a better stabilizer than sucrose (0.5 M) and glycerol 
(12.5%). These results suggest a large discrepancy between the effects on excipients on RiVax in 
His buffer and that in adjuvanted solutions. 
5.3.6. Excipient screening of the mAb at 0.2 mg/mL and 80 mg/mL  
Excipient screening studies for mAbs are routinely performed at low concentration (e.g. 
0.1 – 1.0 mg/mL) due to limited protein quantity and ease of analysis, while actual commercial 
drug products often contain mAbs at very high concentration (50 to 200 mg/mL). The thermal 
stability of mAbs has been previously shown to be dependent on protein concentration (240).  The 
dependency of Tm on protein concentration (0.2 to 80 mg/mL) in 20 mM citrate phosphate isotonic 
buffer (pH 6.0) was investigated here. Figure 5.6 A shows that the Tm values of the mAb gradually 
decrease as the mAb concentration increases and the effect is more pronounced at lower protein 
concentrations. We then studied if excipients affect the thermal stability of the mAb at high or low 
concentrations differently. Thus, their effects on Tm (ΔTm) of the mAb at 0.2 mg/mL or 80 mg/mL 
were further studied using Trp intrinsic fluorescence. As shown in Figure 5.6 B, 0.05% (v/v) PS 
80 and 60 mM histidine did not produce major effects on the Tm at 0.2 or 80 mg/mL. The other 
excipients resulted in a significantly larger ΔTm value at 80 mg/mL compared to the mAb at 0.2 
mg/mL. For example, 1 M sucrose had an enhanced stabilization effect on the mAb at 80 mg/mL. 
Glycerol (25%, v/v) did not thermally stabilize the mAb at 0.2 mg/mL, but improved the Tm of the 
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mAb at 80 mg/mL by over 2 ᵒC. Urea (at 250 mM) decreases the Tm of the mAb at 0.2 mg/mL by 
about 2 ᵒC but did not result in detectable destabilization effects at 80 mg/mL. A similar result was 
observed for 1.5% (w/v) PEG 3350. The destabilization effects of 135 mM arginine and 250 mM 
guanidine HCl were significantly less at 80 mg/mL in contrast to their effects on the mAb at 0.2 
mg/mL. Therefore, it is clear that the excipient screening results (reflected by ΔTm) obtained using 
the mAb at 0.2 mg/mL sometimes fail to predict the results at 80 mg/mL. 
Previous studies have reported that formation of fibrils by several proteins upon stress (e.g. 
elevated temperature) produced a characteristic fluorescence (ex: 355 nm and em max: 470 nm) 
(250-252). The mAb used in this study has been found to form fibrils at elevated temperature 
driven by the formation of intermolecular β sheet (242). We here tested the feasibility of studying 
the formation of fibrils by monitoring this florescence. We monitored this fluorescence using TRF 
using an excitation of 350 nm and emission of 485 ± 20 nm. During thermal unfolding, an increase 
in the intensity of such fluorescence was observed for the mAb at 80 mg/mL (Supplemental Figure 
5.S2), but not at 0.2 mg/mL (data not shown), probably due to the relatively low quantum yield of 
the fibril fluorescence. The Tm values calculated using the 1st derivative method from the fibril 
fluorescence of the mAb at 80 mg/mL showed a good correlation between the data from the Trp 
fluorescence study. This suggests the potential use of this method as a formulation monitor to 
measure the aggregation of high concentration mAbs. 
 
5.4. Discussion 
In the present study, a high-throughput platform for the optimization of protein 
pharmaceutical formulations based on intrinsic fluorescence is described. It employed both TR 
196 
 
and SS modes. Three model proteins (lysozyme, mAb, and RiVax) were tested to investigate the 
feasibility of using this platform for formulation development. These three proteins in a selected 
standard condition (0.2 mg/ml in clear solution) were first subjected to a pH screening study to 
identify optimal buffer conditions. Various Tm generation methods were employed to calculate the 
Tm. Accordingly, an optimal generation method was selected for an excipient screening study. The 
mAb and RiVax were further subjected to excipient studies under both standard and 
pharmaceutically relevant conditions. The results show significant discrepancy in the excipient 
screening data (reflected by ΔTm) of proteins studied under the simplified reference condition 
versus more commercially relevant conditions. 
In the pH screening study, Tm values of each model protein generated using various 
methods overall show a similar trend across all pH conditions tested. A more detailed analysis of 
the dependency of Tm on these generation methods suggests that the type of fluorescence used (TR 
versus SS fluorescence) and the data fitting method (1st derivative versus six-parameter fit) do not 
significantly affect the final Tm values. The parameter selected to monitor protein thermal 
unfolding (intensity versus moment), however, has a significant impact on Tm values. We 
attempted to explain these results by simulating the correlation between changes in the parameter 
signal and the degree of protein unfolding. The simulation study suggests that, in most cases, 
fluorescence intensity is able to reflect the degree of unfolding in a linearly proportional manner, 
making the Tm derived from intensity a “true” value. Moment, however, is not linearly dependent 
on the degree of unfolding in most cases and therefore often results in a “false” Tm value. Similar 
work by Žoldák et al. suggested fluorescent intensity ratio, a commonly used parameter, does not 




The advantages of this high-throughput platform are better manifested in the excipient 
screening study. This technique is based on the intrinsic fluorescence of tryptophan in protein 
molecules. It is therefore label-free and potential interfering extrinsic probes can be avoided. 
Secondly, sample consumption is minor. It requires only 10 μl of sample at 0.2 mg/mL (i.e. 2 μg) 
per well, which means less than 1 mg of protein is needed even if all 384 wells are used. Third, a 
standard thermal scanning of a 384 well plate only takes 4 to 5 h using the thermal ramp described 
in the methods section. Finally, the front-face geometry between the sample plate and detection 
makes it possible to study samples under challenging conditions such as high concentration and 
highly scattering conditions. 
This fluorescence platform was further applied to study the effects of several selected 
excipients on RiVax and a mAb under difficult formulation conditions. In the case of RiVax, the 
protein was first adsorbed to AlOH (forming a turbid solution) and excipient effects on protein 
tertiary structures and melting temperature were studied. A previous study has employed extrinsic 
fluorescence for the high-throughput formulation screening of aluminum adjuvanted vaccines 
(254). However, common detergents such as Triton X100, poloxamers, and PS80 cannot be tested 
because they produce excessive background signals which seriously interference with 
measurements or may themselves interact with excipients. In contrast, with this intrinsic 
fluorescence based high-throughput platform, such detergents can be tested. We were also able to 
observe stabilization effects of sucrose, glycerol, and glycine on AlOH adsorbed RiVax. Our 
findings are in good agreement with previous work, which observed a decreased thermal stability 
of RiVax when adsorbed to AlOH and found that such destabilizing effects were only partially 
diminished by the addition of 15% glycerol. We also observed that these stabilizers reduced the 
binding efficiency of RiVax to AlOH. It is possible that these excipients partially stabilize 
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adsorbed RiVax by decreasing the binding affinity of RiVax to AlOH. Possible mechanisms 
include: 1) a preferential exclusion effect, which prevents the increase in the exposed surface area 
induced by protein adsorption to AlOH and 2) a competitive binding effect between excipients and 
RiVax to AlOH (255). It is critical to study the thermal stability of adsorbed antigen to optimize 
formulations and to better understand the in vivo stability of such proteins. The use of a large 
quantity of stabilizer (1M sucrose, 25% glycerol, or 250 mM glycine) only increased the Tm of 
adsorbed RiVax to near physiological temperature (37 ᵒC). Upon vaccination, due to the loss of 
stabilizing effects of these excipients, adsorbed RiVax may adopt an altered tertiary structure at 
37 o C. This may partially explain the unsatisfactory immunogenicity of RiVax even when adsorbed 
to AlOH (256). It would be interesting to study the dissociation and structural behavior of adsorbed 
RiVax and other protein antigens when exposed to physiological environments to better 
understand effects on immunogenicity. 
In the case of the mAb, excipient effects on high concentration mAb were investigated. 
The requirement for a sample volume as low as 10 μl facilitates such excipient screening. Thus, 
for a mAb at 100 mg/mL, only 1 mg of protein is required for each excipient condition. The sample 
volume can be potentially further reduced if needed. The effects of excipients on the thermal 
stability of the mAb examined here are quite distinctive. Osmolytes (e.g. 1 M sucrose and 25% 
glycerol) show a better stabilization effect on the mAb (at 80 mg/mL) than the more dilute mAb 
(at 0.2 mg/mL), especially for 25% glycerol, which did not thermally stabilize the mAb (at 0.2 
mg/mL). This discrepancy is probably due to a more pronounced preferential exclusion effect for 
high concentrations of the mAb. On the other hand, the destabilizers become less effective for the 
high concentration mAb possibly because of a decreased destabilizer/protein molar ratio. In 
addition, the good agreement between Tm values obtained using fibril fluorescence and those 
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generated using Trp fluorescence shows that the formation of fibrils is concurrent with the 
unfolding of the protein. In other words, the kinetics of fibril formation may be much faster than 
the unfolding process, suggesting the unfolding process may be the rate-limiting step. The 
implementation of fibril fluorescence for studies of mAbs could provide the following insights: 1) 
the formation of fibril as an alternative to look at the aggregation behavior of mAb; and 2) a better 
understanding of the kinetic processes of thermal unfolding and aggregation of mAbs. 
This study establishes a general workflow based on protein intrinsic fluorescence for direct 
optimization of protein formulations. Key steps involve a pH screening study, selection of a 
parameter for monitoring thermal unfolding, and a final excipient screening study. This work 
highlights the importance of performing the excipient screening under pharmaceutically relevant 
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Figure 5.1. (A) A schematic diagram of the high throughput fluorescence plate reader. This 
instrument is capable of recording both time resolved and steady state fluorescence. An emission 
mirror is placed to direct the emission signal to a CCD detector for the measurement of steady 
state fluorescence. Otherwise, the time resolved fluorescence signal is recorded by a PMT. 
(Modified from Schaaf (244)) (B) A general workflow for the formulation optimization of proteins 
using this fluorescence plate reader. Thermal melting study of protein samples using intrinsic 
steady-state fluorescence (C1-C3) or time-resolved fluorescence (D1-D3). Representative 
temperature dependent raw fluorescence spectra (C1) of samples; processed melting curves 
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monitored by moment (red dot) or intensity (black dot). Fitted melting curves using six parameter 
fitting method are shown as continuous line (C2); Calculation of melting temperature (Tm) using 
first derivative (C3). Representative temperature dependent raw waveform (D1) of samples; 
processed melting curves monitored by moment (red dot) or intensity (black dot). Fitted melting 
curves using six parameter fitting method are shown as continuous line (D2); further calculation 





Figure 5.2. pH screening for RiVax, lysozyme, and mAb using Trp fluorescence (A) and 
comparison of Tm values obtained from different methods (B). Summary of pH dependent melting 
temperatures (Tm) of RiVax (A1), lysozyme (A2), and the mAb (A3) in citrate-phosphate buffers 
pH 3.0 to 8.0. The correlation plots of melting temperatures (Tms) obtained using steady-state 
fluorescence versus time-resolved fluorescence (B1), six-parameter fit versus first derivative 
method (B2), and intensity versus mean spectra mass (B3). The straight lines (Y = X) in B1-B3 
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are added for visual guidance. * indicates that no obvious thermal transition was observed. Error 
bars indicate standard deviations (N=3). 
 
 
Figure 5.3. Simulation of thermal unfolding monitored by moment and intensity of steady state 
fluorescence. (A) Spectra of native and unfolded states. Three cases (I, II, and III) are proposed to 
describe different scenarios of fluorescence of the unfolded state depending on the relative 
fluorescence intensity to its native state. Case I, II, and III have unfolded states with higher, lower, 
and the same fluorescence intensities in contrast to the native state, respectively. Correlation plots 
of moment or intensity with the degree of unfolding and melting curves (shown in inset) for case 
I (B), II (C), and III (D). The simulated thermal transitions are performed using a “true” Tm of 72 




Figure 5.4. Excipient screening study for RiVax and the mAb (at 0.2 mg/mL) in 20 mM citrate-
phosphate isotonic buffer pH 6.0 using Trp fluorescence. The stabilization or destabilization 
effects of excipients are indicated by the change in the Tm (ΔTm) of the protein in the presence of 
excipients. A reference line at no change in the Tm (ΔTm = 0 ᵒC) is shown. Error bars indicate 


















































































































































































































































































































































Figure 5.5. Comparison of the effects of excipients on the thermal stability of RiVax in histidine 
20 mM isotonic buffer pH 6.0 in the absence or presence of 2 mg/mL Alhydrogel. Thermal melting 
curves of RiVax in the absence or presence of Alhydrogel (A1-A3). In total, ten excipients were 
tested. According to their effects on the thermal stability of RiVax in the presence or absence of 
Alhydrogel, they are classified into three groups: stabilizer (A1), excipient showing no significant 
209 
 
effect (A2), and destabilizer (A3). Melting curves for RiVax in base buffer were included in each 
figure for comparison. The effects of excipients on the binding of RiVax to Alhydrogel (B1); 
Comparison of the impact of excipients on Tm values of RiVax in the presence or absence of 
Alhydrogel (B2). The reference line at 49 ᵒC corresponds the Tm of RiVax in 20 mM histidine 
isotonic buffer pH 6.0. Comparison of the impact of excipients on MSM peak positions of RiVax 
at 10 ᵒC in the presence or absence of Alhydrogel (B3).  * indicates that no obvious thermal 





Figure 5.6. Excipient screening of the mAb at 80 mg/mL in 20 mM citrate phosphate isotonic 
buffer using Trp intrinsic fluorescence and fibril intrinsic fluorescence. (A) Concentration 
dependent Tm values. (B) Comparison of the effect of excipients on Tm values of the mAb at 0.2 
mg/mL (analyzed using Trp fluorescence) or 80 mg/mL (analyzed using Trp fluorescence and 








Supplemental Figure 5.S1. Melting curves of RiVax (A) and the mAb (B) in 20 mM citrate 
phosphate buffer isotonic buffer pH 6.0 monitored by moment or intensity from steady state 







Supplemental Figure 5.S2. Thermal melting of the mAb at 80 mg/mL in 20mM citrate phosphate 
isotonic buffer recorded using fluorescence and light scattering. The emission spectra of fibril 
excited at 355 nm (A); Melting curves monitored using fluorescence and static light scattering at 











Subunit vaccines are highly defined components of a pathogen that can elicit host immune 
responses against the pathogen (257). Compared to other vaccine types (e.g. live attenuated, 
killed), subunit vaccines are potentially much safer for human use and therefore often a preferable 
form. Its improved safety profile, however, comes at a price. One of the biggest challenges subunit 
vaccines are facing is their relatively low immunogenicity due to two primary reasons: 1) their 
monovalent nature and 2) the lack of immunostimulatory molecules, which are present in the other 
vaccine types. The corresponding strategies to overcome these two issues are polyvalent antigen 
display and the use of adjuvants, respectively. 
Polyvalent antigen display enhances the antigen immunogenicity by enabling the “avidity” 
interaction between a polyvalent antigen with B-cell receptors (BCRs) (121). A B-cell contains on 
its surface numerous BCRs, bivalent transmembrane immunoglobulin molecules. The function of 
the BCRs is to recognize and bind to an antigen’s B-cell epitope, which eventually activates the 
B-cell. A monovalent antigen can only bind to a single binding site of a BCR. Since polyvalent 
antigens display multiple copies of the same types of epitopes in an ordered manner, it is able to 
bind to more than one BCR simultaneously. This polyvalent binding event, also referred as 
“crosslinking”, creates a much more stable BCR-antigen complex and induces stronger 
downstream immune responses than monovalent binding. This strategy can be applied to augment 
the immunogenicity of monovalent antigens by simply clustering them on a nanoparticle scaffold 
system.  A common approach is to genetically fuse the antigen of interest to a self-assembling 
protein scaffold such that antigens can be polyvalently presented upon correct assembly of the 
scaffold. Several self-assembling proteins have shown great potentials as vaccine presentation 
scaffolds. In this thesis, we investigated the feasibility of a polymeric bacterial protein called 
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lumazine synthase (LS) for polyvalent antigen display (258). LS consists of 60 subunits and forms 
an icosahedral structure with a size around 16 nm. Therefore, it can accommodate up to 60 copies 
of foreign antigens on its N or C terminus. 
The use of adjuvants is another effective strategy to improve the immunogenicity of subunit 
vaccines. Commonly used adjuvants include aluminum salts, emulsions, MPLA, etc. A suitable 
adjuvant is selected depending on which type of immune responses (Th1 and/or Th2) is required 
for the efficacy of co-administered antigens. Adjuvants can potentially interact with antigen 
molecules in solution by different mechanisms. The effects of such interaction forces on the 
stability of both antigen and adjuvants (i.e. antigen-adjuvant compatibility) need to be rigorously 
characterized before a rational dosage form can be proposed. If they are compatible with each 
other over the period of storage, they can be stored in a single vial for the purpose of saving storage 
cost and the ease of administration. Otherwise, they should be stored separately and mixed together 
immediately before administration. Emulsion-based adjuvants for human use are generally oil-in-
water emulsions. They often use squalene as the oil phase, which provides a hydrophobic interface 
for adsorption of antigens with hydrophobic patches. Emulsions are heterogeneous systems 
containing several other components, e.g. surfactants and antioxidants, which may also interact 
with antigens. As a part of this thesis, we utilized a variety of biophysical tools to study the effects 
of two emulsion-based adjuvants on the structure and stability of a mutant of the α-toxin from S. 
aureus, a promising vaccine candidate against antibiotic-resistant S. aureus infection.  
Since biologics in solution are subject to both physical and chemical degradations, 
optimization of protein formulations is critical to ensure their storage stability. The goal of liquid 
protein formulation screening is to identify solution conditions (pH, salts, and excipients) that 
provide the maximal protein stability. To screen formulations in a timely manner, we study 
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protective effects of a diverse array of formulation conditions on the stability of a protein exposed 
to one or more stressed conditions often in a high-throughput manner. Because protein stabilities 
contain four primary facets: conformational, chemical, colloidal, and interfacial, a corresponding 
stress condition need to be used to study each aspect. For example, proteins are often exposed to 
heat to screen formulations that can stabilize protein conformation. Protein conformation stability 
is often reflected using a stability indicating parameter, the most common one being a protein’s 
melting temperature (Tm). It is generally assumed that the more a formulation condition increases 
Tm, the better stabilizing effect it has. Protein Tm can be measured using many biophysical 
techniques including FTIR, CD, fluorescence, DSC, etc. Among these, fluorescence is a popular 
method because of its ability to be employed in a high-throughput manner and its relatively high 
sensitivity. 
Specific therapeutic needs often require unique formulations (high concentration mAbs, 
adjuvanted vaccines). Such conditions can pose significant analytical challenges during their 
formulation screening. For example, high concentration mAbs strongly absorb light and may cause 
inner filtering effects in conventional intrinsic fluorescence. Turbid adjuvanted vaccines highly 
scatter light and can interfere with fluorescence signals. To avoid these challenges, they are often 
screened under simplified conditions (i.e. using a clear solution in the absence of adjuvants or the 
use of a low mAb concentration). However, there exist significant differences between the 
simplified and commercially relevant conditions.  For instance, antigen/adjuvant interactions are 
absent under the simplified condition. Short-range interactions are missing in low mAb 
concentration samples. We found that these differences could result in discrepancies in formulation 
screening results performed under these two conditions. It is, therefore, preferable to perform 
formulation screening under a commercially relevant condition. In a later chapter of this thesis, we 
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presented a workflow for direct formulation screening of analytically challenging but 
commercially relevant formulations (e.g. high concentration mAbs, turbid adjuvanted vaccines, 
etc.) using a novel high-throughput fluorescence plate reader. 
6.2. Conclusions and future Directions 
6.2.1. Chapter 2 
In chapter 2, we studied the structural properties and stability of LS using various 
biophysical tools. Chemical unfolding of LS in PBS buffer was performed using urea or guanidine 
hydrochloride as a denaturant. Guanidine was found to be more effective than urea in altering 
protein structure. Urea at 8.5 M was not able to disrupt the oligomeric state of LS. In contrast, 
guanidine at 2 M was able to distort the icosahedral structure of LS. A molten globular state was 
observed for LS in the present of 1.5 M guanidine HCl. Such states were highly prone to aggregate 
and eventually precipitated out of solution. The pH-dependent thermal stability of LS was studied 
over a pH range of 5.0 to 8.0 and a temperature range of 10 to 90 ᵒC. A large data set was collected 
of LS’s secondary structure by circular dichroism (CD), tertiary structure by fluorescence, 
quaternary structure by light scattering, and overall conformational stability by differential 
scanning calorimetry (DSC). Such data sets were then integrated to generate an empirical phase 
diagram and radar charts for visual presentation of the stability of LS as a function of pH and 
temperature. Five distinct phase regions were identified. The stability of LS was found to be highly 
sensitive to solution pH. LS tended to aggregate when the pH value is less than 5.0. The main 
thermal transition (Tm2) of LS was above 80 ᵒC. Fluorescence and DSC also detected a small early 
transition (Tm1) that was not seen by CD and light scattering. The origin of Tm1 was further 
investigated. LS contains 60 binding sites for phosphate anions and can form LS/phosphate 
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complex in phosphate containing buffers. The molecular origin of Tm1 was found to be due to the 
thermal dissociation of phosphate ions from the LS/phosphate complex. Free LS adopts an “open” 
conformation with more exposed hydrophobic patches compared to the LS/phosphate complexes, 
which has a more “closed” conformation. The main transition arises from the combination of 
thermal dissociation of the icosahedral structure, unfolding, and consequent aggregation. 
It would be interesting to obtain a cryo-EM or crystal structure of the free LS and compare 
it with the crystal structure of the LS/phosphate complex currently available in the PDB database. 
Such structural difference would provide useful insights into structural alterations at the atomic 
level and may confirm the “breathing” motion of LS proposed by several laboratories to explain 
the possible release mechanism of lumazine from the cavity of LS to the bulk solution (257). It 
may also be worthwhile to perform a molecular dynamic simulation to visualize the “breathing” 
motions mediated by phosphate binding. 
6.2.2. Chapter 3 
In chapter 3, we utilized LS as a polyvalent scaffold to develop vaccines against ricin toxin. 
Ricin is a highly poisonous toxin produced in caster beans and has long been considered as a 
potential bioterrorism agent. Since there are no approved ricin vaccines and the current vaccine 
candidates under development fail to produce long-term protections in humans, we aimed to 
develop highly immunogenic ricin vaccines to protect the public, military, and first responders 
using a polyvalent antigen display strategy. A linear neutralizing epitope, designated as PB10, was 
genetically fused to the C terminus of an LS subunit. The resulting fusion protein successfully 
assembled and formed a nanoparticle (LS_PB10) displaying in total 60 copies of PB10 epitopes 
on the surface. Fusion of PB10 did not affect secondary or tertiary structure of the scaffold. 
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LS_PB10 showed extremely tight binding affinity to a mouse antibody targeting the PB10 epitope. 
Such strong affinity may be partially attributable to the polyvalency of the PB10 epitope on LS. 
LS_PB10 elicited moderate levels of serum titers against ricin in mouse post three immunizations. 
Unfortunately, these titers failed to protect mice from toxification of ricin during a challenge study. 
Possible reasons include: 1) the use of the PB10 epitope alone may not be able to provide complete 
protection; 2) the immunodominant role of LS may induce epitope suppression; 3) the loss of the 
PB10 peptide’s secondary structure may compromise the quantity and/or quality of induced anti-
ricin titers. Overall, LS is a promising scaffold as a vaccine scaffold. It, however, suffers a critical 
drawback-its intrinsically high immunogenicity, and this is indeed a common issue for protein-
based scaffolds for vaccine use. PEGylation of the surface of a scaffold surface has been found to 
be an effective means to immunologically mask the scaffold (141). The display of a relatively large 
epitope to cover the surface of a scaffold may also be worth considering. 
Since PB10 itself seems to be insufficient to provide protection against ricin, it might be 
worth trying to make LS-based combination vaccines using multiple neutralizing epitopes. Initial 
attempts to express LS-based ricin vaccines presenting several other linear epitopes in E.coli 
systems were not successful due to the formation of inclusion bodies. The expression systems 
and/or conditions may be optimized to achieve a soluble fusion protein with correct assembly. In 
addition, the majority of neutralizing epitopes on ricin have been found to be conformational rather 
than linear, therefore an LS-based vaccine using conformational epitopes may be promising. 
However, presenting a conformational epitope on the surface of a scaffold can be quite challenging 
because it would require careful design of a construct to ensure the correct folding of the 
conformational epitope. An easier and more straightforward idea is to present a mutant of the ricin 
A chain (RiVax or RVEC) on LS. The surface of LS, however, is not large enough to display 60 
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copies of the mutant. In theory, using a longer rigid linker to present the mutant further way from 
the scaffold could provide enough space to accommodate 60 copies of the mutant. Polyvalent 
display of a ricin mutant using a different protein scaffold with sufficient surface area may be an 
alternative. Many other scaffold systems (e.g. gold nanoparticle, liposome, silica, etc.) can also be 
explored to develop highly immunogenic ricin vaccines. 
6.2.3. Chapter 4 
Adjuvants are often used to boost immune responses of subunit vaccines. A key interest 
related to the development of adjuvanted formulations is understanding the compatibility between 
antigens and adjuvants. Antigens can interact with antigens via various types of interactions, which 
may affect the stability of the components. In this chapter, we studied the interactions of two 
emulsion-based adjuvants (ME.0 and SE) with a mutant of S. aureus alpha toxin (AT), a S. aureus 
vaccine candidate, using a diverse array of biophysical tools. Both emulsions use squalene as their 
oil phase with a similar particle size of around 100 nm. The major difference is the type of 
surfactants used. ME.0 contains PS80, while SE uses DMPC and Pluronic F68. In addition, SE 
also contains vitamin E as an antioxidant and immunostimulatory component. Size exclusion 
chromatography (SEC) showed that AT strongly interacted with SE because injection of the 
AT/SE mixture resulted in co-elution of these two components. Conversely, AT in the presence 
ME.0 eluted at the same time as AT in PBS buffer, suggesting a negligible interaction between AT 
and ME.0. FTIR analysis indicated that SE induced a β-sheet to α-helix conversion in the 
secondary structure of AT, and intrinsic fluorescence found a slight but significant blue shift in the 
Trp emission spectra of AT in the presence of SE. ME.0, however, did not have a significant effect 
on structures of AT. AT in PBS exhibited two thermal transitions by DSC analysis. The addition 
of SE dramatically raised the melting temperatures by more than 10 ᵒC, while ME.0 slightly 
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decreased these two melting temperatures. We then studied effects of individual water-soluble 
components of emulsions on the thermal stability of AT.  It was found that the thermal stabilization 
effect of SE on AT is probably due to interactions of AT with the oil phase (squalene, vitamin E, 
DMPC, etc.), and that ME.0 destabilized AT because of changes in solution conditions (pH, salt 
concentrations, etc.) upon mixing. On the other hand, ME.0 in the presence of AT showed 
decreased colloidal stability compared to ME.0 alone upon heating. SE in the presence of AT 
mixtures shared similar colloidal stability with SE alone. This study illustrated the applicability of 
a set of biophysical tools to characterize and understand antigen/adjuvant interactions. 
Although we have proposed that AT interacts with the oil phase of SE, an exact mechanism 
of SE/AT interaction remains unclear. This may be elucidated by labeling lipid using fluorescence 
dyes or performing NMR experiments. Hydrogen deuterium exchange mass spectrometry may be 
utilized to identify the interaction interfaces on AT. It would also be interesting to study other 
stability aspects (chemical and interfacial) of AT in the presence of these two emulsions. 
Furthermore, long-term stability studies of AT/emulsion mixtures at selected storage condition 
(e.g. 2 to 8 oC) should be conducted to justify a final dosage form (single-vial vs. separate-vial). 
The wild type AT self-assembles into a heptamer and contains a lipid membrane bound segment. 
AT used in this study is a mutant of the wild type and lacks the ability to self-assemble. Its sequence 
information is not available for proprietary reasons, but it would be worth the effort to look into 
the crystal structural information of the wild type AT to better understand mechanisms of 
AT/emulsion interactions.  
6.2.4. Chapter 5 
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In this chapter, we compared protein formulation screening studies performed under 
simplified conditions versus commercially relevant but analytically challenging conditions using 
a fluorescence plate reader. This novel instrument is equipped with a 295 nm laser as the excitation 
source, a temperature controllable 384-well sample plate holder, and 2 detectors (a CCD and PMT 
for steady-state and time-resolved fluorescence measurement, respectively). The front-face 
geometry of the sample plate and the requirement of a low sample volume (5 ~ 10 μl) minimize 
inner filter effects for high concentration protein samples. The use of a long-pass filter (≥ 310 nm) 
effectively blocks Raleigh scattering and allows collection of high quality fluorescence data for 
turbid adjuvanted samples. Since formulation rank orders are based on protein Tm values in this 
study, we first explored different methods to obtain Tm values. We performed a pH screening study 
using citrate-phosphate buffers (pH 3.0 to 8.0) for three model proteins: a mAb, lysozyme, and 
RiVax (a vaccine candidate for ricin toxin, see above). Sample Tm values were generated by 
running two fluorescence modes (steady-state versus time-resolved), deriving two stability 
indicating parameters (intensity or moment) to plot melting curves, and finally using two fitting 
methods (six parameter fitting versus first derivative). In total, up to eight Tm values (2*2*2) were 
generated for a sample. We then compared these eight Tm values and found that Tm values are 
independent of the fluorescence mode and the data fitting method. The derived stability indicating 
parameter (moment or intensity) used to plot melting curves can affect Tm values. We explained 
such dependencies by simulating both moment and intensity as a function of temperature during a 
hypothetical thermal unfolding event of a protein. It was found that, in most cases, intensity is 
linearly proportional to the degree of unfolding. In contrast, moment can exhibit a concave-up or 
concave-down relationship with the degree of unfolding depending on the relative fluorescence 
intensity of the protein’s native state over its unfolded state. A key take-home message is that a 
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parameter that is linear with the degree of unfolding can generate a real Tm and therefor is preferred 
for use. 
We then performed excipient screening studies for the mAb at 0.2 versus 80 mg/mL, 
representing a simplified and commercially relevant condition, respectively. We found that the 
magnitude of excipient effects (reflected by ΔTm) are different for these two conditions. Stabilizers 
(e.g. 1M sucrose, 25% glycerol, etc.) resulted in a larger increase in ΔTm on the mAb at 80 mg/mL, 
probably due to a more pronounced preferential exclusion effect of excipients on high 
concentration mAb samples. Destabilizers (e.g. 250 mM Urea, 125 mM Arginine, etc.) became 
less effective for the high concentration mAb possibly because of a lower excipient/protein molar 
ratio.  
RiVax has been found to adsorb onto aluminum hydroxide in solution, and the adsorption 
significantly destabilized the protein by a decrease of more than 10 oC in Tm (259). We then studied 
RiVax in clear solution (a simplified condition) versus in the presence of aluminum hydroxide (a 
commercially relevant condition). We observed both excipient rank orders and ΔTm values are 
different for these two conditions. We found that 12.5% glycerol and 250 mM glycine are a better 
stabilizer for RiVax in clear solution and that in the presence of aluminum hydroxide, respectively. 
It was later found that, compared to glycerol, glycine can weaken destabilizing interactions 
between RiVax and aluminum hydroxide to a larger extend than glycerol. In addition, several 
destabilizers (PS80, guanidine HCl, etc.) slightly decreased the Tm of RiVax in clear solution by 
1.5 oC, but extensively unfolded the protein in the presence of aluminum hydroxide manifesting 
no thermal transitions (10~90 ᵒC). We hypothesized that this is because of a synergetic 
destabilization effect of aluminum hydroxide and destabilizing excipients on RiVax.  
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The high-throughput fluorometer used in this study shows significant potentials for the 
development of challenging formulations. In this study, we demonstrated its applicability for 
screening high concentrations of a mAb and turbid vaccine formulations containing aluminum 
hydroxide. It would be interesting to test the feasibility of using this instrument to screen other 
types of challenging formulations, such as vaccines containing emulsion-based adjuvants. In 
addition, this fluorescence instrument may be upgraded with an ability to measure protein 
aggregation simultaneously. This would help to capture a more comprehensive picture about the 
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